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ABSTRACT 
ASSOCIATION OF HERPES SIMPLEX TYPE 2 WITH CERVICAL CARCINOMA 
Lalitha N. Mendis 
Sera obtained from patients with invasive cervical carcin- 
oma (Britain, Malawi, Sri Lanka and Sudan), with dysplasia and car- 
cinoma in situ (Britain), from matched controls, from patients with aL 
variety of ; 't-her malignancies and from patients with herpetic 
infection were studied. 
Sera were tested by indirect immunofluorescence for IgG 
and IgA antibodies to membrane antigens (MA), and IgA anti- 
bodies to virus capsid antigen (VCA) of HSV-2 infected cells. 
Complement fixation (CF) and enzyme linked immunoabsorbent 
assay (ELISA) for HSV-1 and HSV-2 specific antibody were also 
carried out. Levels of total IgG and IgA and carcinoembryonic 
antigen (CEA) were also determined. 
Compared with controls and patients with non-squamous 
malignancies, IgA anti-MA was detected in higher titres in a 
significantly higher proportion of patients with cervical ana- 
plasia (dysplasia, carcinoma in 
' 
situ, and invasive carcinoma), 
patients with non-genital squamous carcinoma and patients with 
genital herpes. Neither the prevalence nor titres of IgA anti-VCA 
differentiated patients with cervical anaplasia from controls. 
. Evidence is presented which suggests that the high prevalence 
of IgA anti-MA in patients with non-genital squamous carcinoma 
MaY be due to the presence of a cross reacting antigen betreen 
HSV-2 infected cells and squamous carcinoma cells. 
IgA anti-MA persisted in patients with invasive carcinoma 
long aXter treatment as well as in patients with non-recurrent 
genital herpes long after the initial attack. In contrast, in 
patients with genital herpes IgA anti-VCA was transient and 
detectable only for a short period following clinical infection. 
Although the prevalence of HSV-2 specific antibody in 
patients with cervical anaplasia and controls showed the virus 
was associated with cervical carcinoma in Britain, Malawi and 
Sri Lanka, evidence to show that cervical carcinoma may be of 
multiple aetiology is discussed. 
Following treatment for cervical carcinoma, a rise in total 
IgG and IgG anti-MA was'associated with tumor recurrences. Levels 
of CEA were not found to be of diagnostic or prognostic value. 
ELISA was more sensitive than CF in detecting HSV-1 and 
HSV-2 specific antibody. The IgA anti-MA response, was more type 
specific than the IgG anti-MA response. 
Findings relevant to the cervical screening programme in 
the U. K. are discussed. 
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Three main streams of observations and techniques 
contributed to the linking of HSV-2 with cervical carcinoma. 
A. Clinical and virological; 
B. Epidemiological; 
C. Cytological. 
A. --CLINICAL AND VIROLOGICAL OBSERVATIONS THAT LED TO THE 
LINKING OF HSV-2 TO CERVICAL CARCINOMA 
According to Beswick (1962), the word Herpes has. been' 7 
used over a period of 25 Centuries as a medical term to 
describe a variety of lesions. In the Prorrhetics and 
coan Prognostications which date to pre-Hippocratic (430 BC) 
times, it was used respectively to describe serpiginous 
ulcers and lesions which could have been caused by herpes 
zoster. The physician Herrodotus (AD 100) gave a very 
accurate clinical description of herpes labialis (febrilis) 
but did not use the term herpes. Galen (AD 131-201) applied 
the term to almost any ulcerative condition of the skin and 
Actuarius (12th or 13th Century) to cutaneous ring-worm. 
Interestingly the description of a lesion resembling a 
herpetic infection, including its site of occurence came 
from Shakespeare, in the lines by Mercutio in Romeo and 
Juliet (Act I. Scene IV). 
"O'er ladies lips who straight on kisses dream 
which oft the angry Mab with blisters plagues 
Because their breaths with sweetmeats tainted are. " 
2 
However it is Mab, the fairies' angry mid-wife, who has 
been credited with the ability to cause these lesions, and 
for no greater crime than that"their breaths with sweet- 
meats tainter were. "! 
Richard Morton (17th Century) described fevers ac- 
cdmpanied by herpes but did not specify the site of eruption. 
Later, Daniel Turner (18th Century). also stressed the pre--- 
dilection-of herpes for the face, and. recognised both zoster 
and ring-worm as different forms of herpes. The classifica- 
tion of ring-worm as a herpetic lesion prevailed up to the 
mid-19th Century. Robert Williams (early 19th Century) 
described five species of the genus herpes of which H. zoster. 
H. labialis and H. praeputialis are the same as the conditions 
these terms describe today. Finney and Pringle (late 19th 
Century) recognised two species of herpes, herpes catar-, 
rhalis and herpes zoster, the former being subdivided into 
herpes facialis and herpes progenitalis. Herpes gestationis, 
i. e. herpes associated with pregnancy, was described by 
Gibert in 1840. 
- The first classical decription of genital herpes was 
recorded in 1736 by the French physician Jean Astruc, 
(cited in Hutfield, 1966). He described the lesions as 
being "several hydatids, or watery and crystalline-bladders 
which are filled with lymph that is thin, or thick, opaque 
or diaphanous, alone or mixed with air" and seen in both 
men and women - "These disorders are proper to men alone 
but (mutatis mutandis) are common to women from the same 
cause. " The sites at which he observed lesions in women were 
3 
"the labia pudendi, nymphae, clitoris, and its prepuce, 
as also the caranculae myrtiforme-s at the orifice of the 
vagina" and "focal ulcers on the anus by the unnatural 
use of*venery. " The histology of the herpes genitalis 
vescicle was first described by Unna in 1883 (cited in 
Hutfield, 1966). In addition, having studied 200 cases of 
herpes' progenitalis over a four-year period, he observed 
that it "was a very frequent malady" in women of a 
"particular class"And was a "vocational disease" of women 
rather than men although both sexes were susceptible. 
Herpetic ulceration of the cervix was also noticed in the 
latter part of the 19th Century and Rollet (1869) first 
implicated it as a cause of vaginal discharge. The virus' 
was first isolated from lesions in the eye onto rabbit 
corneal tissue by Gruter (1924), and for the first-time 
from three cases of vulvo vaginitis by Slavin and Gavett 
in 1946. This isolation too was made on rabbit cornea. By 
the mid-1960s the clinical condition and its aetiological 
agent, the herpes simplex virus type 2,, were well documented. 
The findings of Slavin and Gavett were confirmed in three 
more cases of vulvo vaginitis. (Lazar, 1955) and involvement of the 
cervix coincident with vulvo vaginitis (Dooley . 
2t al, 1957; 
Yen et al, 1965) and as an isolated cervicitis (Nigogosyan 
and Mills, 1965) were described. Evidence that the cervix 
is a major site of genital infection in the female was shown 
by Josey et al in 1966. From the descriptions of genital 
herpes by Jean Astruc and Unna, it is clear that they clas- 
sified it as a venereal disease. Direct evidence of 
venereal transmission of the virus was shown by clinical diagnosis 
and virological isolation from sexual contacts of infected consorts 
L. 
(Nahmias et al, 1969; Rawls et al, 1971). As Kessler (1976) 
has pointed out, it was not possible to distinguish without 
a doubt at the time whether these post coital attacks of 
HSV-2 infection were primary attacks (brought on by venereal 
transmission) or recurrent attacks occurring in people with 
endogenous latent herpes virus. These questions caft-now be 
answered with the development of. restriction enzyme tech- 
nology as demonstrated by the work of Buchman et al (1978) 
and Lonýdýle et-al (1978). By this technique different 
variants of the virus within the two main serotypes are 
recognised by the cleavage patterns produced in their 
nucleic acids by various bacterial endonucleases. These 
patterns persist after the virus is propagated in the-- 
laboratory. As an.,. epidemiologic tool this technique is 
analogous to phage typing in bacteriology. I 
B. EPIDEMIOLOGICAL OBSERVATIONS THAT LED TO THE LINKING 
OF HSV-2 TO CERVICAL CARCINOMA 
The role of coitus 
The most important and fundamental-epidemiological clue 
in cervical carcinomaAs the freedom of the virgin vroman ., 
from squamous carcinoma. Domonico Rigoni Sterne, the 
chief physician of the Verona Hospital (Rigoni Sterne, 1842), 
concluded a study on cloistered nuns and married women, 
from which he concluded that the susceptibility of the 
uterus to cervical cancer in the two groups varied according. 
to "the natural exercise of its function. " This was con- 
firmed by several subsequent studies (Table 1.1). Precise 
information on the histology of the rare cases of cervical 
5 
Table 1.1 Studies which examined the incidence of cerv leal 
carcinoma among celibate women. 
REFERENCE STUDY GROUP OBSERVATIONS 
Gagnon (1950) a) Medical records over a Expected number of cases 
in Quebec 20 year period of aPprox 72. 
13,000 nuns representirg Observed number - none. 
in civilian life a popu- 
lation of 65,000 people. 
b) Approx. 3,280 nuns over No cases of cervical 
a 20 year period. carcinoma. 
Towne (1955) a) 574 women with carcin- 37 (6.4%) were unmarried 
Chicago oma of the cervix. 3 were nuns (0-52%). 
b) 20 year siirvey of con- 3 cases of carcinoma of 
vents with a total an- the cervix detected. 
nual average of 10,000 
women. 
Taylor (1959) The'medical records of 3 cases of carcinoma of 
2,700 Catholic nuns in the cervix. The total 
the USA belonging to 3 rate of cancer of the 
orders. genital organs in nuns 
calculated to be 22% 
lower than that for all 
white women. 
Rotkin (1967b) 416 patients with carcin- All had experienced 
oma of the cervix. heterosexual contact. 
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carcinoma occurring in nuns (Taylor et al, 1955; Towne, 1955 
in Table 1.1), i. e. whether they -orere squamous carcinomas 
or adenocarcinomas, is not available. This information 
is important as the epidemiology and aetiology of adeno- 
carcinomas of the cervix with respect to coital factors is 
different to squamous carcinomas (Martin, 1967). 
(b) Age at first coitus 
Early age of onset of sexual activity stands out as 
the single most important coital factor associated with the 
development of carcinoma of the cervix',, (Wynder et al, 1954; 
Rotkin, 1967a and 1967b; Stewart et al, 1966; Boyd and Doll, 
1964; Christopherson and Parker, 1964). - i 
(C) 
-Number 
of coital partners and coital frequency 
is suggestive that multiple coital partners 
is also an important risk factor (Rotkin, 1973)., Studies 
which have examined the influence of coital frequency are 
contradictory, some showing a positive relationship (Boyd 
and Doll, 1964), others not (Rotkin, 1967; Stewart et al, 
1966; Jones et al, 1958). 
Prostitution and venereal diseases 
Prostitutes have been found to carry a four to six 
times greater risk of developing cervical carcinoma than 
women of comparablesocioeconomic groups (Rojel, 1953; 
Pereyra, 1961). A high frequency of previous or concurrent 
venereal disease has been found in women with cervical car- 
cinoma (Levin et al, 1942; Jones et al, 1958; Segi et al, 
1957; Moghissi et al, 1968). 
7 
(e) Socioeconomic factors 
Studies in a number of countries have shown cervical 
carcinoma to be more common in women belonging to low in- 
come groups (England and Wales Kennaway, 1948; United, 
States - Dorn and Cutler, -1959; 
China - Li, 1959; Denmark - 
Clemmeson, 1951', Jamaica - Cummins, 1960). Suggestions 
- offered to explain this increased incidence include 
(i) nutritional deficiency (Wynder, 1968 - subclinical 
vitamin A deficiency), (ii; ) rapid sexual maturity, i. e. 
early initiation of coitus/marriage (Christopherson, 
1965), (iii) poor obstetric care leading to higher incidence 
of lacerated and ulcerated cervices (Lombard and Potter, 1950; 
Smith, 1941), and (iv) a higher protamine to histone ratio 
in sperm head proteins (Reid et al, 1978). 'The freqency 
of genital herpes has been shown. to be higher among lower 
s ocial classes than upper (Ng tt al, 1970) and highest 
among Patients seen in venereal disease clinics (Skinner, 1976)- 
C. CYTOLOGICAL OBSERVATIONS AND TECHNIQUES WHICH CONTRIBUTED 
TO THE LINKING OF HSV-2 TO CERVICAL CARCINOMA 
These cytological observations fall into two broad 
categories: 
(a) Studies which described the cellular manifestations of 
viral-infection, and 
(b) those correlating the changes in exfoliated cervical 
cells with the. histological diagnosis of cancer. 
(a) Cytologicil manifestations of viral infection 
The intranuclear inclusions of herpes were first 
8 
described by Lipschutz in 1921. In. 1949 Blank demonstrated 
hovy Giemsa stained smears of fluid from skin vesicles 
could differentiate herpes simplex, zoster and varicella 
from other bullous lesions. Varga and Browell, (1960) 
reported viral inclusion bodies in the vaginal smears 
taken from 11 women with vaginal erosion. The agent from 
such vaginal lesions was identified as being HSV-2 by 
Sterne and Longo in 1963 following the detection of multi- 
nucleate--cells and type A inclusions in the vaginal, smears. 
The specificity of these cytological changes-for the HSV-2 
virus was demonstrated later by human studies as well as 
studies on mice genitally inoculated with HSV-2 (Naib, et al, 
1973). In these studies the sensitivity of the cytological 
techniques for identifying HSV-2 infection was compared 
with virological isolation and found to be of the order of 
65-75%. 
(b) Exfoliated cervical cell cytology 
In 1943 Papanicolaou and Traut described a method for 
diagnosing uterine cancer by the study of exfoliated cells 
seen in a vaginal aspirate from the posterior vaginal fornix. 
Ayre (1947) suggested the use of a spatula to scrape the 
cervix in the region of the squamocolumnar junction and 
it was found that dysplasia and carcinoma in. situ produced 
cells that could be recognised as abnormal and that sub- 
clinical invasive carcinoma could be discovered in an ap- 
parently healthy cervix by a cytological smear. This method 
furnished a useful means of studying the pathogenesis, 
epidemiology and aetiology of cervical carcinoma more 
9 
Table 1.2 Studies reviewed in Stanley (1958) which prove'd 
the viral aetiology of some malignancies seen in animals. 
REFERENCE HOST TUMOR 























extensively. Furthermore, by the use of this technique, 
cervical carcinoma became the first cancer to be diagnosed 
before the appearance of clinical signs and symptoms. 
Evidence for the viral aetiology of some animal 
malignancies had aCCUmulated from the turn O-f the century 
(Table 1.2). Against this background it did not seem 
impossible that two diseases, i. e. genital herpes of proven 
viral aetiology and cervical carcinoma, both with similar 
epidemiology and involving-the same target organ should 
be linked. Thus the three streams of independent observa- 
tions (page 1) converged in and contributed to the first 
study linking HSV-2 to cervical carcinoma which was conducted 
by Naib, Nahmias and Josey in 1966 at the Emory University 
School of Medicine in Atlanta, Georgia, USA. In this studyp 
62 of approximately 40,000 patients screened for malignancy 
by vaginal smears showed cellular changes compatible with 
herpes simplex infection. On histologic examination of 
cervical biopsy material from 32 of these 62 patients, four 
patients were found to have carcinoma in situ, six patients 
dysplasia and 11 had acute cervicitis - i. e.. 10/62 (16%) of 
patients developed cervical anaplasia (used to denote dys- 
plasia, carcinoma in situand invasive carcinoma). Similar 
studies carried out later demonstrated subsequent develop- 
-ment of cervical anaplasia in a higher proportion of women 
with genital herpes (studies 1 and 2 in Table 1.3), whereas 
in others the proportion was much-lower (studies 3-6, Table 
1-3). The incidence of cervical anaplasia in a control 
population was determined only in study 1 and was 1.6% (4/245)- 
The number that regressed spontaneouslY to - normal cervical 
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cytology was mentioned only byNg tt al (1970) (study 3). 
Thus, although these studies were suggestive of a positive 
correlation between genital herpes and cervical anaplasia, ' 
they lacked proper controls and sufficient follow-up cytology 
for firm conclusions to be drawn. As far as is known, no 
further prospective studies of patients with virologically- 
or cytologically-confirmed genital herpes has been reported 
since. Thereafter, the emphasis of. research shifted to 
retrospective seroepidemiologic studies in a number of 
countries (Table 1.4). Although they yielded quicker results 
they failed to yield precise information for reasons discussed 
below. 
The studies listed in Table 1.4 varied in the herpes 
0 
virus strain used and the serologic technique employed. 
Of the nine assays listed in the table, the plaque reduction 
test, the microneutralization test and the kinetic neutral- 
ization test, were compared by Rawls et al (1970a) and 
found to agree in 83% to'89% of the"determinations. - When 
compared with controls, a higher proportion of women with 
cervical anaplasia had antibody patterns which were thought 
to represent previous infection with HSV-2, with the excep- 
tion of patients with cervical anaplasia in study no. '28 
(Israel), no. 18 (Formosa), no. 26 (Colombia) and no. 20 
(Japan). The sera of patients in studies 28,13 and 26 and 
in no. 30 (New Zealand) were tested by the same technique 
and laboratory in Houston, USA as sera in study no. 24- 
(Uganda), in studies no. 5 and 6 (Negro and Caucasian 
patients in Houston, USA) and no. 7 (Caucasian patients) in 
Virginia, USA. Since in studies 5,6 and 7a significantly 
14 
higher proportion of patients with cervical carcinoma 
were shown to possess HSV-2 antibodies, the lack of similar 
results among patients from Israel, Taiwan and Colombia 
cannot be attributed to difference in laboratory or tech- 
nique. The results on sera from New, Zealand, (studY 30) 
were in agreement with results observed in New Zealand 
sera in a previous study (no- 31) i. e.. the proportion of 
invasive carcinoma patients with HSV-2 antibodies was low 
ft 
and not much higher than the proportion of controls having 
HSV-2 antibodies. Colombia has one of the highest incidence 
rates for cervical cancer in the world (Table 4.4). Al- 
though study no. 26 showed the prevalence of HSV-2 anti- 
bodies was similar among patients and controls in Colombia, 
it is of interest that study no. 27, employing an immuno- 
fluorescence technique, showed that patients had higher 
titres than controls. Among patients from Israel, a sub- 
sequent study (no. 29j showed a higher proportion of 
patients than controls to possess HSV-2 antibodies but this 
proportion was even lower (15.4%) than that observed in the 
New Zealand studies (31-35%). Within the studies in which a 
higher proportion of cervical carcinoma patients were found 
to possess HSV-2 antibodies, there was considerable variation 
in the porportion of patients who were considered to be HSV-2 
positive, e. g. 15% to 100%. This considerable variation 
in the prevalence of HSV-2 antibodies in the above sero- 
epidemiological studies precludes drawing definite conclusions 
regarding the aetiologic role of the virus in cervical car- 
cinoma. The serologic assays used in these studies are only 
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for they detect antibodies to type-common as well as 
type-specific antigens. It has been shown by McClung et I al 
(1976) employing a 
51Cr 
release assay, by Skinner et al 
(1974) employing immunoprecipitation, and by Vestergaard 
(Personal communication) by crossed immune electrophoresis 
that the-predominant antibody activities following any 
HSV-1 or HSV-2 infection are to type-common - antigens. 
McClung ftt al (1976) showed that 80-90% of antibody activity 
was directed towards type-common antigens and only 10-20% 
to type-specific antigens. He also observed that the. type- 
common antigens of the two viruses were not identical 
because serum raised against the HSV-2 virus bound at similar 
rates to cells infected with either HSV-1 or HSV-2, in contrast 
to'serum raised against HSV-1 which reacted more slowly with 
cells infected with HSV-2 than to cells infected with HSV-1- 
Therefore, since a proportion of the' antigens on the cell 
surface are similar to those'on the viral envelope (Lesso 
et al, 1970) it may be expected that whereas a serum with 
anti-HSV-2 antibody will have equal avidity for HSV-1 and 
HSV-2, a serum with anti-HSV-1 will have greater avidity 
for HSV-1, i. e. this could result in the inability to 
recognise low titre anti-HSV-2 antibody by kinetic neutral- 
ization assays which are a measure of both antibody avidity 
and antibody quantity. Smith et al (1972a) found by 
51Cr 
release assay that production of HSV-2 specific antibody 
was greater among patients without prior HSV-1 infection. 
Skinner et al (1976) found neutralization test capable of 
predicting with 95% confidence limit the immunising virus 
type only in seven of 40 antisera of known antitype. It is 
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expected that there would be variation in levels of exposure 
to the two viruses in different socioeconomic settings and 
in different countries. This, in combination with the nature 
of the immune response described above to the two viruses, 
may account for the wide variation observed in these case 
controlled studies. Attempts to overcome the obvious 
disadvantages of neutralization tests has leý to the develop- 
ment of a complement-fixation assay, employing type-specific 
antigen -(Skinner et al, 1976), a solid phase radioimmunoassay 
(RIA) based upon absorption of sera separately with uninfected 
cells, HSV-1 infected cells and HSV-2 infected cells, fol- 
lowing which the absorbed sera are tested for residual 
antibody (Forghani et al, 1975), and an enzyme linked- 
immunoabsorbent assay (ELISA) employing HSV-1 and HSV-2 
specific antigens (Vestergaard et al, 1977b; Grauballe and 
Vestergaard, 1977). The ELISA technique may be as sensitive 
as RIA (Voller et al, 1976). 
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SEVEN CRITERIA WHICH IF FULFILLED WOULD PROVIDE EVTDENCE 
THAT HSV-2 WAS AETIOLOGICALLY RELATED TO CERVICAL CARCINOMA 
The earlier prospective and retrospective studies 
described were very suggestive that HSV-2 was associated with 
cervical carcinoma. However they yielded no information as 
to whether the relationship was of a causal nature. Rawls 
et al (1977) have proposed ciriteria, which if fulfilled 
would provide evidence that a particular virus was the caus- 
ative agent of a particular malignancy. In this thesis 
these criteria have been modified. The evidence linking 
HSV-2 to cervical carcinoma has been weighed against these 
modified criteria in order to assess to'what extent they 
have been fulfilled so far. 
The epidemiological characteristics of women with 
cervical carcinoma and genital herpes should be similar. 
2. Women with cervical carcinoma wo'uld be expected to have 
a higher frequency or higher titres of antibody to virus 
specified antigens and assays of cell mediated immunity C. 
should show positive or negative correlation. 
The virus should be, shown to cause cervical lesions 
which should occur well. before the onset of neoplastic 
change and a higher incidence of the tumor should be 
observed in these women. 
Similar viruses of the herpes group should cause 
naturally occurring malignancies in other animals. 
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The virus should be able to induce tum6rs in its 
natural host or in similar species and be able to 
transform cells in culture. The transfor . med cells 
in turn should be similar to tumor'cells cultured '' 
in vitro and be able to induce tumors similar to 
naturally occurring ones. 
There should be biological evidence linking one to 
the--other, i. e. it should be possible to detect. viral 
-, products_(viral antigen), enzymes and nucleic acid 
in the tumor. 
Individuals protected from developing genital herpes 
infection should demonstrate a lower incidence of 
cervi6al anaplasia in later years. 
CRITERION NUMBER 1 
THE EPIDEMIOLOGICAL CHARACTERISTICS OF WOMEN WITH CERVICAL 
CARCINOMA AND GENITAL HERPES SHOULD BE SIMILAR 
Evidence for the venereal mode of transmission of the 
virus is reviewed on page 3 and from the description of 
the epidemiological features of the malignancy (pagw. 4-7) 
it is evident that the epidemiological features are similar. 
one epidemiological feature, however, requires further 
resolution, i. e. the mechanism whereby early ageýof first 
coitus acts as a high risk factor. Two possibilities 
have been suggested: 
The importance ofýbiological factors during early 
adolescence 
26 
From the colposcopic and laboratory. studies of the 
cervices of 14,000 females of all ages (Coppleson and Reid, 
1967), adolescence and first pregnancy were identified as 
periods of active squamous metaplasia. in the cervix (page 73). 
Their studies and those of Singer (page 73) on the differ- 
ences in the transformation zone of sexually active 
adolescents and virgin adolescents emphasise theýimportance 
of biological factors during a period of active metaplasia, 
which malýes the cervical epithelium more susceptible to the 
action of a sexually transmitted agent and results in the C) 
development of an abnormal transformation zone. Since, an 
abnormal transformation zone is suspected of harbouring 
cells with neoplastic potential, this provides one explana- 
tion for the importance of early age of first coitus as a: 
high risk factor. 
The importance of behavioural factors 
The second suggestion has come from Rawls et al (1976) 
that women who begin sexual activity at an early age also 
have multiple sexual partners. 
CRITERION NUMBER 2. 
WOMEN WITH CERVICAL CARCINOMA WOULD BE EXPECTED TO HAVE A 
HIGHER FREQUENCY OR HIGHER TITRE OF ANTIBODY TO VIRUS 
SPECIFIED ANTIGENS, AND ASSAYS OF CELL MEDIATED IMMUNITY 
SHOULD SHOW POSITIVE OR NEGATIVE CORRELATION 
Following the earlier case control studies employing 
mainly neutralization assays, 'later studies examineýd antibodies 
to antigens other than those involved in neutralization. 
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Antibodies to AG-4 
Aurelian et al (1973) harvested an antigen (AG-4) -- 
four hours after infecting cells at low multiplicity 
(0-5 pfu cell) and used this to detect antibody by means 
of a microcomplement fixation test. Antibodies to AG-4 
were detected in the sera of 35% of patients with dysplasia, 
65% of patients with carcinoma in situ and 35% of patients 
With invasive carcinoma, but only in 12% of controls. 
These antibodies belonged to the IgM class, and disappeared 
with--successful treatment and reappeared with recurrence of 
the cancer. It was claimed that thesp. antibodies wer e riaýassociatecj 
with malignancies at other sites. The antigen was character- 
ised as a molecule of molecular weight 161,000 which co-- 
migrated'on polyacrylamide gel with: a minor virion protein 
(Aurel'ian and Strnad, 19706) - The antigen y., as present in 
the cytoplasm as well as on the cell surface of infected 
cells. The reactivity of 8 of 10 tumor tissue biopsy ex- 
tracts, (Aurelian et al, 1977) with AG-4 positive sera 
constituted the evidence that AG-4 was present in cervical 
cancer cells. Kawana and his colleagues (1976) detected a 
lower prevalence of AG-4 antibodies among Japanese women 
with cervical cancer and suggested that this might be ex- 
plained by th'efre'quent isolation of HSV-1 from cases of 
genital'herpes in Japan and that HSV-1 too may be related 
to cervical carcinoma. 
Notter and Docherty (1976a) confirmed the, high-pre- 
valence of AG-4 antibodies (78%) among cervical'carcinoma 
patients but in contrast with earlier reports, detected, the 
antibodies in one-third of patients rith, extra-genital-non- 
squamous malignancies and two-thirds of patients with non- 
, genital squamous malignan i cies 
28 
Antibodies to VP-134 
VP-134 is. a non-virion polypeptide described by Anzai 
, ft-t 
2_1 (1975) which is synthesised early in the infectious 
cycle and has a molecular weight of 134,000. These workers 
demonstrated quantitatively employing a method of immune 
precipitation that sera from cervical cancer patients pre- 
cipitated more VP-134 than sera from patients with breast 
carcinoma or from women who did, not have cancer. 
Antibodies, to NVA-TAA-(non-virion antigen-tumor associated 
antigen) 
This is a soluble membrane antigen which was first 
isolated from the supernate of sonicated vaginal, vulval, 
10 cervical and lip cancer cells, which cross-reacted with an * 
antigen on cells infected by herpes simplex virus (Hollins- 
head et al, 1972; Hollinshead and Tarro, 1973). - A high 
proportion of patients with a varie. ty of squamous cell 
tumors, including patients with cervical, carcinoma possessed 
antibody to these antigens, (Hollinshead and Tarro, 1973)- 
This antigenIs discussed in detail on page 282. 
Evidence for a cross-reacting antigen between HSV-transformed 
cells and squamous carcinoma cells 
(Notter and, Docherty, 1976b) 
Antigen prepared from HSV-1 and HSV-2 transformed cells 
were tested in a microcomplement fixation assay with sera 
from patients with squamous carcinoma. Ninety-four per cent 
of the sera reacted with-the. HSV-1 transformed cell antigen 
and 84% with HSV-2 transformed cell antigen., The proportion 
of sera from patients with other non-squamous malignancies 
which reacted with these antigens was similar to that among 
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controls with no malignancy. When sera from all individuals 
(normal and cancer) were tested against. similar antigen pre- 
pared from CMV transformed cells, no significant reaction 
pattern was observed. 
Cytotoxic antibodies 
Women with progressing cervical lesions were found to 
have lower complement-dependent cytotoxic. antibody titres to 
HSV-2 infected cells and HSV-2 transformed cells than women 
with_regressing-lesions (Thiry ftt al, 1974) 
Christenson (1977) found that patients in the terminal 
stages of cervical carcinoma had higher cytotoxic antibody 
titres to cell lines derived from squamous cell tumors of 
the cervix than to HSV-2 infected cells. 
The titres of cytotoxic antibody to, HSV-2 infected cells 
thus appear to be inversely related to the severity. of disease. 
These results are similar to the prevalence in these patients 
of antibody to HSV-2 infected cells, as determined by the 
mixed haemadsorption assay. 
-Christenson 
and Espmark (1976) 
detected decreasing prevalence of these antibodies with 
increasing stage of disease. 
Cell-mediated immunity (CMI) to HSV-2 antigen in patients 
with cervical carcinoma 
Sprecher-Goldberger et al (1975) detected a. non-specific 
cell mediated immunosuppresion in women with cervical car- 
cinoma when compared with control women as judged by phyto- 
haemagglutinin (PHA) stimulation of the whole white cell 
fraction from blood samples. Women who had been treated 
had indices of stimulation which were similar to those of controls. 
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In contrast with the results with PHA stimulation, indices of 
stimulation by HSV-2 and by HSV-2 transformed cells were higher in 
cervical carcinoma patients than controls. Here too stimulation 
indices of treated patients were similar to those of controls. 
Although the results of seroepidemiological studies and the 
studies on cell mediated immunity are suggestive of an aetiologicalL 
role for the virus, the association may also to a large extent 
be explained if a) one postulates that HSV-2 is a co-variable 
of the real carcinogen, or b) that the virus is a secondary 
invader of tumor tissue which favours its replication. While 
studies up till-now have left the former possibility unanswered, 
evidence is available which argues against the. latter possibil- 
ity (see Criterion Number 3 below). The presence of a cross- 
reacting antigen between squamous carcinoma cell and HSV-2 
infected and transformed*cells could also confuse the results 
of both antibody assays and assays of cell. mediated immunity, 
e. g. it may explain higher titres of antibody to HSV-2 in- 
fected cells among cancer patients compared to controls, as 
well as increasing titres of antibooy with increasing stage 
of disease, if the particular assay believed to be HSV- 
specific is a test of antibody to this cross-reacting 
antigen as well. 
CRITERION NUMBER 
THE VIRUS SHOULD BE A PROVEN CAUSE OF CERVICAL LESIONS, WHIC 
SHOULD OCCUR WELL BEFORE THE ONSET OF NEOPLASTIC CHANGES AND A 
HIGHER INCIDENCE OF THE TUMOR SHOULD BE OBSERVED IN THESE WOMEN 
The cervix as a frequent site of infection in'genital herpes 
is well-documented (page 3 Naib et. al (1969) reported 
the mean age of women with genital herpes, dysplasia, 
carcinoma in situ and invasive carcinoma to be 20,25,31 
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and 48 respectively. This argues against the possibility 
that the virus is a secondary invader of tumor tissue and 
also provides evidence that cervical lesions occur before 
the onset of neoplastic change. Further evidence for this 
is seen in a study by Catalano and Johnson (1971) who 
demonstrated HSV-2 specific antibody in the sera of five 
of 14 women who developed carcinoma in situ one to eight 
years after that particular sample of serum had been collect- 
ed. Rawls and Gardner (1972) demonstrated that 80% of 
women with normal cervical cytology were infected when 
exposed to men with penile herpes. Since the infectivity 
rate of normal cervical epithelium is high it appears un- 
necessary to postulate previous anaplastic change to explain 
the high prevalence of HSV-2 antibody in women with carcinoma 
of the cervix. However, the possibility that (in a woman 
harbouring the latent virus) the neoplastic epith_elium is 
more suscepti ble t0 recurrent attacks (clinical or sub- 
clinical) has not been explored. This possibility could 
also provide explanations for higher titres as well as fluc- 
tuating antibody with tumor progression, treatment and recur- 
rence. As far as is known and suprisingly, there is no 
study which has-examined the frequency of isolation of virus 
from tumor-bearing cervices in contrast with normal cervices. 
CRITERION NUMBER 
SIMILAR VIRUSES OF THE HERPES GROUP SHOULD CAUSE NATURALLY 
OCCURRING MALIGNANCIES IN, OTHER'ANIMALS 
There is no malignancy in animals which is analogous 
to squamous carcinoma of the cervix. However, other members 
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of the Herpes group of viruses can induce malignancies in 
animals and the Epstein-Barr virus has been strongly linked 
to two human malignancies - Burkitt's lymphoma. and naso- 
pharyngeal carcinoma. 
Renal Adenocarcinoma of Frogs 
The Lucke renal adenocarcinoma is histologically sim- 
ilar to the equivalent human tumor and occurs naturally in 
Rana pipiens, the leopard grog (Lucke, 1952). It exists in 
two states which are temperature-dependent. In winter 
tumors. contain herpes virus-like particles whereas in the 
summer they do not. However, virus specific m-RNA 
has been detected in summer tumors (Collard et al, 1973a) 
6. explants from which develop virus nucleic acid-and virus 
antigen and infectious,, particles when incubated in vitro at 
7-50C (Breidenbach et al, 1971). These findings indicate 
that although virus genetic information necessary for pro- 
duction of structural proteins is temperature-ýdependent, 
information necessary for'cell transformation continues 
independently of temperature. 
Marek's Disease of Chickens 
This is a malignant lymphoma-leukaemia of T-lymphocytes 
which is developed by chickens infected with Marek's disease 
virus (MDV) shortly after they are hatched. It is prevented 
by'vaccination of day-old chicks (Jose, 1978). There is 
evidence to suggest that the MDV may activate endogenous 
C-type RNA leukaemia virus but it it not known if this RNA 
virus is essential for the development of the disease 
(Frankel and Groupe, 1971). 
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Lymphoma of Guinea Pigs 
The guinea pig; herpes virus was isolated from leukaemic C> 
lymphoblasts and normal lymphocytes from a strain of guinea 
pigs with a high incidence of spontaneous leukaemia (Hsiung 
et al, 1971). An RNA virus has been found to be associated 
with these leulaemic cells and neoplastic disease could be 
induced only in guinea pigs inoculated with both viruses 
(Hsiung and McTighie, 1976). 
Malignant Lymphoma of Monkeys 
Herpes virus siamiri (HVS) and Herpes virus ateles (HVA) 
are not pathogenic in their own hosts, the South American 
squirrel monkey. and the South American spider monkey respective- 
a 
ly. However, both viruses induce a lymphoproliferative dis- 
ease with leukaemia of the T-cell type in New World monkeys, 
e. g. cotton topped and white lipped marmosets and owl mon- 
keys, and in New Zealand white rabbits (HVS). Virus particles 
and antigens have not been detected in malignant cells ob- 
tained directly from the tumors but were detectable in a 
small proportion (1-5%) of tumor cells when explanted into 
tissue culture. HVS and HVA genome has been demonstrated in 
the neoplastic lymphoblastic cells (reviewed in Jose, 1976). 
Burkitt'S Lymphoma (BL) 
Lhe concept of the viral aetiology for Burkitt lymphoma T 
has gained strength on the following evidence. 
i) The virus was first detected in the culture fluid of a 
cell line established from a Burkitt lymphoma 
(Epstein et al, 1964). 
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ii) It has in vivo-oncogenic potential in non-human 
primates (Werner et al, 1972). 
iii) BL patients have higher levels of antibody against a 
wide range of EBV determined antigens, e. g. -EBV capsid 
antigen, early antigen, and membrane antigen (Epstein, 
1978). Also viral antibodies vary with disease 
events, e. g. a fall in antibody titre to late membrane 
antigens have been noticed four to six months prior to 
recurrence (Klein, 1975). 
iv) Every tumor cell has been found to carry virus DNA 
(Epstein, 1978b) and EBV determined nuclear, antigen 
has often been detected in BL cells (zur Hausen, 1970)- 
ft 
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Nasopharyngeal Carcinoma (NPC) 
This is the commonest malignant tumor in Chinese males 
and the second commonest in Chinese females (Shanmugaratnam, 
1967). The tumor arises in the post nasal space, and more 
viral genome has been found in the epithelial tumor cells 
than the lymphoid cells (Klein et al, 1974). Also, inocula- 
tion of tumor cells into athymic mice results only in the 
outgrowth of epithelial cells (Trumper et al, 1977) sug- 
gesting, the epithelial cell to be the primary malignant cell. 
Genetic factors-appear to play a role in the pathogenesis of 
NPC as an association has been shown between HLA types 
A2 -B Sin 2, BW 17-AW 19, and BW17-A blank, and the tumor 
(Simons et al, 1978). On the other hand although NPO has C) 
a marked geographic prevalence, no definite-environmental 
co-factor has yet been identified as'influencing its patho- 
genesis. However a study of Chinese immigrants from South- 
east Asia living in Australia and the United States has shown 
that environmental factorsmust-play a part. The first 
generation of these immigrants had the same high incidence 
of NPC as the Chinese in China. A lower incidence of NPC 
was seen in Chinese descendents born in Australia and the 
USA which was-nevertheless higher than that of the sur- 
rounding caucasian. population (Epstein and Achong, 1977). 
Thus it would appear likely that EBV acts with some as yet 
unknown environmental co-factor, on a susceptible genetic 




THE VIRUS SHOULD BE ABLE TO INDUCE TUMORS IN ITS NATURAL 
HOST OR IN SIMILAR SPECIES AND BE ABLE TO TRANSFORM CELL 
IN CULTURE. THE TRANSFORMED CELL IN TURN SHOULD BE SIMILAR 
TO TUMOR CELLS CULTURED IN VITRO AND BE ABLE TO INDUCE 
TUMORS SIMILAR TO NATURALLY OCCURRING ONES. 
For obvious ethical reasons the ability of the virus 
to induce-tumors in humans cannot be experimentally tested. 
The alternative of proving tumor induction in animals has 
been attempted but has remained a relatively ill developed 
field. 
i) Experiments in Hamsters 
The inoculation of newborn hamsters with HSV-1 and HSV-2 
intravaginally with virus doses greater than 103 TCD50 
resulted in nearly 100% mortality. About 75% survived with 
lower doses of live virus-or UV-inactivated virus. Two to 
three per cent of HSV-2 infected, but not HSV-1 infected, 
animals developed undifferentiated sarcomas 5-28 months after 
inoculation (Nahmias et al, 1970b). Neither HSV-2 antibody 
nor viral antigen could be demonstrated in the serum or 
tumors of these animals. However, HSV-2 antigens were detect- 
ed in two transplanted tumors (note similarity in this respect 
to malignant lymphoma in monkeys). These tumor explants were 
examined for C-type particles but none were detected. 
ii) Experiments on Mice 
Adenocarcinomas have been observed in a few mice fol- 
-lowing genital inoculation of formaldehyde treated HSV-2 
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(Wentz et al, 1975). Also a few cases of squamous carcinoma 
in mice which were inoculated genitally with non-inactivated 
HSV-2 while they were being given female hormones (Munoz, 
1973)- In the latter experiments the administration of 
hormones confused the interpretation of these results. 
Experiments on Cebus Monkey 
Nahmias et al (1971b) demonstrated that cebus monkeys 
inoculated vaginally with HSV-2 developed genital infection 
which was similar to that developed by women. Similarities were 
seen in the incubation period, clinical-appearance-of lesions, durp 
tion of virus recovery, and the development of serum neutralising 
antibodies. * On reinfecting these monkeys 6-i: 2 vreeks following init 
ial inoculation, -'3 of 7-monkeys developed lesions despite having 
high neutralising antibody titres.. However*in th-Is study or in 
the subsequent study conducted on cebus monkeys, it is not stated 
whether-these animals once infected suffered from recur- 
rent infection as-women do. Similar attempts at infecting 
squirrel monkeys and rhesus monkeys. were unsuccessful. - 
Palmer et al (1976) reported on an ongoing study 
investigating the oncogenic potential of HSV-2 in 301 fe- 
male, cebus monkeys. The virus was inoculated intraepithel- 
ially into the cervix every six months. Control animals 
received an inoculation of 10% salicylic acid in mineral 
oil which produced severe lesions which subsequently healed. 
Sixty-six virus recipients have so far been followed up over 
a period of 14 or more months up to the time of reporting. 
Thirteen (19.7%) developed mild-moderate dysplasia. These 
dysplastic lesions persisted up to 12-32 months. The results 
on the salicylic acid inoculated animals were not reported. 
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These results -are encouraging from the point of view 
of establishing a suitable animal model for the study of 
cervical carcinoma. However no firm conclusions can be 
made as to the oncogenic potential of HSV-2 until the re- 
sults of follow up studies show that the animals develop 
malignant lesions. Because in these experiments inoculation 
of-virus was repeated every six months it is impossible to 
judge if dysplasia would have regressed with time. This is 
an important question among humans, i. e. whether the dys- 
plastic lesions which have been observed in greater numbers 
among women with genital herpes are a transient feature. 
These experiments may have been designed better by inoculat- 
ing, some animals repeatedly and others only once. 
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Transformation of Cells 
Transforming assays are usually carried out on non- 
permissive cells in which transforming functions are expressed 
but replication blocked. Since no cultured cell which is 
totally non-permissive to HSV-1 and HSV-2 is available, 
the earliest experiments on transformation by these two, 
viruses employed viruses inactivated either. by ultraviolet 
irradiation or a combination of visible light and neutral 
red (Studies 1-5, Table 1-5). By these methods viral 
replication was blocked but transforming activity was not. 
Other methods'employed to evade productive infection of 
cells included growing the cells at non-permissive tempera- 
tures (Study 6, Table 1-5) and the use of temperature 
sensitive mutants (Studies 7,8 and 9). Recently, mechanical- 
ly sheared DNA has been used as the process of mechanical 
\ 
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Table 1.5 Transformation of-cells by HSV-1 and HSV-2 
REFERENCE CELL LINE ONCOGENICITY HERPES ANTIBODIES 
AND VIRUS IN ANIMALS AND 
HERPES-ANTIGENS 
IN TUMORS 
1. Duff and Rapp, Primary hamster Induced fibro- Low levels of 
1971 a and b. UV embryo fibro- sarcomas in ham- neutralising anti- 
inactivated HSV-2. blasts. sters, 10-16 body against HSV-1- 
weeks after in- and HSV-2 in the 
oculation. serum of tumor- 
bearing animals. ' 
2. Rapp and Duff, Primary hamster Adenocarcinoma- Ditto. 
1973; Duff and embryo fibro- like tumors in 
Rapp, 1973- UV blasts. 47% of newborn 
inactivated HSV-1 hamsters, in 
3-11 weeks. 
3. Kutinova et al, Continuous line Cells became more Not done. 
1973. - UV-inactiv- of hamster cells oncogenic - only 
ated HSV-2. which had onco- 1/10th the prev- 
genic potential. ious dose being 
sufficient for 
tumor formation. - 
4. Boyd and Orme, Non-oncogenic 75-80% of mice-. Tumor-bearing ani- 
1975. UV inactiv-, M-like line ingected with mals developed 
ated HSV-2. of Balb/C mouse 10 cells neutralising anti-, 
cells. developed body HSV-2 antigen 
fibroblasts. in cytoplasm of 




2t al, Hamster embryo Not tested Cytoplasmic fluor- 
1973- Visi'Ffe fibroblasts. escence in trans- 
light and neutral formed cells test- 
red inactivated ed against anti- 
HSV. HSV hamster serum. 
6. Munk and Darai, Human embryo liot inoculated Viral antigens 
1973; Darai et al, - - 
lung cells. into animals. demonstrated in 
tjv- 1975. Unina7c Cell line main- the cytoplasm of 
ated HSV-2 tained for over the cells. 
8 days at 420C. 65 passages. When 
subsequently 6n- 
cubated at 37 C, 
unable to undergo 
replication al- 
though viral DNA 
was presentIn 
the cells. 
7. Macnab, 1974 Rat embryo cell Oncogenic in Viral antigens de- 
and 1975. ts line. rats. tected in the 
mutants of HSV-1. -cytoplasm and the 




Table 1.5 (cont'd) 
REFERENCE CELL LINE ONCOGENICITY HERPES ANTIBODIES 
AND VIRUS IN ANIMALS AND 
HERPES ANTIGENS 
IN TUMORS 
3. Macnab, 1979. Rat embryo Fibrosarcoma Perinuclear and 
ts mutants of HSV-2 cells in immunosup- cytoplasmic fluor- 
and UV irradiated pressed rats. escence in the 
HSV-2. Latent period cells of tumors 
as long as 2 which developed as 
years in some long as 36 weeks 
cases. following inocula- 
tion. 
9. Takahashi and Hamster embryo Viral antigens de- 
Yamanishi, 1974. cells and tected in the 
HSV-2 ts mutants. human. cytoplasm of 5 10% 
of transformed 
cells. 
10. Wilkie et al, Primary rat 
1974. fdech7a-RiZaily embryo cells. 
sheared HSV-1 DNA. 
11. Jariwalla et Syrian hamster Produced fibro- HSV type common 
al. 1978. Cal-Flum, embryo. sarcoma in 100% antigen (Ag-e) 
phosphate co-pre- 
-of 
newborn demonstrated in 
cibitated RSV-2 hamsters. the transformed 
DNA. cells and tumor 
cells. 
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shearing eliminates the ability'of' viral DNA to replicate, 
(StudieslO and 11). Virus specific RNA (Collard et al, 
1973b) and 1-3 copies per cell of viral DNA sequences 
representing 8-32% of the genome (Frenkel et al, 1976) have 
been demonsýrated in some of'the-HSV transformed cell lines 
but not in others (Davis and Kingsbury, 1976). Transforma- 
tion experiments up to date have proved that the virus is 
capable under certain conditions of bestowing, on cells 
properties that are associated with human malignant cells, i. e. 
The ability to produce neoplasms in animals 
Of being "immortal" 
iii) Of being able to grow-in soft agar 




This property of the-virus provides a-good foundation 
for the hypothesis that it may be a cause of human malignancy. 
It also provides a model -f or virus genome, _, 
and cell genome 
interaction in a malignant cell. In, addition the production,,., 
of tumors in animals by the inoculation of transformed cells 
may provide information about host factors which are important 
in tumor'development. 
Flowever, few transformation experiments have, been per- 
formed on human cells (Study 6) and these were not, tested 
for their oncogenic potential in animals. -The physical 
state of the viral DNA_within'the transformed cell too has 
not been. established. The rat model (Study 8) is. interesting 
as the latent period between inoculation of transformed cells 
and tumor development was as long as two years in some rats. 
Elucidation of the mechanism whereby_oncogenic potential is 
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conferred on the rate embryo cell by the virus would be 
relevant to the possible mechanism (if be) in cervical 
carcinomat which also often has a long latent period in 
development. This aspect of long latency in the rat model 
is being studied further by these workers. 
CRITERION NUMBER 
THERE SHOULD BE BIOLOGICAL EVIDENCE LINKING ONE TO THE OTHER, 
I. E. IT SHOULD BE POSSIBLE TO DETECT VIRAL PRODUCTS (VIRAL 
ANTIGEN)-ENZYMES AND NUCLEIC ACID IN THE TUMOR 
Viral antigens in cervical carcinoma cells 
AG-4 (page 27) and NVA-TAA (page 28') are two HSV 
antigens-which have been demonstrated in cervical carcinoma 
tissue and which have been subsequentlý characterised. So " 
far, AG-4 has been reported as detected in eight tumor 
biopsies. NVA-TAA is not specific for cervical carcinoma 
and has beeý extracted from lip, 'v . aginal and vulval squamous 
cancers as well. 
Royston and Aurelian (1970b) demonstrated herpes sim- 
plex'-antigen in the exfoliated cervical cells of patients 
with cervical, anaplasia by a direct"fluorescent technique 
and an indirect-fluorescent technique employing rabbit anti- 
serum raised against HSV-2. Exfoliated cells from 21 of 26 
patients with dysplasia or carcinoma in situ and 7 of 10 
patients with invasive carcinoma gave positive fluorescence 
with rabbit anti-HSV-2 serum in contrast with negative 
fluorescence'observed in specimens of exfoliated cervical 
cells from 10-women with normal cervices. 
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Pacsa et al (1977) conducted similar experiments using 
an indirect fluorescent test. The study group consisted of 
a representative sample of women. Herpes antigen was detect- 
ed in a significantly high proportion of women with cervical 
cancer (91.8%) (Table 1.6). Similar results were obtained 
by Adelusi et al (1976). 
Table 1.6 Incidence of herpes simplex virus capsid antigen 
in exfoliated cervical cells of virgins and sexually active 
women. From Pacsa et al (1977). 
- -7 
GROUP NO. TESTED NO. OF POSITIVES 
1. Virgins 1o6 00 
2. Women with normal 710 64 9.1. 
cervical epithelium 
3. Women with non- '205 79 38-0 
malignant disorders 
4. Patients with cervical 62 35 -56.4 dysplasia 
5- Patients vhth invasive 49.45 91.8 
cervical carcinoma 
No further work has'been reported which has attempted 
to characterize these antigens. Although monospecifi: c bera 
to a number of herpes polypeptides have been prepared in 
several-laboratoribs, attempts have not been made to detect 
viral polypeptides in biopsied tumor tissue., 
Viral Nucleic Acids in Human Tumors 
Frenkel et al (1972) reported the detection of HSV-2 
t 
specific DNA and RNA in one cervical carcinoma. The segment 
44 
of DNA detected represented 39% of the HSV-2 genome. Al- 
though attempts were made by other workers to repeat these 
experiments (zur Hausen et al, 1974; Schulte-Holthausen, 
1975; Pagano, 1975) they yielded no success. 
CRITERION NUMBER 
INDIVIDUALS PROTECTED FROM DEVELOPING GENITAL HERPES INFECTION 
SHOULD DEMONSTRATE A LOWER INCIDENCE OF CERVICAL NEOPLASIA, IN 
LATER YEARS 
This is a logical and an attractive idea. However 
conducting, such experiments is fraught with difficulty. 
There is current speculation on the possible protection 
that previous HSV-1 infection may confer on the development 
of genital herpes. These are described on page105 of the 
Introduction, and discu'ssed further on page 318 of the 
Discussion. 
Ij 
Thus none of the criteria have so, far been cpmpletely 
satisfied. The_epidemiological features. of genital herpes 
and cervical carcinoma are almost identical but the 
significance of the early''o'nset of coitus in the pathogenesis 
of the malignancy in relation to the herpes hypothesis needs 
11o be clarified. 
Retrospective and seroepidemiologic studies and pro- 
spective studies strongly suggest that HSV-2 may be aetio- 
logically related but the question of whether the virus is a 
co-variable of the real carcinogen has not been answered. 
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Experiments on cebus monkeys, although encouraging, 4: 2 1 
are so far inconclusive as none of the monkeys have devel- 
oped a pre-invasive or invasive lesion. It may provide a 
suitable experimental model for the study of co-factors, 
It L. ut as an experimental model is, expensive. 
The failure to demonstrate the herpes genome in tumor 
cells may reflect the insensitivity of currently available 
probes in detecting fractions of the genome. - In adenovirus 
transformed cells as little as 4-5% of the genome is present 
in transformed cells '(Pitot, 1978). However two techniques 
which have recently been developed may help to increase the 
sensitivity of molecular probes: 
41 Restriction enzyme technology 
ii) Transformation of cells with DNA fragments. 
If a particular fragment of DNA is found to consistently bring 
about oncogenic transformation of cells, it would enable 
sensitive probes to be prepared from such fragments in order 
to identify similar genetic material in tumor cells. This 
technology is at present being rapidly developed. 
Another approach would be to identify the part of the 
genome which codes for tumor associated, antigens such as 
AG-4, Vý134, and others demonstrated by immunofluorescence 
(pages 42&. 43)and to search f or this part of - the genome in 
tumor cells. A number of herpes polypeptides have been mapped 
on the herpes genome in Roizman's laboratory (page 61). 





Since the epidemiological features of cervical carcinoma 
point to a venereally transmitted agent as the aetiologic 
agent, other such agents have to be considered (Table 1 -7) - 
This aspect of cervical carcinoma has remained a neglected 
field. 
OTHER VENEREALLY TRANSMITTED AGENTS 
Smegma 
The increased incidence of carcinoma of the penis in 
uncircumcised males (Bleich, 1950) led to the consideration 
of smegma as a possible aetiologic agent. The evidence from C, 
experiments conducted in mice is contradictory (reviewed by 
0 
Coppleson, 1969) and has failed to prove its mutagenic action. CD. 
In addition, two studies showed no relationship between t)je 
occurrence of carcinoma of the cervix and" the circumcision 
status of the husband (Aitken-Swan and Baird, 1965; Terris 
et al, 1972). 
S-Dermatozoa 
The possibility of spermatozoa being mutagenic was I 
first suggested by Reid (1964). These studies investigated 
the role of sperm head DNA (Coppleson and Reid, 1967) as well 
as sperm head proteins (Reid et al, 1978). ' The development 
of the transformation zone of the cervical epithelium has 
been described on page 73 When semen was cultured in vitro 
with biopsied mature squa mous epithelium from the transforma- 
tion zone or with cervical columnar epithelium, sperms never 





Venereallv transmitted aa. ents of -possible 
importance in cervical carcinoma 
AGENT OBSERVED WITHIN THE CAUSES RECOVERY 
CELLS OF THE CERVICAL CERVICAL FROM 
EPITHELIUM LESIONS SEMEN 
Smegma 
Spermatozoa Phagocytosed by _No 
epithelial cells in 
metaplastic phase 
Trichomona No Yes 
vwzinalis 
Neisseria No. Yes 
gonorrhoea 
Tre-Donem No Yes 
Raliisiw 40%, of 
cases 
Mycoplasma Yes -Yes- 
Chlamydia Yes -Yes 
Cytomegalo-drus Yes 'Yes + 






semen was cultured with biopsy material removed from the 
cervix during a phase of metaplasia, e. g. immediately fol- 
lowing first pregnancy, the cells at times phaged sperms 
In vivo studies where biopsy material was taken from immature 
metaplastic epithelium of the cervix 7-9 hours after coitus 
confirmed these in vitro studies. Similar experiments con- 
ducted on mouse uterus employing tritiated thymidine labelled 
mouse sperm demonstrated labelled sperm within the nucleus of 
dividing cells and chemical analysis of such DNA molecules C) 
demonstrated a change in chemistry, showing a graph peak in 
the same area as the -donor sperm. These'experiments demonstrated 
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one possible manner in which mutational change could be brought 
about in the cervical epithelium and more important, emphasized 
the possibility that the target tissue had its own periods 
of susceptibility, i. e. during its phases of metaplasia. 
This hypothesis offers one possible explanation for the 
decreased incidence of cervical carcinoma amongst Jewish 
women. Jewish religious- doctrines forbid coitus during and 
immediately following menses, during certain antepartum and 
postpartum periods and during any vaginal haemorrhagic r-> 
discharge. 
Studles on the two basic sperm head proteins, histone 
and protamine, showed wide variation amongst different 
males and a ratio between the two proteins which correlated 
with social class. The lower the social class, the greater 
the proportion of protamine. This was'so for specimens 
of seminal fluid collected from Australia as well as England. 
These workers (Reid et al, 1978) suggest, that sperm head 
protamine may thus have a role in squamous carcinoma of the 
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cervix which is also commoner in the lower social classes. 
Thus, according to the spermatozoan theory, the Mut agenic 
event is limited by properties of sperm head proteins as well 




Trichomonas is sexually transmitted and has been shown 
to be associated with abnormal cervical cytology (Bechtold 
f-t al, 1952; Meisels, 1969) and with invasive carcinoma 
(Berggren, 1969). However, it was demonstrated that with 
treatment of the infection early neoplastic changes regressed 
(Bertini and Hornstein, 1970). These lesions therefore may 
not be truly precancerous. Also, there is no evidence to 
show that these organisms can enter cells of the genital 
tract. 
Neisseria gonorrhoea 
It has been suggested by Beilby. 2t al (1968) that , 
Neisseria gonorrhoea may activate latent cervical herpes in' 
a manner similar to the reactivation of oral herpes by acute 
respiratory infection. In their study, eight of 209 womeri 
attending a venereal disease clinic had cytological and 
virological evidence of herpes virus infection of, the cervix 
although clinical appearance of the lesion did not siiggest a 
diagnosis of herpes. Fifty-four of the 209 women had gono- 
coccal infection detected by culture and microscopy. Seven 
of the eight women from whom herpes virus was isolated were 
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among these 54 women infected with N. gonorrhoea in, contrast 
with one patient from whom herpes virus was isolated among 
155 women without gonococcal infection. In a study in a C) 
Seattle venereal disease clinic (Alexander, 1973) N. gonor-, 
rhoea infection was also found to be associated with both 
HSV-2 and chlamydial infection. ,ý 
TreDonema Dallidum 
Syphilis was the first venereal disease to be associated 
with cervical carcinoma (Levin et al, 1942). Ho%ever more 
recent studies in the USA have failed to confirm this 
I 
association (Wynder et al, 1954). This is probably a. reflec- 
a tion of two factors: 
a) the recent change in the epidemiology of venereal disease 
in the USA with declining incidence of syphilis, and 
b) the possibility that the early association noticed 
was only a marker of greater sexual promiscuity-in cervical 
carcinoma patients. A more recent study in Taiwan (Alexander, 
1973) showed 25% seropositivity to Treponoma pallidum among 
cervical carcinoma patients in comparison to 10% seropositiv- 
ity among matched-controls. It, is noteworthy'that two studies ID 
in Taiwan failed to demonstrate an association between HSV-2 
and cervical carcinoma (Table 1.4). Cervical involvement 'is 
seen in approximately 40% of women-with syphilis, (Slavin, 1976). 
However, the parasite is not usually seen within the epithel- 
ial cells. 
Mycoplasma I 
The T strains of Mycoplasma and Mycoplasma hominis have 
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been more frequently isolated in populations attending 
venereal disease clinics (Gregory 2t al, 1970; Holt et al, 
1967; Gutman et al, 1972), among prison populations (Ford 
and Du Vernet, 1963), and promis'cuous persons. (Solomon et al, 
1970). Recovery of Mycoplasma from seminal fluid in. males 
correlated with-recovery from the cervical secretions of 
their partners (Gnarpe and Friberg, 1972). 'Myc'oplasma 
has been isolated from cases of chronic inflammatory disease 
of the cervix (Dunlop Rt al, 1974). In the study done by 
Gregory ftt Ll (1970) a correlation was observed between 
mycoplasma infection and dysplasia. However no serologic 
studies have been reported in which the prevalence of 
mycoplasma. antibodies in patients with cervical carcinoma 
and controls were examined. 
Phlamydiae 
Schachter et al (1974) made a study of chlamydial 
infection in women with dysplasia (Table 1.8 There was 
a higher isolation rate -from these women in comparison 
with women attending a cancer screening clinic. The highest 
isolation rate was from women seen at a women's clinic '(which 
included women with inflammatory disease of the genital tract). 
The proportion of patients with dysplasia who had complement 
fixing chlamydial antibody titres of greater than 1: 16 was 
higher than that seen in many women attending the cancer 
screening clinic (Table 1.8A), the venereal disease clinic 
or women with gonorthoea (Table_1.6B). A significantly hig her 
proportion of women with dysplasia had immunofluorescent 
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of titre >1: 16 
TRIC fluorescent 
antibody of titre 
>1: 8 
TRIC fluorescent 
antibody of titre 
> 1: 64 
127 WOMEN FROM 90 WOMEN FROM A 176 WOMEN FRO 
CANCER SCREENING WO'EVIEN'S CLIKIC* A DYSPLASTA 
CLINIC CLINIC 
0.13% 7.8% 4.1% 
1.0% 1.0% 1.0% 
11.0% 21.0% 21.0% 
67.8% 63-3% 77.6% 
16 (22%) 3-4 (45%) 22 (88%) 72 74 72 
* included women with inflammatory disorders of the ýýenital tract 
B. Chlamvdial (TRTC) comT)lement fixinz antibodies in 
selected -DoiDulations 
Normal premarital women 
Pregnant women 
Women from venereal diseases clinic 
Women with ! ýonorrh'oea 
Prostitutes 
Women with proven TRIC agent infection 









the cancer screening clinic. Representative antigen from 
Trachoma inclusion conjunctivitis -(TRIC) 
immune. types A, B, 
C and-D and F were used in these tests and most sera had 
broad reactivity to most or all of the antigens. Although 
this study does not demonstrate a specific association 
between TRIG agents and the dysplasia process, it does 
provide sufficient evidence for implicating it as a possible 
agent or co-agent - more so because it is an intracellular 
parasite. In a study conducted by Gutman et al (1972) 
among veneral disease clinic patients, chlamydiae were 
isolated from 26% of 100 cases of cervicitis in contrast 
to 11% of controls. 
ft 
Cvtomegalovirus 
The results obtained, in studies assessing the associa- 
tion between cytomegalovirus and carcinoma of the cervix 
has been contradictory. Fucillo et al (1971) examined the 
sera of patients in the USA who later developed'carc'inoma 
in situ (Table 1.9, Group a), sera of patients with concurrent 
carcinoma in situ (Group b) and sera of patients after they 
had had cone biopsy for carcinoma in situ (Group c). Both 
the prevalence of CMV antibodies and the titres in patients 
compared with controls indicated that CMV was not a causative 
agent or a secondary invader-of neoplastic tissue. Both the 
prevalence of CMV antibodies and their titres were lower in 
patients who had had cone biopsy suggesting the cervical 
epithelium as the site of-infection responsible for the 
maintenance of antibody levels. 
ýn 
a study done by Munoz et al (1975) (Table 1.9) on 
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Table 1.9 StUdies-'examining the association of cytomegalovirus; 
(M) and cervical anaplasia 
REFERENCE AND STUDY GROUP PROPORTION HAVING TITRES P 
TECHNIQUE ANTIBODIES (LOG ) 
PATIENTS CONTROLS 2 
Fucillo et al -a) Serum from 71.0% 4.21 
(1971) 14 patients 
Indirect prior to 0.2 haemagglutina- developing CIS. 
tion 
a') 28 matched 51% 3.57 
controls. 
b) Serum from 63-0% 4.6 
30 patients with . 
CIS at time 
lesion was 0.2 
present 
b') 60 matched '71% 
controls. 
c) Serum from 37.5% 2-75 
11 patients 
after conisation 0- 03 for CIS 
. 
c') 22 matched 69% 4.03 
contr6ls 
Munoz et al 22 patients with 100% 
(1975) byý CIS and 35 
Indirect with invasive 
immurofluor-_-_ carcinoma 
escence- 
1) VCA of CMV 104 matched 100% 
controls 
2) EA of. 'CMV ', 50 patients with 36% 
CIS 
99,, controls 19% 
Vestergaard 135 patients 80% 
et al (1972) with cervical 
Complement- carcinpma 
fixation 
115 controls 65% 
CIS - carcinoma in situ,,. VCA - virus. capsid antigen 
CMV - cytomegalovirus EA - early antigen 
I 
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invasive carcinoma patients and controls in Colombia, loo% 
of patients and controls had antibodies to virus capsid 
antigen of CMV- However, higher frequency of antibodies 
to early antigens of CKV was observed in patients compared 
with controls. This may suggest a higher prevalence of 
active CMV infection in these patients. 
In a study done by Vestergaard et al (1972) a higher 
proportion of cervical carcinoma patients were found to pos-4 
sess CMV complement fixing antibodies and in significantly 
higher titres. 
The conflicting results in these studies may be attributed 
to the varying techniques employed in each study. It'has been 
shown that the complement fixation test for CKV is less sensi- 
tive than the immunofluorescent test (Tsi., ýtnto Is et'al, 1974). 
Further studies on antibodies to the early antigens'of CMV 
infected cells have not been conducted. '' Although virus 
specific surface antigens have been demonstrated on the 
surface of CMV infected as well as CKV transformed cells 
(Albrecht and Rapp, 1973; Langenhuysen et al, 1970; ''Lausch 
et al., 1974) antibody to these antigens have not been studied 
in women with cervical anaplasia. It is avirus which 
deserves further investigation as a possible-cervical 
carcinogen. 1t has been isolated from the uterine cervix 
(Goldman et al, 1969, collaborative study, 1970) more frequent- 
ly, than HSV-2 (jordari-et al, 1973) and more frequently in 
late pregnancy and the post partum period-than in early 
pregnancy (S. tagno et al, 1975)- (During, the post partum 
period*after the first pregnancy there is active metaplasia 
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of the cervical epithelium, page 73 It has been 
demonstrated in the-semen of asymptomaýic carriers for over 
one year (Lang tt al, 1974). 'Transformation of hamster 
embryo fibroblasts has been demonstrated after exposure to 
UV inactivated CMV (Albrecht and Rapp, 1973) and of human 
embryo lung fibroblasts persistently infected with a genital 
isolate of CMV (Gedder et al, 1976). It is likely that CMV 
is venereally transmitted as it is a labile virus, it is 
recovered from semen, -and because there is a high isolation 
rate from the genital tracts of women attending venereal 
disease clinics. (Jordan et al, -1973; Wentworth et al, 1973;. 
willmott, 1975). 
& Although CMV commonly infects the female genital tract, 
CMV infected cells are seen rarely in cervical smears. One, 
possible explanation for this is'seen in the results of-in. 
vitro studies conducted by Vesterinen et al (1975). into the 
cytopathogenicity of CUV for ecto- and endocervical epithel- 
ium. The endocervical cells were clearly more conducive to 
viral growth than-the ectocervical cells. - Endocervical, cells 
are rarely seen in a cervical smear. Occasional CMV inclusion 
bearing cells have been reported in endocervical biopsies 
(Goldman et al, 1969; Ross, 1966; McCracken et al, 1974). 
CMV was isolated by Melnick et al (1978) from two of 
10 cell cultures derived from cervical cancer biopsies from 
patients in an advanced stage of the disease. The two CMV 
positive biopsies were from two elderly women who had been 
sexually inactive for many years and therefore suggested 
persistent latent CKV infection with intermittent periods of 
activity, rather than recent veneral transmission. 
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Human papilloma virus 
Condyloma acuminatum is relatively common in patients 
attending venereal disease clinics (Skinner, 1976), and is 
venereally transmitted (Theokarov, 1969; Oriel, 1971). 
Evidence has been shown that the virus causing genital 
condyloma is immunologically distinct from that causing C) C) 
non-genital condyloma. The virus is morphologically identi- 
cal to SV40 and polyoma virus which are oncogenic in certain 
animals and morphological transformation of primary human 
embryonic skin -cells by pooled human wart material has been 
reported (Noyes, 1965). Penile carcinomas have been observed 
to develop close to or at a site of condyloma acuminaýa 
(Sims and Garb, 1951). The cervix is less frequently in- 
volved than the vulva (Oriel, 1971). It is a virus which has 
received little attention in epidemiological and serological 
studies relating to cervical,, penile, vulval. or perýLanal 
-carcinomas (zur Hausen, 1976). 
Discussion of studies on the role of other venerall 
transmitted agents 
The spermatozoan theory is a startling one. It dares 
to link an agent as universal as a sperm with the develop- 
ment of cervical carcinoma. The studies of Coppleson and 
those of Singer (page. 73 on the differences in the trans- 
formation'zone of the cervical epithelium in sexually active 
adolescents and v irgins were unfortunately carriedýout on 
girls in a state institution and in prison respectively.. 
Although the authors do not say so, it is possible that 
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sexually active adolescents may have been promiscuous and 
may have had previous venereal disease. Therefore, it. ', is 
difficult to determine from their experiments whether the 
abnormal transition zone results from the action of a sexual- 
ly transmitted infective agent or from the action of sperm- 
atozoans. (The abnormal transition zone is believed to har- 
bour potentially malignant cells. ) A recent study (Sumithran, 
1977) on the rarity of cervical carcinoma among the Malaysian 
Orang Asli (Aboriginal group) is helpful in clarifying this. C) 
4w 
Of 18,000 females seen at the Gombak Orang Asli Hospital over 
a 13 year period, only three patients were diagnosed as car- 
cinoma of the cervix. Interviews with 200 Orang Asli females 
showed their mean age of marriage to be 14 years, mean age 
of first pregnancy 16 years, and mean number of pregnancies 
five. Ninety per cent of the women were married only once, 
14% used contraceptives of which none were barrier methods 
and none of the husbands were circumcised. The tribe followed 
a strict moral code which is applicable to both males and 
females and has a low incidence of venereal infection. Since 
in these women adolescent marriage and childbearing and the 
non-usage of barrier contraception would have resulted in the 
exposure of their cervices during metaplastic periods to the 
action of spermatozoans, this study argues against the sperm- 
atozoan theory, and supports the aetiological action of 
another venereally transmitted agent in the pathogenesis of 
the cancer. Returning to the Coppleson and Singer studies on 
sexually active adolescents, it is possible that the abnormal 
transformation zones in these girls resulted from the action 
of a sexually transmitted agent other than spermatozoa*lý i. e. 
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such an agent was the initiator of the malignant process 
which is believed by some to develop from groups-of cells in 
the abnormal transformation zone. Up to date research efforts 
have concentrated mainly on the role of HSV-2 in cervical 
carcinoma. However the studies quoted above indicate that 
Chlamydiae, mycoplasma and cytomegalovirus may play a role 
in-cervical anaplasia, that gonococci may act as co-agents, 
and that the role of human papilloma virus has not been 







THE HERPES SIMPLEX VIRU 
I 
Classification- 
Herpes simplex virus belongs to. the family of H. erpes 
viruses i--hich are relatively large ether serisitive DNA 
viruses, and to the subfamily of Alphaherpesvirinae 
(provisional classification of herpes viruses 1977). 
Morphology o. C the herpes simplex vir s 
--- C5 -IU 
The virus has an icosahedral capsid urith 162 capsomeres 
on the surface (Wildy gt al, 1960). Each capsomere is- a 
hollow prism 12.5 9-5 nm in diameter. The core within 
the capsid is doughnut shaped and consists of proteins 
around which DNA is coiled (FurlQng et 2.1,1972). The. 
envelope consists Of liPid and polyamines (Gibson and 
Roizman, 1971Yand virus specified glycoproteins (Heine 
. 
ttý al,. 1972). Particl6ý may be found with'or without the 
core or envelopes (Watson et al, 1963) -'. Nakedý particles 
have a diameter of 100 nm (Aurelian. 1974a) and ý, -the enveloped 
particles a. diameter o-LE' 140-160 run (Nalunias and Roizman., 1973) ! 
There is evidence to suggest that naked particles are not 1: 1C) ---- 
infectious (Gibson and Roizman, 1972; Roizman, 1969). 
Replicative and metabolic events iIna herpes simplex_virus 
infected cell 
Following entry of the virus into the cell, the outer 
protein coat is removed and the DNA protein complex enters 
the nucleus, where most of the subsequent' events 'occur 
(Roizman and Furlong, 1974). Viral DNA is transcribed and 
the membrane bo. Und polyribosomes iii the cytoplasm synthesize 
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structural and functional proteins which are 
the mRNA. Most of the proteins migrate back 
and comprise three sequentially synthesized, 
regulated groups designated a, O and*Y(Honess 
1974; Roizman and Morse, 1977). A few prote 
the cytoplasm and bind to cellular membranes 
antigdnically modified. 
apolypeptides 
coded for by" 
to the nucleus 
co-ordinately 
and Roizman, 
ins remain in 
which become 
-These polypeptides reach peak production two to four 
I hours after infection and three have been recognised as being 
virus specific - infected cell protein (ICP) 4,, 0 and 27. 
Prior protein synthesis is not required for the formation 
of a polypeptides. 
0 polypeptides 
These require the presence of apolypeptides for their 
synthesis. Viral DNA polymerase, thymidine kinase, and pro- 
teins responsible for the inhibition of cellular macro- 
molecular metabolism and of polypeptide synthesis,, Com- 
prise the spolypeptides. 
y polypeptides 
These require the presence of Opolypeptides for their 
synthesis and comprise the structural polypeptides of the 
virus. The rate of production of ypolypeptides increases 
up till 15-18 hours post infection. 
Thirty of these polypeptides have now been mapped on 
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the herpes genome by Roizman's group (Unpublished - presented 
at herpes virus workshop, Cambridge, 1978). 
The transition from a toa polypeptide synthesis is in 
most cases independent of viral DNA replication (Wolf and 
Roizman, 1977). The y messenger RNA's have a short func- 
tional half life compared to the a andý mRNA's which have 
a considerably longer half life. For this reason some 
polypeptides are not detectable in cells infected at low 
multiplicity, in which the*synthesis of viral progeny DNA 
is inhibited. On infecting such cells at high, multiplicity, 
however, these polypeptides are seen in larger quantity. 
The shorter half life of the polypeptide mRNA is thought to 
provide an effective method or regulating viral assembly 
in infected cells. Thus in the early stages of infecti'on 
the rate of synthesis of structural proteins would be low 
and would be accelerated when the pool of DNA increases by 
DNA replication. This also explains why on inhibiting DNA 
synthesis cells infected with some human herpes viruses do 
not-possess structural viral components. 
New virus capsids are formed in the nucleus. Envelopment 
occurs at the inner lamella of the nuclear membrane and some- 
times also at the cytoplasmic membrane (Strandberg and 
Aurelian, 1969). Virus release has been described as a 
process of inverted pinocyt'Osis (Morgan et al, 1959). ' 
DNA of the herpes simplex virus 
The, DNA of the virus is a linear double stranded 
molecule 100 x 10 
6. 
daltons in molecular weight (Keiff 
63 
211,1971) which is larger than the DNA molecules of 
some of the other non-herpes oncogenic DNA viruses (Table 2-1). 
Each molecule consists of two unique components UL and US, 
each of them bound by an inverted repetitive region (Roiz- 
man and Morse, 1977). 
ab UL b'a' a'c' us c. a 
The--UL component and the repetitive regions bounding 
it comprise 82% of the molecule and the US region and its 
repetitive regions comprise 18% of the molecule. 
Fifty per cent of the viral DNA is expressed during 
I 
a productive infection (Roizman and Frenkel, 1973). From 
the size of the DNA molecule it*was estimated that it could 
code for approximately 65 proteins (Nahmias and Roizman, 1973)- 
Forty-seven have now been identified of which 27 are structural 
(Aurelian, 1974a). The DNA's of HSV-1 and HSV-2 show 47%- 
homology by nucleic acid hybridization (Keiff et al, 1972). 
Therefore most antigens coded for by the two viruses are 
type common. 
The physical state of virus DNA in cells transformed by 
oncogenic viruses 
In cells infected as well as those transformed by 
RNA tumor viruses, papovaviruses, and adenoviruses the 
viral DNA is carried in a linearly integrated form (Martin 
and Khoury, 1976; Pitot, 1978). In some cells both integrated 
DNA as well as non-integrated circular viral DNA has been 
reported (Prasad et al, 1976; Ringold et al, 1977). 
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Experimental techniques employed in work of this nature 
depends on the size difference between free virus DNA and 
cellular DNA. Such techniques are not easily applicable 
to the herpes viruses with DNA of molecular weight 100 x 106. 
Therefore, although virus DNA has been demonstrated in the 
cells transformed by many herpes viruses, by means of 
nuclear hybridization techniques, the physcial state of the 
DNA has'-, been partly established, only in the case'of the EB 
virus, herpes virus siamiri and the herpes virus papio. 
EBV DNA was found in Raji cells (cells established from a 
Burkitt's lymphoma (BL) patient) as well as BL-, tumor cells 
and nasopharyngeal carcinoma (NPC) tumor cells, mainly in 
the form-of circular episomal DNA (Adams and Lindahl, -1975; 
Kaschka Dierich et al, 1976). Integrated sequences-were 
also found in Raji cells'(Adams et al', 1973) and BL tumor 
cells and NPC tumor cells (Kaschka Dierich et*al, 1976). However, 
although in these cells the episomal DNA had a molecular 
weight similar to virus DNA, it-is not known how much'of 
the viral genome the integrated viral DNA represents. 
B cells from a case of infectious . mononucleosis had episomal 
DNA which was smaller than the episomal DNA from BL tumor 
cells (Adam et al, 1977). The episomal DNA in these tumors 
is similar to episomes in bacteria. It is possible that all 
herpes viruses may be carried as episoMes during latency. 
The difference in size of the episomal DNA in infectious 
mononucleosis and BL and NPC tumors suggests that the host 
cell determines partly the physical state of ýthe viral DNA 
in different tumor cells associated with the same virus. 
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Similarities and differences between HSV-1 and HSV-2 
Table 2.2 is a summary of some studies which have 
demonstrated biological, antigenic, genetic and protein 
differences between HSV-1 and HSV-2. 
The latent herpes simplex virus 
The clinical features of recurrent-herpes simplex 
infection-point to it being caused by endogenous rather 
than- exogenous virus, because a) the, site of recurrence 
is usually the same or a closely neighbouring site, and 
b) it is often associated with a particular event, e. g. 
fever, injury, exposure-to sunlight in the case of 
oro-facial, lesions, or menstruation, coitus, masturbation 
in the case of genital herpes. The patient is often able 
to predict when a r6currence is likely. Reactivation of 
herpes timplex infection is also common in immunosuppressed 
6 
patients, e. g. due to underlying disease such as, Hodgkin's r> 
disease or deliberate immunosuppression during organ trans- 
plantation. 
Roizman (1965) has suggested two possible states of 
latency: 
t 
I.. The dynamic state. ' 
2. The static state. 
The dynamic state hypothesis postulates that low grade 
multiplication of the virus continues between recurrences. 
The static state hypothesis postulates that the virus 
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recurrence. In support-of the"dynamic state hypothesis - 
are the reports of isolation of the virus from the male 
genitourinary tract (Centifanto, 1972) and the uterine 
cervix (Rattray et al, 1978) betweenrecurrent episodes, '- 
However, skin biopsies taken between attacks from the sites 
at which recurrences occur failed to yield infectious virus 
(Roizman, 1965). -In support of the static state hypothesis 
is, the isolation of HSV-1 from the trigeminal and sacral 
ganglia of human cadavers (Bastian et al, 1972) and sacro- 
scia: t-ic spinal, ganglia of mice infected vid'their foot 
pads (Stevens and Cook, 1973). The virus present in these 
nerve ganglia could not be cultured by the usual straight- 
forward isolation methods, indicating that it was not 
present in the infectious form. 
It is necessary for the survival of the virus lying - 
latent in its host cell that it should not inhibit host 
cell macromolecular synthesis, i. e. the translation of its 
DNA needs to be arrested before its a polypeptides are 
formed. The questions which arise are: 
1. Is this switch off of viral DNA translation virus- 
coded or host-coded? 
2. Is there any viral expression in the latent state, 
e. g. are the apolypeptides formed? 
If the switch off is host cell coded, are recurrences 
due to these host cells being subject to stress, thereby 
altering or diminishing their normal function? Similar 
expression of the EBV in lymphoblastoma cells which were 
stresspd by the use of 5-iododeoxyuridine has been 
described (Hamparet al, 1972). 
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These questions about. virus latency have not yet been 
answered. In addition it is not known whether there are 
sites besides the nerve ganglia in which virus latency 
occurs, or whether within the nerve ganglion the virus is 
latent in the neurones or the supporting cells. It has 
also not been established whether the viral DNA lies in a 
free episomal state or in an integrated form. Pagano (1975) 
has suggested that the genome which is reactivated in 
recurrent infection may be in an episomal state and that 









THE UTERINE CERVIX AND ITS EPITHELIUM 
The cervix is'the lower part of the uterus, the upper 
limit of which is the internal os (Figure 3-1). Itopens 
into the vagina by the external os. Between the internal os 
and the external os lies the endocervical canal. The shape 
of the cervix is basicallycylindrical and the vaginal por- 
tion (edtbcervix), cqnsists of an anterior lip and a longer 
posterior lip. The vaginal mucosa is reflected onto the 
ectocervix anteriorly, laterally and posteriorly forming 
the vaginal fornices. Anteriorly't the supravaginal portion 
is. separated from the bladder bj a layer of connective tis- 
sue called the parametrium. The-parametrium'extends 
laterally into the'space between the two layers of the 
broad ligament. Posteriorly, the supravaginal portion of' 
the cervix is covered with peritoneum which continues down 
over the posterior vaginal wall to be reflected onto the 
rectum, thereby forming the pouch of Douglas. 
In late-fetal life the original columnar epithelium 
derived from the Mullerian duct covers the uterine cavity 
and extends downwara through the cervical canal where it 
meets the original squamous epithelium lining the vagina 
which is derived from the urogenital sinus. The boundary 
between these two types of epithelium occurs at an easily 
recognisable-point called the squamocolumnar junction. ', 
This could be at any point across the ectocervix or endo- 
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Figure 3.1 Cross-sectional diagram of the uterus and cervix. 
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the vaginal fornix (Singer and Jordan, 1976). During-' 
late fetal life, adolescence and following first preg- 
nancy, the more distal portion of the original columnar 
epithelium is partly or wholly replaced with squamous 
e ithelium by a physiological process called squamous pi 
metaplasia. This process occupies a short period of time 
measureable in days or weeks and its natural history has 
been studied by the use of the colposcope. The new 
squamous--epithelium laid down is called metaplastic 
epithelium. It lies between the old squamocolumnar junc- 
tion and the new squamocolumnar junction and is termed 
by colposcopists the transformation zone. In some women 
a colposcopically normal transformation zone is seen which 
is termed the physiological transformation zone. In others 
there is a colposcopically abnormal transformation zone. 
which is termed the atypical transformation zone. 
THE EFFECT OF COITUS DURING EARLY ADOLESCENCE ON THE. 
COLPOSCOPIC APPEARANCE OF THE TRANSFORMATION ZONE 
Epidemiological studies have repeatedly demonstrated . 
the importance of coitus in relation to the aetiology of cervical 
carcinoma (Rotkin, 1967 (a), and (b) and 1973)- Copple- 
son et al'(1975) and Singer (1975) studied the appearance 
and size of the transformation zone-in sexually active 
adolescents and virginal adolescents (Table 3-1). There 
was a higher incidence of both an atypical transformation 
zone and retraction of the new squamocolum. - 
nar junction into the endocervix in the sexually active, 
in comparison with the virginal girls. There was also a 
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significant difference (P<. Ol) between the size of the 
transformation zone observed in sexually active adolescents 
in the Coppleson study in comparison with that of virginal 
girls in the Singer study (Singer, 1976). These findings %: I 
are of possible relevance to the aetiology of cervical 
carcinoma. It has been suggested by Coppleson and Reid 
(1967 and 1975) that in the process of the development- 
of an area of atypical-metaplasia a mutation may be. induced 
- in the epithelium and subepithelial area which endows it 
with-a neoplastic potential. 
MICROSCOPIC APPEARANCE OF THE CERVICAL EPITHELIUM 
Microscopically the squamous epithelium consists, of five 
layers of cells which are separated from the fibrous 
stroma by a basement membrane. - 
Basal cell layer This is the deepest layer'which lies 
adjacent to the basement membrane, consisting of a, sin- 
gle row of small cylindrical cells with relatively 
large nuclei. 
2. Parabasal cell laver (Prickle cell layer) This con- 
sists of several layers of polyhedral cells with fairly 
large nuclei. 
Mitotic figues are occasionally found in these two layers. 
Intermediate cell layer (Navicular cells) A layer of 
cells which begins to show flattening and have a cyto- 
plasm rich in glycogen with frequent vacuolation. 
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Intraepithelial layer (Condensation zone) A-layer. 'of'- 
closely packed polyhedral cells with keratohyalin 
granules. 
Stratum corneum Elongated flattened cells with'-small 
nuclei and a large amount of cytoplasm. 
CLASSIFICATION OF CERVICAL'SMEARS 
As suggested by Papanicolaou, cervical smears are 
classified into five categories (Wachtel, 1969). 
Grade 1- All normal smear patterns. 
Grade 2- (2N) Abnormal but benign, types of, cells as-výiell 
as inflammatory smear patterns-. 
Grade 3- (3A"or 3B) Abnormal cells falling short of the 
description of a malignant-cell,, but-sufficientlY 
different from the'normal to create apprehension. 
3A smears arebild dysplasias. and. 3B a, -moderate - 
severe dysplasia. 
Grade 4 (Positive 4) (Carcinoma in situ or invasive car- 
cinoma) These are smears showing a few malignant 
cells. At times-they include cases of severe 
dysplasia. The differentiation between a severe 
dysplasia carcinoma in situ and an invasive car- 
cinoma is made on histological examination of 
biopsy material. 
Grade 5 Large numbers of malignant cells are seen in 
these smears. 
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ABNORMAL FEATURES MOST FREQUENTLY SEEN IN MALIGNANT CELLS 
(WACHTEL, 1969) 
Nuclear changes 
a) There is gross enlargement of the nucleus without cor- 
responding enlargement of the cell body. 'The nuclear/ 
cytoplasmic ratio is disturbed, the nucleus filling at 
least one-third of the cell volume. 
b) The -nuclei lose their smooth rounded shape and'assume 
an irregular outline. They also appear in a variety 
of sizes 
c) Whereas the chromatin of normal cells is evenly distrib- 
uted and appears smooth or finely granular, malignant 
a cells have irregular chromatin distribution giving 
r-ough'Arregular appearance. 
d) Additional features such as hyperchromasia, multi- 
nucleation and enlargement and/or reduplication of 
nucleoli are often but notinvariably observed. 
2. Cytoplasmic changes in malignant cells- 
The cytoplasmic changes in malignant cells are-less distinctive 
and may also be found in severe inflammatory disease, meta- 
plasia or under the influence of radiation. 
a) Alteration in staining properties. 
b) Cellular enlargement and bizarre cell shapes. 
c) Cellular inclusions. 
d) Degenerative changes. 
- 
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STAGING OF CARCINOMA OF THE CERVIX 
The disease is staged for purposes of international 
classification and therapy according to the degree of 
spread. The classification currently in ope - ratiorý is 
the one laid down by the International Federation of 
Gynaec-ology and Obstetrics. (F. I. G. O. News, 1965). 
-I I-... 
Stage la - Subclinical-lesion whichis minimally but clearly 
invasive, i. e. extends deeper to the basement 
membrane. 
Stage lb - Clinical lesion - confined to the cervix or extend- 
ing only to the corpus. 
Stage 2a - Extends to the vagina but not the lower third. 
Stage 2b - There is parametrial involvement which does not 
extend'to the pelvic wall- Vaginal involvement 
but not to the lower third. 
Stage 3a - Involvement of the lower-third of the vagina. 
Stage 3b - Involvement of pelvic wall. 
Stage 4 - Involvement of the bladder or rectal mucosa or 







INCIDENCE OF CERVICAL CARCINOMA IN BRITAIN, SRI LANKA, 
MALAWI AND SUDAN 
Cervical carcinoma is the commonest genital tumor in 
the United Kingdom (Chamberlain and Dewhurst, 1977. Table 4.1), 
Sri Lanla-(Fernando, 1974. Table 4.2), Malawi (M. S. R. Hutt, 
Personal communication. Table'4.3) and one of the common- 
es, t tumors in females in Sudan (M. S. R. Hutt, Personal com- 
munication). 
It is well established that various population groups 
either show a low risk or a high risk of developing cer- 
vical carcinoma. Table 4.4 demonstrates the variation in. 
incidence of the disease among women in different countries. 
Attempts have been made to search for a pattern, of epidemio- 
logical and aetiological variables which might account for 
the enormous difference. 
SOME SOCIAL ASPECTS RELATED TO CERVICAL CARCINOMA 
Table 4.5 contrasts the incidence of carcinoma of the 
cervix among different groups of women sharing the same 
environment. The study done by Stewart et al. (1966) 
showed a striking difference in the incidence rates in', 
New York City between Puerto Rican women (105-7AOO, 000 
population), Negro women (49.6/100,000), non-Jewish 
white women (151100,000) and Jewish women (4-1/ioo, ooo). 
80 
Table 4.1 (From Chamberlain and Dewhurst, 1977) 
Gynaecological diagnoses of patients admitted to National 
Health Service hospitals in England and Wales in one 
year recently 
Malignant tumors Cervix 14,650 
Body of uterus 4,520 
Not stated (uterus) 2,470 
Ovary and Tube 6.670 
Other genital 2 24o 
30.550 
Benign tumors Fibroids 26,640 
Ovary 12,430 
Other genital 4,270 
43,340 
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Table 4.2 (From Fernando, 1974) 
An analysis of 17,277 cases with female genital cancer 
admitted from 1968 - 1972 to the Cancer Institute, 
Maharagama, Sri Lanka 
Number of cases of all admissions 
Carcinoma of cervix 2316 13.4% 
Carcinoma of ovary 189 1.9% 
Carcinoma of vagina 86 0.49% 
Carcinoma of vulva 52 0-306% 
Carcinoma of body of uterus 46, 0.26% 
Carcinoma of Fallopian tube 0 0% 
Seen less frequently in the series as they are treated 
in other hospitals as well 
Early stages are treated by surgery alone in, other 
hospitals 
Table 4.3 (M. S. R. Hutt, Personal communication) 
Incidence rates (per 100,000 per year) of carcinoma of the 
cervix, bladder, skin and breast in females in Malawi of 
-the age'group 35-64 
MALAWI 
Carcinoma of the cervix 79.6 
Carcinoma of the bladder 30-8 
Carcinoma of the skin 26 
Carcinoma of the breast 23 
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Table 4.4 (Adapted from Coppleson, 1969) 
Incidence of carcinoma of the cervix in some countries - 
world standard rate (WSR) for all'ages 
Country ýJorld Standard Rat 
Columbia, Cali 






England (4 regions) 
Norway 
Iceland' 
















Groups of women found to be at relatively low and high 
risk of developing cervical carcinoma 
Grou-os at low risk 
Jewish women in 
New York City 
(Stewart et al, 
Groups at hi, -h risk 
Puerto Rican women and 
Negro women in New York City 
1960) (Stewart et al, 1966) 
Irish and Italian immigrant 
women in the USA 
(Haenszel, 1961) 
Protestant and Catholic 
women who regularly 
attend religious services 
in li. Tashington County, USA 
(Naguib et al, 1966) 
Seventh Day Adventist 
women 
(Wynder et al, 1959) 
Protestant and Catholic 
women who rarely or never 
attend reli, -,:, ious services 
in Washington County, USA 
(Naguib et al, 1966) 
Malaysian Orang Asli Chinese and Indian women 
(Sumithran, 1977) in Malaysia 
(Marsdon, 1958) 
Prostitutes 
(Rojel, 1953 and Pereyra, 1961) 
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In a study conducted in the Washington County, in the USA, 
Naguib et al (1966) found a higher'incidence of abnormal 
cervical smears among Protestant and Catholic women who 
were not practicing Christians in contrast to-those who 
were. Similarly, Haenszel (1961) found a low incidence 
among Irish and Italian immigrant women in the USA who 
were Roman Catholics, and Wynder et al (1959) a low 
incidence among Seventh Day Adventist women. Sumithran 
(1977) faported a very low incidence among the Malaysian 
Orang Asli in comparison with the Chinese and Indian women 
in Malaysia in whom Marsdon (1958) reported cervical car- 
cinoma to be the commonest cancer. These differences. 
may be due to the effect that such influences as cultural 
background, socioeconomic status and religicuscommitment' 
have'on individual attitudes, towards sexual conduct. Thus 
Jewish doctrine, Roman Catholicism, The, Seventh Day, Advent- 
ists, and many Protestant deominations, preach a conservative 
attitude towards sexual, conduct. In addition among Jews, 
another relevent cultural factor is the practice of one 
of the Mosaic laws, the law of Niddah relating to 
abstinence from coitus during and immediately following 
mentruation and childbirth (see page 48). A feature among 
the Malaysian Orang Asli which is stressed by. Sumithran 
is their custom of early marriage and their strong dis- 
approval of adultery. This combination results in strictly 
monogamous relationships. Reports of the high incidence 
of carcinoma of the cervix among prostitutes (Rojel, 1953; 
Pereyra, 1961. Table 4.5) contrasts with the above 
f indings. 
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Of the four countries from which samples were. col- 
lected for the studies reported in this thesis, religion 
has considerable influence in the behavioural character- 
istics of the people in Sri Lanka and Sudan. Permanency 
of marriage is favoured and pre-marital and extra-marital 
sex frowned upon. This same degree of influence of 
religious ideals on sexual behaviour is not seen in 
Malawian and British society. 
Ethnically, Sudan and Malawi provide a relatively 
ft 
homogeneous population, in contrast to Britain (Caucasian, 
Negroid and Asian) and Sri Lanka (Sinhalese, Tamil, Muslim 
and other). 
The social class structure - of 
Malawi, Sudan, and, Sri 
Lanka has not been classified as exhaustively as for 
Britain (Office of the population censuses. and surveys, 
1970). However there are accepted low', middle and upper 
classes in these countries and the proportion of people 
falling into the middle and upper classes are approximately 
1% in Malawi, 10% in Sudan, and 15% in Sri Lanka. 
86 
RELEVANCE OF SURFACE ANTIGENS IN CERVICAL CARCINOMA 
Much of the normal protective work of the immune sys- 
tem is directed against cell surface antigens, and depends 
on cell surface receptors. This has found important ap- 
plication in many fields of medicine, e. g. blood grouping, 
tissue matching, control of haemolytic disease of the new- 
born and immune tolerance. The growing importance of 
oestrogen-receptors in deciding treatment strategy for 
breast cancer (McGuire, 1978), and glucocorticoid recep- 
tors in human; leukaemia (Lippman et al, 1978) are tvro of the 
many possible applications in the future. 
New antigens have been demonstrated on the surface 
of cells infected by non-oncogenic, as well as oncogenic 
viruses (Table 4.6). These antigens are virus specific 
(Hyashi et al, 1972). Table 4.7 shows. some of the tech- 
niques used to demonstrate virus specific antigens on 
cells infected by some of the herpes group of viruses. 
They were first demonstrated on cells infected by Herpes 
simplex viruses by O'Dea and Dineen (1957) using an 
indirect fluorescent test on live cells. Their time of 
appearance after infection, as demonstrated by different 
techniques, ranges from two hours (Tevethea et al, 1977) 
to six hours (Lowry 
. 2t 
al, 1971) (Table 4.8). Also ex- 
plained in the same table is the use of Actinomycin D, 
IUDR, cytosine arabinoside and cycloheximide in establish- 
ing that the surface antigens are codeý for at least partly, 
by infecting DNA and do not require the prior. production 
of progeny DNA. Herpes simplex induced membrane antigens Co 
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have not been sub-typed into early and late components 
as have the EB virus coded membrane antigens (Epstein 
and Achong, 1977). Ithas been*established however that 
they are composed of antigens common to HSV-1 and HSV-2 
as well as antigens specific for each (Nahmias et al, 
1971a, and Geder and Skinner, 1971). 
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Table 4.6 Demonstration in vitro of virus specific antigens 
on the surface of infected cells-(modified from Table by 
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monkey pox 
shope fibroma 
IEM, CT, -IF 
















IF, IA, CT, RI 
IF, CT 
IF Immunofluorescence CT Complement dependent cytotoxicity 
LC Lymphocyte mediated cytotoxicity RI .. Radioimmunoassay 
IA Immune adherence IEM Immune electron microscopy 
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Table 4.7 Demonstration in vitro of virus specific antigens 
on the surface of cells infected by members of the herpes group 
of viruses (modified from a table by Burns and Allison, 1977) 
VIRUS TECHNIQUE REFERENCE 
Herpes simplex IF O'Dea and Dineen (1957) 
Nahmias et al (1971a) 
Espmark (1965) 
MHA Ito and Barron (1972) 
Espmark (1965) 
CT Roane and Roizman (1964) 
IEM Nii et al (1968) 
RIA Hyashi et al (1972) 
Varicella-zoster IF Gershon et al (1974) 
CKV IF deThe and Langethuysen (1972)' 
EB IF Klein et al (1968) 
Marek's disease IF Chen and Purchase (1970) 
IF Immunofluorescence MHA Mixed haemagglutination 
CT Complement dependent cytotoxicity 
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NATURE OF MEMBRANE ANTIGENS ON HSV INFECTED CELLS 
New antigens induced by viral infection are either 
virus specified (virion or non-virion) or host specified. 
They remain unaltered or are modified by glycoselation 
by host enzymes and inserted into cell membranes (Burns 
and Allison, 1977). 
VIRUS CODED ANTIGENS ON THE SURFACE OF HSV INFECTED CELLS 
51) Envelope antigens 
Lesso et al (1970) demonstrated that rabbits inoculated 
with a membrane preparation from HSV, developed neutralizing 
antibody in high titre. Smith -et -al 
(1972b) found a good 
correlation between antibody to membrane antigen of HSV-1 
and HSV-2 infected cells and neutralizing-antibody. 
These findings support the view that a proportion of the 
antigens on the surface of infected cells are similar to 
those of the virus envelope. 
b) Non-virion antigens 
A virion coded soluble non-virion antigen NVA-TAA 
(non-virion antigen - tumor associated antigen) has 
been described, associated with the membrane fraction 
of HSV-1 and HSV-2 cells, which reacts with membrane 
antigens on carcinoma of the cervix, vagina, vulva and 
lip (Hollinshead and Tarro, 1973, and Hollinshead et al, 
1972). These studies and their relevance to the present 
study are described in greater detail on page 232. 
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c) Fc recel3tors 
Receptors for the Fc portion of non-herpes 'specific 
IgG have been demonstrated on cells infected or'trans- 
formed by HSV (Westmoreland and Watkins, 1974, ''and West- 
moreland et al., 1974). These receptors are seen in 
increased numbers, 8-10 hours post infection, at a time'when 
host cell macromolecular synthesis has been largely 
turned off. For this reason, they are believed to be 
viral coded proteins. 
HOST CODED MEMBRANE ANTIGENS IN RELATION TO VIRUS INFECTIONS 
Petal anti, ---ens 
Some new membrane antigens are believed to result 
from derepression of host geneszor by the unmasking-, of 
antigenic substructures already present, e. gg- the , 
demonstration of Forssman antigen on SV-40 and polyoma 
virus transformed BHK cells (Fogel and Sachs,. 1962, 
Robertson and Black, -1969). 'The fetal antigen that has 
received prominence in relation to cancer of the cervix 
in carcino-embryonic antigen (CEA) (see page 102). The 
exact location of CEA on the malignant cell has not been 
described. 
b) His . tocompatibility antigens 
The possibility that new membrane antigens are formed 
either by viral antigens forming a composite with the H-2 
material or by modifying the H-2 antigen is suggested by 
the behaviour of cytotoxic 'T-cells of donor mice immunized 
with LCM virus (Zinkernagel and Doherty, 1974-& 1975). - 
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The T-cell was able-to perform lytic activity only if 
there was some degree of histocompatibility between it and 
the target cell. Koenig et al (1976) have shown'a 
stýLtistically positive relationship between patients 
with cervical cancer and the HLA-B-12 type. Could a mod- 
ification of this antigen by the virus help the cell to 
escape immune surveillance? 
c) Lectin receptors 
Infection of cells with HSV brings about in two hours 
changes in the cell membrane which make the cell more 
susceptible to agglutination with concanavalin A 
(Tevethia et al, 1972) (Table 4-8). Concanavalin A is a 
lectin which is able to agglutinate cells transforiýed by 01 
both RNA and DNA tumor viruses and also normal untrans- 
formed cells which have been infected by a variety of 
viruses (Burns and Allison, 1977). 
MEMBRANE ANTIGENS ON HSV TRANSFORMED CELLS 
Antiseru. M prepared against VP 123 and VP 119, the 
major glycoprotein region of HSV-1 and HSV-2 infected 
cells respectively, was found to react type specifically 
with HSV-1 and HSV-2 Infected and transformed cells in an 
indirect immunofluorescence test on live cells (R. J. Courtney, 
Personal communication). HSV neutralizing antibodies to 
HSV-1 and HSV-2 were present in sera of newborn hamsters in 
whom tumors were induced by HSV-1 and HSV-2 transformed 
cells (Duff and Rapp, 1971; Rapp and Duff, 1973). Since 
infectious virus could not be isolated from either trans- 
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formed cells or the induced tumor, it was concluded that 
antibodies were directed against a membrane antigen, on the 
tumor. 
Membrane antigens were demonstrated on cells trans- 
formed by mutagenised HSV by a lymphocyte cytotoxicity 
test (Lausch et-al, 1975). 
MEMBRANE ANTIGENS ON VIRUS-INDUCED (DNA AND RNA) ANIMAL 
TUMORS AND IN HUMAN SQUAMOUS CARCINOMAS 
Tumor specific transplantation antigen (TSTA) and 
other membrane antigens have been detected in DNA and 
RNA induced tumors, e. g. 1) TSTA in SV-40 induced 
tumors - found only in cells carrying the virus genome, 
2) S-antigen also in SV-40 induced tumors found also in cells 
with no detectable levels of SV-40rrr-RNA and SV-40 DNAP 
TSTA in leukaemic cells caused by mouse leukaemic 
virus. In this instance the leukaemic cells perpetually 
synthesize virus particles (Maruyama and'Dmochowski, 1973; 
Tevethia, 1975). NVA-TAA referred to earlier, is an 
antigen found on the surface of squamous carcinoma cells 
(cervix, vagina, vulva and lips) which reacts with a 
herpes virus induced non-virion antigen (Hollinshead 
et al., 19706). Antibodies to NVA-TAA have been detected 
in sera from a high. proportion of patients with squamous 
carcinoma (Hollinshead et al, 1973). It also produced a 
delayed hypersensitivity reaction specific for. patients 
with squamous carcinoma (Hollinshead et al, 1976). 
There is growing evidence to indicate the importance 
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of the humoral antibody response in tumor immunology. 
Antibodies can either enhance or inhibit tumor growth 
(Bansal and Sjogren, 1972; Moller, 1964; Ting and 
Herberman, 1974). With DNA tumor viruses, virus induced, 
non-virion antigens have been separated from cells under- 
going lytic infection by the virus, as well as from tumors 
(Hollinghead et al, 1968). Hence it is possible that an 
assay of antibodies to the surface antigens of such a 
virus infected cell may be'also an assay of antibodies 
to antigens present on an aetiologically related tumor. 
At the time this study was begun, three studies 
had been reported which examined the importance of anti- 
bodies to membrane antigens of HSV-2 infected cells in 
patients with pre-malignant and malignant cervical lesions. 
Smith et al (1972b) employed indirect immunofluorescence, 
Thiry.. 2t 2,1 (1974) a, complement dependent cytotoxic, anti- 
body test, and Christenson and Espmark (1976) a mixed 
haemagglutination test. These studies and a subsequent 
study'by Christenson (1977) also employing a complement 
dependent cytotoxic assay had interesting diagnostic and 
prognostic implications and have been described 
on page 322. ' 
Membrane antibodies detected by different'techniques 
may be a test of different populations of these antibodies. 
As far as is known this_study is the first class specific 
(IgG and IgA) evaluation of these antibodies, in patients 
with cervical anaplasia. 0 
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LEVELS OF SERUM IMMUNOGLOBULINS IN CERVICAL CARCINOMA. - 
Since the introduction of the method of single radial 
immunodiffusion by Mancini et al in 1965 several studies 
have been made on the levels of immunoglobulins in a 
variety of diseases, malignant (Table 4.9) and non- 
m6Llignant (Table 4.10). 
Three studies have been reported which have examined 
levels of total immunoglobulin in cervical carcinoma (Table 
4.11). Levels of IgA were elevated among patients-in all 
three studies. Values of IgG were significantly elevated 
in the two studies which examined these levels (Vasudevan 
et al, '1971; Pleisnicar, 1970). The controls chosen in 
all three studies are not entirely satisfactory. In the 
, study by Vasudevan et al, the control values used are 
ones established by Sehgal and Aikat (1970) in the same 
population but by a different modification of the Man- 
cini method, and in a group with a heavy preponderance of 
males (107 males and 11 females). Within the same environ- 
ment, levels of serum immunoglobulins vary with age, sex 
and social class (reviewed in McFarlane, 1973). In the 
other two studies two controls have not been matched for 
any attribute - in fact in the Pleisnicar (1970) study 
the average age of controls was 18 years younger than 
that of patients. 
The lower levels of IgG and IgA in treated patients 
compared to untreated ones in the study done by Vasudevan 
et al imply that levels of total immunoglobulin may be of 
prognostic value. The value of levels of immunoglobulins 
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Table 4.9 Studies showing changes in level of IgG and 
IgA in malignancies other than carcinoma of the cervix 
IMMUNOGLOBULIN MALTGNANC REFERENCE 
IgA 
Elevated levels 
Cancer of larynx -Dostalova et al Cancer of breast (1970 and 1ý775T 
Cancer of epithelial, Waldman et al 
surfaces (1970) 
Hodgkin's disease Dienstbier et al-(1978) 
Oral cancers Brown et al (1975) 
I P: G 
Elevated levels 
Cancer of the Dostalova et, al 
kidney (Grawitz) (1975) 
IaG and Ig 
Elevated levels 
Cancer of the 
urinary bladder Dostalova et al, 
(1975) Cancer of the 
bronchu s 
Primary cancer Chew et al 
of the liver (1970) 
Kaposi sarcoma Master et al (1970) 
Increasing levels 
with, stage o 
disease 
Cancer of breast 
Cancer of bronchus Dostalova. et al. 
Cancer of larynx (1970) 
Cancer of bladder 
IgG 
Increasim levels 
with staýre of 
disease 
Cancer of breast Dostalova, et al. 
Cancer of bronchus (1976) 
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Table 4.10 Non-malignant conditions associated with 
changing levels of immunoglobulins 
DISEASE IMMUNOGLOBULIN AFFECTE REFERENCE 
Malaria Elevated IgG 
Elevated IgM 
Elevated JaA g 
Leishmaniasis Mild elevation of IgA 
possible 
Filariasis Mild elevation of Ig M. 
and IgG 
African Elevation of IgM 
trypanosomiasis 
Helminthic infection Elevation of IgM, IgG 
and IgA 
SchistosomiasiS Elevation of IgM, IgG 
and IgA 
Amoebiasis Elevation of IgG, IgM 
and IgA 
Tuberculosis Elevation of IgG, IgM 
and IgA - mostly IgA 
Syphilis, gonorrhoea Elevation of IgM and 
and salmonella IgG 
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as markers of occult tumor recurrence has not so far 
been studied. 
In this study, levels of IgG and IgA in the first 
serum samples of patients with cervical anaplasia have 
been compared with those of controls matched for age, 
sex and ethnic origin. In addition levels in serial 
samples of serum have been tested with a view to examining 
their prognostic value. 
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BIOCHEMICAL MARKERS IN MALIGNANCY 
A number of antigen systems have recently been 
investigated for their value as immunodiagnostic pro- 
cedures in human cancers (Table 4.12). Of these up to 
present time, human choriogonadotrophic determination 
(HCG) in chorioncarcinoma has been the most successful 
immunodiagnostic method in reducing mortality from any 
one malignancy. 
CEA was first-described by Gold and Freedman in 1965. 
It is a glycoprotein of approximate molecular weight 
200,000 which is found in the alimentary tract, liver and 
pancreas of fetuses between the second and sixth months 
of intrauterine life. With the development of sensitive 
radioimmunoassay, CEA has been detected in the serum or 
plasma of patients with a variety of tumors (Lo. Gprfo et al, 
1971), but the main problem with CEA as a marker of malig-- 
nancy is that there is a high rate of false positives 
(Stevens et al, 1975). For this reason it has limited 
use as a diagnostic marker. Serial estimations however 
have proved to be of prognostic value in gastric cancer 
(Freeman et al, 1979) and colorectal cancer (reviewed in 
Neville and Cooper, 1976). 
Elevated levels of CEA were first reported in patients 
with gynaecological malignancies in 1971 (Lo Gerfo et al, 
1971), after which it was shown that CEA from cervical 
cancer and CEA from colonic cancer are immunologically 
similar (Goldberg 
. 2t al, 
1976). 
103 
Recent studies have also indicated the possible use 
of CEA as a marker of occult recurrence in cervical-cancer 
(Di Saia et al, 1976; Khoo and Mackay, 1974; van Nagell et 
dl, 1978). In the study by van Nagell et al (1978), 
serial estimations of CEA were done on 143 patients with 
carcinoma of the. cervix (number of adenocarcinomas among 
them has not been stated). Forty-four of these patients 
developed-tumor recurrence and 99 progressed well. Rising 
1 evels of CEA were observed in 29 of 44 (65%) patients 
who developed tumor recurrence and in only 1 of 99 (1%) 
who progressed well. 
It has been suggested that in the : immunodiagnosis of 
a malignancy, several tests used concurrently may provide 
more discriminatory data than a single test (Herbermann, 
1977). This concept has been extended in this study to 
the detection of tumor recurrence, and the possibility 
has been explored of several tests used in combination 
providing specific and sensitive information of occult 
recurrence. The markers that have been studied are 
a) membrane antibody to viral antigen (HSV-2), b) fetal 
antigen (CEA), and c) levels of total immunoglobulin 
(IgG and IgA)- 
lo4 
Table 4.12 Some antigen systems of use in the immunodiagnosis 
of human cancer 
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Ferritin in plasma Breast carcinoma 
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SPECULATION ON THE PREVENTION OF HSV-2 GENITAL HERPES AND 
THEREBY CERVICAL CARCINOMA BY VACCINATION 
Melnick (1976) foresees that cervical carcinoma may be 
irradicated by the development of a suitable herpes simplex 
vaccine. - 
Skinner et al (1977) have made the observation 
that more controls than patients with cervical anaplasia 
poss ess only HSV-1 specific antibody without HSV-2 specific 
antibody, They suggest that this inverted case control 
prevalence of HSV-1 specific antibody alone may be an indica- 
tion that pre-pubertal exposure to HSV-1 portects from or 
modifies infection by HSV-2. 
Nahmias et al (1978), have drawn an interesting analogy 
between the role of Turkey herpes virus (THV) in preventing 
Marek's disease and HSV-1 in preventing cervical carcinoma. 
Both whole virus and virus capsid vaccine of THV protects 
from the lymphoproliferative disease caused in chickens by 
MDV but not from infection caused by MDV (Purchase, 1976). 
These workers have proposed that previous HSV-1 infection 
may similarly protect from malignant change induced by HSV-2- 
Because HSV-1 infection is commonly acquired in early child- 
hood, primary HSV-2 genital herpes (i. e. HSV-2 genital herpes 
in a patient with no prior exposure to HSV-1) is rare.. How- 
ever, if the hypothesis by Nahmias et al is correct, a greater 
proportion of patients with cervical anaplasia could be ex- 
pected to possess only HSV-2 specific antobody in comparison. 
with the proportion of women in the general Population 'who 
have only HSV-2 specific antibody. 
lo6 
AIMS AND OBJECTIVES OF THIS STUDY 
The primary aim of cancer research is to determine its 
cause and by so doing if possible to prevent it. Improved 
methods of early diagnosis which may reduce morbidity and 
mortality are two important objectives. Epidemiological 
s tudies may identify groups at high risk due to genetic, 
environmental, dietary, behavioural, occupational or infective 
reasons. Screening tests of high sensitivity and specificity 
are sought for the detection of pre-malignant and pre-clinical 
lesions. Theraýpeutic methods and tools are continuously. 
assessed and reassessed. Laboratory tests are sought for 
monitoring treated patients to determine the effectiveness 
ft 
of treatment and to detect occult tumor recurrence. Lastly, 
methods of immunological control are sought by means of vac- 
cination and immunotherapy. Thus the aims of the studie's 
described in this thesis were: 
1. To conduct a pilot study which tested the strength of 
the association between HSV-2 and cervical carcinoma in 
three countries - Sri-Lanka, Malawi and Sudan - in which no 
studies have yet been conducted and to confirm this association 
which two previous studies conducted in the U. K. have 
demonstrated. 
2. To study some of the relevant epidemiological character- I CD 
istics of women with cervical anaplasia in these four countries. 
3. To assess the effect that screening by Papanicolaou smear 
has had on the incidence rates and mortality rates from cer- 
vical carcinoma in England and Wales. g 
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4. To study the occurrence of antibodies to membrane anti- 
gens (MA) of HSV-2 infected cells, virus capsid antigens 
(VCA) of HSV-2 infected cells, and HSV-1 and HSV-2 type 
specific antigen, in women with cervical anaplasia, controls 
matched for sex, age, ethnic origin and social class, and in 
other control groups such as patients with genital and extra- 
genital herpetic infection and patients with a variety of 
other malignancies. To examine the antibody profiles of the 
above groups of patients from the view-point a) of early 
diagnosis and prognosis, b) of the possible protection that 
previous HSV-1 infection may confer on subsequent infection 
by HSV-2 or subsequent malignant transformation by HSV-2, and 
a c) of 
the nature of the association between HSV-2 and cervical 
carcinoma. 
5. *To study levels of serum IgG and IgA and carcinoembryonic 
antigen in patients with cervical anaplasia and to assess-if 
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FATIENTS AND CONTROLS 
Table 4.1 contains the groups of patients and controls 
in the study. '' These included patients with cervical anaplasia 
(dysplasia carcinoma in situ and invasive carcinoma) from 
Britain (Groups 1-4), and patients with invasive carcinoma 
from Sri Lanka, Malawi and Sudan (Groups 5.6 and 7). 
Controls for patients with cervical anaplasia were matched 
for age, sex, social class, and ethnic, origin. - 
Other control 
groups included. patients with genital and, extra'-genital 
herpetic lesions'(Groups 11 and, 12)'and patients with 
malignancies other than cervical carcinoma. 'The patients 
with malignancies other than cervical careinoma"were divided 
ft into three broad categories', (GroUps 8,:, g and 10). 'Group 8 
consisted of patientsvith genital malignancies'other than 
squamous cervical carcinoma; -group-9 of'patients, with non- 
genital squamous carcinoma, and group 10 of patientS"'with 
extra-genital non-squamous malignancies. 
The majority of sera from British patients were col- 
lected personally at St. Thomas' Hospital, London. The 
names of patients having abnormal smears was obtained from 
the cervical cytolog report book in the department of 1-13Y 
cytolog ., These patients were met at the gynaecology clinic my 
by tracing their names in the consultant's appointment book 
at the gynaecology clinics and seen at the wards by following 
the admissions lists to the wards. Patients who were'treated 
by radiotherapy were met at the combined gynaecology and 
radiotherapy clinic. The names of patients with malignancies 
other than cervical carcinoma were, obtained from the surgical 
pathology, report book. There were both caucasian and negrold 
log 
(mainly West Indian) patients among those seen at-St. Thomas' C) 9 
and they'are collectively referred to in this thesis as 
British patients. I 
PATIENTS WITH-DYSPLASIA OF THE UTERINE CERVIX (GROUP 1. TABLE 4.1) 
-These were patients seen at the g aec*ology clinic at CDM 
Stý- Thomas' Hospital. The diagnosis of dysplasia. was made 
on cervical cyt - ology alone and consisted of patients with a 
ýgrade 3A or 3B Papanicolaou(Pap) smear (see page 76 f or 
grading of Pap smears). Serial samples of serum were collected 
from 30 ofýthese patients when they presented for-repeat 
smear which wa's-'approximately once in every six months.. The 
epidemiological7. data of a further, 22-. patients, from whom it 
was not possible to obtain serial samples of serum was-made 
use of for analysis of data according to age, social class 
and ethnic origin (Part I of Results). 
PATIENTS WITH-CARCINOMA IN SITU OF THE UTERINE r-'RRVTX 
(GROUP 2. TABLE 4-1) 
These were also patients seen at the gynaecology clinic 
at St. Thomas' Hospital. The diagnosis of carcinoma in situ 
was made on histological examination of cone biopsy material 
following the detection of a grade 4 Pap. smear. ' Serial sam- 
ples of serum'were collected from 29 of these patients, of 
which the first serum was in each case collected prior to 
cone-biOpsy, -and subsequent samples when patient presented 
for follow upýat the clinic. The epidemiological, data, of 
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15 patients from whom serial samples could not be collected' 
were used in epidemiological analysis. 
PATIENTS. WITH INVASIVE SQUAMOUS CARCTNOMA OF THE UTERINE CERVIX 
Sera from patients with invasive carcinoma were obtained from 
four countries - Britain, Sri Lanka, Malawi and Sudan. They had 
been staged according to the recommendation of the Federation of 
International Obstetricians and Gynaecologists (FIGO, 1965) 
(see. page 78). 
_ 
13RITISH PATIENTt WITH INVASIVE SQUAMOUS CARCINOMA OF THE 
UTERINE CERVIX (GROUPS 3 AND 4. TABLE 4.1). 
S 
All British patients with invasivecarcinoma were ones 
treated at St. Thomas' Hospital. The diagnosis was made by 
histological examination of biopsy material after: 
a) Patient presented with symptoms suggestive ofý 
cervical carcinoma, e. g. vaginal discharge or-post coital 
bleeding, or- 
b) following the detection of a grade 4'Pap smear. 
In 29 patients, the first serum sample was obtained 
prior to treatment (Group 3, Table 4.1). The second serum 
sample was collected at the termination of treatment and 
thereafter at follow up visits to the clinic. 
In 41 patients (Group 4, Table 4.1), the first serum 
sample was collected 1-12 years after treatment. These were 
patients being followed up at the combined radiotherapy and 
gynaecologY clinics. Thereafter, serial samples of serum 
were collected from 30 patients - at each subsequent visit 
ill 
to the clinic. The epidemiological data from the 11 patients 
from whom no serial samples could be obtained was made use of 
for appropriate analysis. 
SRI LANKAN PATIENTS WITH INVASIVE SQUAMOUS CARCINOMA OF THE 
UTERINE CERVIX (Group 5, Table-4.1 
These were patients from Ward 8 of the Cancer Institute 
at Maharagama Sri Lanka, who had been referred from hospitals 
in all parts of the island. The diagnosis of squamous carcin- 
oma of the cervix was made on histological examination, of 
biopsy material following clinical examination for symptoms 0ý 
suggestive of the tumor. Routine cervical cytology is not 
yet carried out in Sri Lanka. The first serum samples from 
all Sri Lankan patients was obtained prior to treatment. The 
initial few were collected personally on a visit to Sri 
Lanka and thereafter both pre-treatment samples from fresh 
cases as well as serial samples, were collected by Dr. 
Lorraine Senarath, the house officer in charge'of Ward 
It was not Possible to obtain serial samples for as long a 
period of follow up as for British patients because some of 
these patients were referred to their local hospitals for 
follow up and others defaulted attendance at the follow up 
clinic at,, the-cancer institute. Among the Sri Lankan 
patients there were both Sinhalese and Tamils. 
MALAWIAN PATIENTS WITH INVASIVE SQUAMOUS CARCINOMA OF THE 
UTERINE CERVIX (GRoup 6, TABLE 4.1) 
Sera from these patients was arranged for by Professor 
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M. S. R. Hutt of the Geographical Pathology Unit at St. Thomas' 
Hospital and were collected and shipped by Dr. J. Chiphangwi 
of the Queen Elizabeth Central Hospital at Blantyre, Malawi. 
Pre-treatment samples of serum were sent from 27 patients 
with invasive squamous carcinoma diagnosed by histological 
examination of biopsy material from the tumor. Post-treatment 
s amples of serum were obtained only from four of these 
patients. These patients had been drawn from the area 
around ýIantyre and were all Malawian. 
SUDANESE PATIENTS WITH INVASIVESQUAMOUS CARCINOMA OF THE 
UTERINE CERVIX (GROUP 7, TABLE 4.1) 
Pre-treatment samples of serum from, 27 patients with 
histologically confirmed squamous carcinoma of the cervix 
was provided by Dr. M. O. A. Malik. These were control sera 
being used by him on a study-on. nasopharyngeal carcinoma in 
Sudanese in collaboration with the department of pathology 
and virology at St. Thomas' Hospital. For this reason it 
was not possible to obtain either serial samples of serum 
from patients, or sera from matched controls. 
CONTROLS FOR PATIENTS WITH CERVICAL ANAPLASIA 
Controls for British', patients with cervical anaplasia .1 
A pool of 133 control sera were collected at the- - 
gynaecology clinic at St. Thomas' Hospital. These were all 
patients who presented with complaints such as-menorrhagia, 
dysmenorrhoea, subfertility, etc. on whom a recent normal 
smear report was available. They were later matched with 
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patients with cervical anaplasia according to age, ethnic 
origin and social class. 
Onntro q, fr Sri Lankan patients with invasive carcinoma 
A pool of 44 Sri Lankan control sera were collected 
personally on a visit to Sri Lanka at the gynaecology clinic 
at-the De Soysao maternity home at Colombo 8. Since cervical 
smear reports were not available on these patients, 'patients 
who had apparently healthy cervices on speculum examination 
were chosen. These were patients who presented for symptoms 
unrelated to cervical carcinoma. Of this pool, of 44 con- 
trols, only 17 could be matched with Sri Lankan patients- 
with invasive carcinoma on the basis of age, social class 
and ethnic. -origin. e-I 
QUESTIONNAIRE FOR PATIENTS WITH CERVICAL ANAPLASIVAND 
FOR CONTROLS 
A specimen of the format for personal history and clini- 
cal history of patients with cervical anaplasia and of con- 
trols is given in Appendix A. Precise informaýion was not 
available on the Sudanese patients. 
PATIENTS WITH OTHER GENITAL MALIGNANCIES (GRoup 8, TABLE 4-1) 
Pre-treatment samples of serum were collected from 33 
patients with other genital malignancies who were treated 
in the gynaecology wards at St. Thomas' Hospital. They 
consisted of the following groups of patients: 
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Adenocarcinoma of the cervix 7- 
Leiomyosarcoma of the uterus 1 
Endometrial carcinoma 17 
Adenocarcinoma of the ovary 3 
Teratoma of the ovary 
Cystadeno carcinoma of the ovary 1 
Squamous carcinoma of the vulva 3 
ATIENTS WITH NON-GENITAL SQUAMOUS CARCINOMA (GROUP 9, TABLE 4.1) 
Pre-treatment samples of serum were collected from 24 
patients with squamous carcinoma at different sites of the 
body. Samples from three patients with squamous carcinoma 
of the larynx were provided by Dr. K. E. K. Rowson of the 
Institute of Laryngrology and Otology at Gray's Inn Road and C) CD 
samples from four patients with squamous carcinoma of the 
bronchus were provided by'Dr. 'K. J. Randall-of the Orpington 
Hospital at Kent. The sites of occurrence of squamous 
carcinoma in these patients were as follows: 
Squamous carcinoma of the bronchus 6! 
of the lung 3 
of the larynx 7 
of the oral cavity 2" 
of the oesophagus 2 
of the ano-rectal junction 11 
Secondary Sq. Ca. metastasis in cervical nodes, 
primary not known 3 
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PATIENTS WITH EXTRA-GENITAL NON-SQUAMOUS MALIGNANCIES 
(GROUP 10, TABLE 4.1) 
Pre-treatment samples of serum from 24 such patients " 
výer-_ collected- Thirteen pre-treatment samples were pro- 
vided by Dr. K. J. Randall. The malignancies in these 
patients were as follows: 
Adeno carcinoma of the colon and rectum 
Invasive carcinoraof the breast 8 
Adeno carcinoma_of the prostate 4 
Adeno carcinomaýof the, bile-duct,, testis and pancreas 3 
(one each) 
Anaplastic car'cin"oma I of the stomach' 4 
Poorly differ, entiated malignancy of the bladder"' 5 
Malignancies of the kidney 2 
PATIENTS WITH GENITAL HERPES (GROUP 11, TABLE 4.1)"", 
Serial samples of serum from more than 16 patients with. 
genital herpes were provided by Dr. B. F. Carrol 'of the genito- 
urinary department at St. Thomas' Hospital. ' Of these, 16 
patients were chosen for the study in whom there was viro- 
logical confirmation that the infecting virus was HSV-2. 
Typing of the viral isolate was on the basis of cytopathic Cý 
effect (CPE) on human embryo lung cells and pock size on 
the choriallantoic membrane (CAM) of eggs. The first serum 
samples from all these patients was collected within two 
months of their first clinical attack of genital herpes. 
Thereafter, attempts were made at virus isolation from the 
cervix and vulva at subsequent visits to the clinic despite 
there being no apparent clinical lesions. 
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PATIENTS WITH EXTRA-GENITAL HERPES (GROUP 12, TABLE 4.1) 
Serial samples of serum were collected from 16 patients 
presenting with extra-genital herpetic lesions to the depart-' 
ment of Virology at St. Thomas' Hospital. Following initial 
diagnosis by elctronmicroscopy the infecting virus was con- 
firmed as being HSV-1 by the appearance of CPE on human I 
embryo lunjo,, cells and pock size on CAMs. 
SOCIAL CLASS GRADING 
British patients were divided into five-social classes 
using the system of the U. K. Registrar General: (Classifica- 
tion of-, occupations, 1970). The husband's, job was used, as 
the index for classifying married women, divorcees and 
widows, the father's job to classifSr unmarried women who 
were not employed, and unmarriedwomen who were employed 
were classified according to their own jobs. 
Sri Lankan patients were classified into three social 
class groups: low, middle and upper. This division was 
guided by job status and income. 
Malawian and Sudanese patients were classified into three 
groups: low, middle and-upper, by Dr. - Chipangwi and Dr. 
M. O. A. Malik respectively. 
Collection and storage of sera. 
Twenty millilitres of blood was-dr4vln from the cubital vein. 
It was allowed to clot at 37 0C in a water bath for 15 minutes, 
left overnight at 40C and the serum separated by centrifugation 
in a bench centrifuge. Serum was aliquoted and stored at -200C. 
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Table 5.1 Country of origin, Patients and controls 
DIAGNOS12 NUMBEIR SERTAL 5Avs COUNTRY 
1 Dysplasia 30 (22) Yes Britain 
Controls 27 
2 Ca in si tu 29 (15) Yes Britain 
Controls 29 
3 Untreated invasive Ca. 29 Yes Britain 
Controls 22 
4 Treated invasive Ca. 30 (11) Yes Britain 
Controls 15 
ý5 
Invasive carcinoma 32 from 29 Sri lanka 
Controls 17 
.6 Invasive carcinoma 27 
from 4 Malawi 
Controls", 18 
7 Invasive carcinoma 27 Sudan 
Controls 
8 Other genital malignancies 33 Britain 
9 Non-genital squamous 18 Britain 
carcinoma 
10 Extra-genital non-sq. Ca. 37 Britain 
11 Genital herpes 16 Yes Britain 
12 Extra-genital herpes 16 Yes Britain 
no. of patients from whom it was'not possible to 
collect serial samples 
METHOD 1 
IgG AND IgA MEMBRANE ANTIBODY 
ASSAY ON HSV-2 AND HSV-1 
INFECTED CELLS. 
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D-rG AND IgA MEMBRANE ANTIBODY ASSAY ON HSV-2 INFECTED CELLS 
All equipment and materials employed in the membrane 
fluorescent assay are described in Appendix B. 
CELLS ' 
Rabbit kidney cells (RK13) (B17) were grown in C> 
2 
polystyrene disposable bottles of surface area 150 cm 
Both the growth medium (B18) and maintenance medium (B19) 
contained minimal essential medium supplemented with fetal 
calf serum, glutamine and sodium bicarbonate. The quantity 
of medium used was 50 ml per 150 cm 
2 bottle. When the cells 
a were confluent, 
they were split ýone bottle to three bottles 
using a solution of trypsin and versene (B22). They were 
grown at 37 0C and inoculated with virus on the third day after 
splitting by which time the cell sheet was confluent. 
VIRUS 
The Bry strain of HSV-2 virus was used (B30A) which was 
grown on RK13 cells and titred on the chorioallantoic membrane 
of fertile incubated eggs (Appendix C). 
INFECTING CELLS WITH VIRUS 
A virus inoculum of 1 p. f. u. per cell was used and left 
to adsorb at room temperature for one hour. Thereafter the 
virus inoculum was discarded and 50 ml of, rpaintenance medium 
added. The infected cells were incubated at 370C till there 
was a 50-75% cytopathic effect (CPE) which usually developed 
in 15-17 hours. 
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CONTROL CELLS 
RK13 cells were mock inoculated with sterile phosphate 
buffered saline (PBS - B25) which was discarded at the end 
of one hour after which maintenance medium was added and the 
cells incubated for the same length of time as the infected 
cells. 
Harvestin7- of infected and control cells 
- Both control and infected cells were harvested into the 
maintenance medium by introducing into the bottle glass 
beads of diameter 3-4 mm, and shaking gently with the bottle 
closed and held horizontally, till all the cells had been 
detached from the bottle surface. 
Washing of 'cells 
The infected cells and control cells were, separately 
pooled into two or more centrifuge bottles and centrifuged 
(B13) for 10 minutes at 1000 x g. The supernate was dis- 
carded and the cells washed twice in freshly prepared non- 
sterile PBS. 
Distribution of cells into microtitre plates 
The cells were resuspended in freshly made PBS and 
distributed into the wells of U-shaped microtitre plates 
(B2) such that wach well received approximately 2-5 x 105 
cells, i. e. 




Each microtitre well was filled with'0.2 ml of cell suspension. 
Theref_ore 16 x 10 
6x0.2 
= 6.6 mi 
5x 10 5 
i. e. the cells from one bottle required to be suspended in 
6.6 ml of PBS such that 0.2 ml would contain approximately 
5 5-x 10 cells. Thus the cells harvested from one bottle was 
sufficient for approximately 32 wells. Control cells were 
distributed into control wells and infected cells into test 
wells as indicated in Figures 4.1 and 4.2. The plates were 
spun at 1000 xg for 5 minutes and the supernate removed 
with a finely drawn pasteur pipette which was attached to 
a vacuum pump. 
SERUM DILUTIONS 
N, 
All'sera were tested under code. All sera were heat 
inactivated at 560C for half an hour. ' This' reduced the 
tendency of some sera to cause clumping''of cells. Serial 
samples of serum from a sinrgle patient were always tested 
the same day. DilutiDns were made in freshly made PBS in 
microtitre plates. The starting dilution in the IgG mem- 
brane fluorescence assay was 1: 8 and in the IgA assay 1: 4. 
A hand multidilutor (B6) was used with 0.05 dilutbrs 
and employing two rows of wells for each serum. 0.05 ml, 
disposable pipettes (B3) were used to distribute PBS to the 
plates and Kim pipette (B4) and disposable tips (B5) to 
transfer aliquots of serum to the starting well. By pool- 
ing similar serum dilutions in both rows. 0.1 ml of each serum 
dilution was added to each well containing the infected or r> 
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control cells using-a Finn pipette and disposable tips. 
One tip was used per serum starting at the highest dilution.. 
As experience was gained, the dilutions indicated in Figure 
4.1 were found to be the most convenient for use in the'IgG 
assay and those in Figure 4.2 for the IgA assay. Any serum 
which had no detectable antibody at'a 1: 64 dilution or 
appeared to be of a higher titre than 1 1024 in the IgG 
assay was retitred using the appropriate dilution range. 
Similarly, in the IgA assay, sera which appeared to be of a 
higher titre than 1: 64 were retitred. The serum'dilution 
added to the control cells was always 118 in the IgG assay 
and 1: 4 in the IgA assay"'in order to detect non-specific 
fluorescence. 
CONTROLS 
The same positive control serum and negative control 
/ 
serum was used in all tests. These sera were stored in 
aliquots of 0.2 ml. Thus a fresh aliquot was used in each 
test.. In addition, a PBS control was used in each test. 
It was thus possible to test 30. sera per day (2 plates). 
Incubation of serum with cells. 
Once the serum dilutions were added to the cells, the 
plate was placed very lightly on a rotor mixer (B11) so that 
good mixing of cells and serum was ensured. The plates were 
incubated for one hour in an airtight moisturized plastic 
sandwich box. 
--122 
Eigure 4.1 Tem-plate for IgG mbmbrane'fluoresýence asszLy.. 
a 
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Washing of cells 
At the end of one hour, each well was topped with PBS 
with a pasteur pipette and centrifuged at 100 xg for 5 
minutes. The supernate was sucked out as explained above. 
The cells were agitated very briefly by placing the plates 
ori the rotor mixer and the washing procedures repeated 
twice more. The supernate was carefully and completely 
sucked out at the end of the third wash. 
Adding of conjugat 
Rabbit antihuman IgG fluorescein isothiocyanate was 
used in the IgG membrane fluorescence assay and rabbit anti- 
human IgA fluorescein isothiocyanate, in the IgA membrane 
fluorescence assay (B31)- 
The conjugate had been previously absorbed (Appendix E) 
with pig liver powder (Appendix D) and control cells, and 
the optimum working dilution decided on by means of checker 
board titration. 0.05 ml of conjugate at the optimum work- 
ing dilution was added per well. The cells and conjugate 
were mixed well on the rotor mixer and incubated for one 
hour at 37 0C as described above. 
Washing of cells 
As described above. After the third wask the supernate 
was withdrawn as completely as possible using a finely 
drawn pasteur pipette. 
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Resuspension of cells in glycerol-PBS 
A 50% solution of glycerol (B27) in PBS was prepared 
fresh and a minute drop added to each well employing a 
finely drawn pasteur pipette. The cells and glycerol-PBS 
were mixed well by pla cing the plate lightly on the rotor 
mixer. 
Spotting the resuspended cells on microscope slides 
Employing a Finn pipette and a disposable tip per serum, 
0 
cells in each well were spotted on glass microscope slides 
(B7) beginning with the well containing the control cells 
and working through from the well with the highest serum 
dilution. 
One slide was sufficient for the cells reacting with 
one serum (6 spots). Round glass coyerslips (B9) were 
dropped over each spot. 
Storing of slides 
The slides were placed in a cardboard slide holder and 
stored at -20 
0C for 24-118 hours before reading. 
Reading of slides 
The slides were read using a fluorescent microscope with 
an epifluorescence condepser and phase contrast (B14). 
Determination of end-point 
The positve control serum used in the IgG assay repeatedly 
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titred at 1: 128 or 1: 256. This slide was examined after 
the slides containing PBS controls and the negative control 
serum, and the proportion of fluorescent cells at the 1: 128 
dilution noted. In each test serum the end point was the 
reciprocal of the serum dilution which gave a similar 
proportion of fluorescent cells of the same degree of bright- 
ness as observed in the 1: 128 dilution of the positive 
control serum. In this manner the best possible standard- 
ization was achieved not only between the sera in one assay 
but also of sera tested on separate days. , 
Nature of membrane fluorescence 
a Only cells showing clear membrane fluorescence such as 
shown in Figure 4.3 were considered, e. g. dead cells as 
showing in Figure 4.4 in which the whole cell takes-up 
fluorescent stain was not considered. When the site of 
fluorescence was in doubt it was helpful to observe them 
under phase contrast together with fluorescence, Figure 4.5. 
Slides chosen randomly were 
independent reader. 
Non-specific ftuorescence 
sometimes checked by an 
The sera which showed non-specific fluorescence on 
control cells were re-tested after prior absorption with 
control cells (Appendix F). 
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Figure 4.3 Rabbit kidney cells infected with HSV-2 
ýhowimý membrane fluorescence. 
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Figure 4.4 Appearance of dead HSV-2 infected 
rabbit kidney cells in the membrane fluorescence assay. 
Figure 4.5 Rabbit kidney cells shovring membrane 
fluorescence, observed with pha. se contrast and red 
filter. 
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The membrane fluorescence assay for IgG and IgA antibody to 
the membrane antigens of HSV-1 infected cells 
All the equipment and materials employed in this 
assay are described in Appendix B. 
The method was the same as described above for IgG 
and IgA antibody to membrane antigens of HSV-2 infected cells 
except for the following: 
1. Virus - the HFEM strain of HSV-1 virus was used (B30B) 
2. Concentration of infected cells - On distributing 
ft 
infected cells into microtitre wells, a slightly higher 
concentration of cells was used per well as the HSV-1 
infected cells tended to disintegrate more rapidly than 
the HSV-2 infected cells. Each well received approximately 
6x lo 
6 
cells, i. e. each bottle yielded approximately 
16 x 10 
6 
cells. 
Each microtitre well was filled with 0.2 ml, of cell suspension. 
There fore 16 x 106 x 0.2 :'4.6 mi 
. (approximately) 
6x 105 
i. e. the cells from one bottle required to be suspended in 
4.6 -5 ml of PBS. Thus the cells harvested from one 
150 cm 
2. bottle was sufficient for approximately 24 wells. 
METHOD 2 
a 
FLUORESCENT ASSAY FOR IgA ANTI- 
BODIES TO VIRUS CAPSID ANTIGEN 
OF HSV-2 INFECTED CELLS 
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ZLUORESCENT ASSAY FOR TgA ANTIBODIES TO VIRUS CAPSID ANTIGE 
The equipment and materials used in this assay are 
described in Appendix B. 
QELLS - 
Rabbit kidney cells (RK13) cells (BI7) were grown in 
polystyrene bottles (Bl) of surface area 150 cm 
2 
using 
growth medium (B18). On the third or fourth morning after 
splitting the cells, a confluent cell layer:, kas obtained. 
They were then infected with virus. 
VIRUS 
The Bry strain of HSV-2 virus-was used (B29A). A virus, 
inoculum of 1 p. f. u. /cell was used. The virus was allowed to 
adsorb for one hour at room temperature (RT) after which it 
was discarded, and 50 ml of maintenance medium (B19) added 
0 to the bottles. The infected cells were incubated at 37 C 
for nine hours. 
CONTR L CELLS 
Control cells were mock inoculated with PBS and incubated 
for the same length of time. 
HarvestinR and-washing of cells 
The maintenance medium was discarded and 20-30 ml of 
ice cold veronal buffer (B26) (VB) and a few glass beads of 
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diameter 3-4 mm were added to each bottle. The cells were 
gently detached from the surface of the bottle by shaking 
the bottle held in a horizontal position. The infected and 
control cells were pooled separately into centrifuge bottles 
and centrifuged at 40C at 1000 xg for 10 minutes. The 
washing process with ice-cold VB was repeated twice more and 
the supernate discarded. The cells were suspended in 20 ml 
of VB per 150 cm 
2 bottle, mixed well using a 10 ml pipette in 
order to break up clumps of cells and counted in a Neubauer 
counting chamber. The cells were diluted further with VB eD 
to give a cell concentration of 2.5 
.x 105 c*ells/ml. 
Placing of cell suspension on slides 
0.05 ml of cell suspension was dropped in each spot of 
multispot microscope slides (B8) using a disposable pipette 
(B3) - 
Drying of slides 
The slides were allowed to air dry overnight'at 
room temperature (RT). 
Acetone fixation 
The next morning the dry slides were placed in coplin C. 
jars, washed briefly with ice cold acetone which was dis- 
carded and left to fix for 20 minutes in'fresh ice cold 
acetone. During this 20 minutes the coplin jars were kept 
at 40C. The acetone was discarded and the slides allowed 
to air dry. 
. 
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Storage of slides 
The slides were wrapped in parafilm and stored at -700C 
in cardboard boxes. 
They were used within two weeks of preparing. Beyond 




The slides were placed', on a plastic mesh. work, frame 
which fitted into the lid of a sandwich box and allowed to 
come to RT. 
Serum dilutions 
The sera were thawed and heat inactivated (560C for 
half an hour). Sera were tested under code. Serial sam- 
ples of sera from one patient were tested in the same assay. 
Approxiamtely 41 sera were tested in one day. Two-fold 
serum dilutions were made in microtitre plates using a hand 
multidilutor (B6). 0.025 ml of each serum dilution was 
placed on each spot using a Finn pipette and a disaposable 
tip per serum, beginning at the highest dilution. 
Controls 
The same positive control serum and a. neggative control 
serum were used in all tests. In addition, PBS controls 
were set up both on infected and control cells. 
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Incubation 
The sandwich box was mois. turized, closed and incubated 
for, one hour at 37 OC. 
Washins 
At the end of one hour each slide was briefly rinsed 
with"VB, usin-v a drop bottle and placed in coplin jars con- 
taining ice cold VB. The coplin jars were placed on a shaker 
at RT and the slides allowed to wash while the buffer was 
being gently agitated. Washing proceeded for half an hour, 
replacing with fresh buffer every 10 minutes. The. slides * 
were drained, gently mopped with tissue, replaced on the 
plastic mesh. in the sandwich box lids and allowed to air 
dry. When completely dry the conjugate was added to each spot. 
Coniugat 
Rabbit anti-human IgA conjugate (B31) was used which had 
been previously absorbed (Appendix E) with pig liver powder- 
(Appendix D) and control cells. The optimum working dilution 
of the conjugate had been previously determined by checker 
board titration 0.25 ml of conjugate of the working 
0 dilution was added to each spot and incubated at 37 C for 
one hour in the air-tight moisturized box. C) 
Washing 
The slides were washed as described above. 
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Mounting of slides 
The slides were mounted in 90% PBS glycerol (B27) 
using rectangular cover slips (B10). They were placed in 
cardboard slide holders and stored at -200C and read within 
48 hours. 
Reading slides 
The positive serum titred at 1: 32 or 1: 64 in. each test. 
The end, point of the test serum was the one in which clear 
cytoplasmic or perinuclear fluorescence was observed similar 





HSV-1 AND HSV-2 SPECIFIC ANTI- 
BODY BY ENZYME LINKED IMMUNO- 
ABSORBENT ASSAY (ELISA) 
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ENZYME LINKED IMMUNbABSORBEýT ASSAY (ELISAYFOR HSV-1 AN 
HSV-2 SPECIFIC ANTIBODY 
These tests were conducted by Dr. B. F. Vestergaard of 
the Department of Clinical Virology, Institute of Medical 
Microbiology, University of Copenhagen, Denmark (Grauballe 
and Vestergaard, 1977; Vestergaard et al, 1977)- 
ANTIGEN 
HSV-2 type specific antigen 
I 
Crude antigen was prepared from Triton X-100 solubilised 
HSV-2 infected rabbit cornea cells. The solubilised HSV-2 
AP proteins were purified by ion exchange chromatography. The 
chromatographically purified glycoprotein preparation 
designated fraction 1 (Vestergaard and Grauballe, 1975) was 
next passed through a cyanogen-bromide activated Sepharose-4B 
column coupled previously with purified immunoglobulin of 
rabbit anti HSV-1 anti serum. The fractions which contained 
HSV-2 specific antigen were identified by screening by ELISA 
against a pool of HSV-1 antisera from children aged 6-11 years, 
and a pool of sera from patients with virologically confirmed 
HSV-2 infection. The fractions obtained'immediately after 
the void volumn contained HSV-2 type'specific antigens ''- 
exclusively and were pooled and used in ELISA. 
JISV-1 tyne specific antige 
HSV-1 type specific antigen was prepared in the same 
manner employing HSV-1 infected rabbit cornea cells. Sepharose 
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B was coupled with purified immunoglobulin from rabbit serum 
raised against HSV-2- 
General virus antige 
Fraction I glycoproteins obtained following purification 
bý ion exchange chromatography was used as'general virus 
antigen. 
Control antigen 
Triton-X solubilised, uninfected rabbit cornea cells 
were purified by ion-exchange chromatography and the fraction 
I glycoproteins used as control antigens. ' 
VIRUS 
HSV-1 strain F 
HSV-2 strain G 
SERA 
Test sera were tested at a dilution of 1: 100. 
The positive reference serum used against general virus, 
antigen. as a control for estimating antibody to type common 
antigen gave an optical density (OD) value of 70. The 
positive reference serum used against HSV-1 type specific' 
antigen gave an OD value of 20, and that used against HSV-2 
type specific antigen gave an OD value of 30- 
Test sera which gave an OD value of greater than or 
equal to 10 were considered definite positives. Values 
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between 6 and 10 were considered as possible positives. 
METHO 
Microtitre plates were used (Cooke M220-25A). The 
lip 
plates were pre-coated with 100 ul per well of 0.1% bovine 
albumin (Fraction V, Sigma no. A-4503) in distilled water. 
The bovine albumin solution was allowed to dry out at room 
temperature. 100 ul of 0.25% glutaraldehyde (25% glutar- 
aldehyde, Fluka AG pract 49630) in PBS adjusted to pH 7.0 
with NaOH added-to each well. After 30 minutes at room 
temperature, the wells were emptied and washed three times 
in 150 ul of distilled water. 100 ul of a 1: 200 dilution 
of antigen was then added to each well and allowed to dry 
out at room temperature followed by washing three times as 
described above. Test sera and peroxidase conjugated rabbit 
anti-human IgG (P-1090, DAKO Immunoglobulins, Copenhagen, 
Denmark) were diluted in a 0-5% bovine albumin with 0.05% 
Tween 20 (Art 822184, Merck) in PBS. 100 pl of test serum 
dilutions were added to each well and incubated for one hour 
at 370C followed by washing three times with 150 tLl Of 0.05% 
Tween 20 in PBS. 100 pl of the enzyme conjugate diluted 
* as 1: 200 was then added, followed by incubation and washing 
described above. 55 mg of 1: 2 phenylendiamindihydrochloride C-D 
(Fluka AG, puris) was dissolved in 100 ml of an 0.04 M Tris-HC1 
buffer pH 7.6 with 0.9% NaCl. Just before use, 30 Rl of 30% 
H202 was added and 100 V1 of the reaction mixture was placed 
in each well. The reaction proceeded for 5 minutes at room 
temperature and was stopped by the addition of 50 A of 
0.1 NH 2S04 . The contents of each well were transferred to 0.5 ml, 
if 0.1 NH2 so 4 and the OD was read in a Zeiss spectrophotometer 




HSV-11 AND HSV-2 SPECIFIC ANTI- 
BODY BY COMPLEMENT FIXATION TES5 
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QETECTION OF HSV-1 AND HSV-2 SPECIFIC ANTIBODY BY COMPLEMENT 
FIXATION TEST (SKINNER, HARTLEY AND WHITNEY, 1976) 
Some of the sera used in this study were tested-for 
HSV-1 and HSV-2 specific antibody usiAg, the above test by 
Dr. G. R. B. Skinner of the Department of Virology, The Medical 
School, Birmingham, England. 
gummary-of the test 
Type-specific antigen of HSV-1 and HSV-2 were prepared 
by rigorous absorption of HSV-1 and HSV-2 infected cell ex- 
11 
tracts with heterotype immune sera. The sera under test were 
heat inactivated, and tested at a dilution of 1: 10 by complement 
fixation assay against the following five antigens: 
1. Control antigen prepared with uninfected cells. 
2. General virus-antigen (unabsorbed) prepared from HSV-1 
infected cells. 
3. General virus antigen (unabsorbed) prepared from HSV-2 
infected cells. 
4. HSV-1 type specific antigen. 
HSV-2 type specific antigen. 
MATERIALS AND METHODS 
lZiruses 
a), HSV-1 - The, HFEM derivative if the Rockerfeller strain 
of HF was used. 
, b) HSV-2 - Strain 3345, a penile isolate from the venereal 
disease clinic of the General Hospital, Birmingham. 
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Preparation of general virus anti-ge 
Rabbit kidney (RK13) cells were infected at. 10 pfu/cell 
with HSV-1 or HSV-2 and incubated at 37 0C for 24-36 hours. - 
The infected cells were removed from the glass, washed with 
PBS and resuspended in veronal buffer (VB) at a concentration 
8 
of 10. cells per ml and disrupted ultrasonically. The anti- 
gen thus prepared when tested by immunodiffusion against 
homologous immune sera, gave multiple precipitin lines. The 
antigen was stored at -70OC- 
Immunod if fus t 
_es 
It 
This was carried out in 1% w/v ionagar in isotonic 
saline containing, 0.1% sodium azide., Six hexagonally 
arranged wells surrounded a central well, each separated by 
2 mm from margin to margin. The plates were incubated at 
room temperature in a humidified chambered for. 72 hours 
before reading. 
Preparation of control antige 
Control antigen from uninfected RK13 cells was prepared 
in the same manner as general virus antigen was prepared. 
Preparation of type-specific antige 
11 
1 ml of general virus I antigen prepared as described 
above was diluted five-fold with VB and mixed with 0.25 ml 
of*undiluted heterotypic serum. It was gently agitated at 
40C for 12 hours. The precipitate was removed by 
I centrifuga- 
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tion at 3000 rpm for 15 minutes* in a bench centrifuge at 40C. 
This absorption procedure was repeated three times more and 
the final process of centrifugation carried out at 100,000 xg 
for one hour at 40C. This was to remove insoluble complexes 
and virus particles. The antigen was stored at -700C in 
0.2 ml volumes. No decline in complement fixing activity 
was observed during three months' storage at this temperature. 
Checking the type, sDecific antigen bv immunodiffusion 
The type specific antigen gave no 4etectable precipita- 
tion lines on testing at different concentrations against 
heterotypic serum by immunodiffusion. 
4p 
Pre. paration of antiserum to HSV-1 and HSV-2 
This method was as described by Watson et al (1966). 
HSV-1 and HSV-2 general virus antigen was prepared as 
described above. ' Rabbits were given three weekly intra- 
muscular injections of 200 ma of antigen in Freund's in- ID 
complete adjuvant and thereafter a booster injection at 
three-monthly, intervals. 
Serological proceedure 
A microtest was carried out in Linbro trays. 
Complement: Guinea pig (Wellcome). 
haemolytic doses were used. 
Sheep red cells: The sensitized sheep red cells were used at 
a concentration of 5x 107 cells per ml. 
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Antigen: 8 complement fixing units of antigen were used. 
Sera': Heat inactivated (560C for I hour) at a 1tIO dilution 2 
was used and tested in triplicate. 
Antigen, serum and complement were left at 40C over- 
night for fixation to occur. On the next day the indicator 
0 red cells as well as plates were brought to 37 C and the plates 
were further incubated for 30 minutes at 370C, and 30 minutes 
at 40C, after adding the red cells. 
Controls 
The controls used in the assay were: 
a) control antigen 
b) positive control serum for HSV-1 antibody 
C) positive control serum for HSV-2 antibody 
d) seronegative serum 
e) complement control 
f) cell control 
g) antigen control 
Reading of results 
I The results were read as indicated in Table 4.2. 
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Table 5.2 Classification of serotvpes according to the 
complement fixation test. 
CONTROL GENERAL GENERAL HSV-1 HSV-2 SER6TYPE 
ANTIUEN VIRUS VIRUS TYPE TYPE 
ANTIGEN ANTIGEN SPECIFIC SPECIFIC 
HSV-1 HSV-2 ANTIGEN ANTIGEN 
SN 
+ + HSV-l 
specific 
antibody 
+ + + HSV-2 
specific 
antibody 
+ + + + HSV-1 & HSV. 
specific 
antibody 
+ + Seropositiv, 








DETERMINATION OF LEVELS OF 
SERUM IgG AND IgA BY SINGLE 
RADIAL IMMUNODIFFUSION 
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MFTHOD FOR DETERMINING LEVELS OF SERUM IgG AND IgA BY SINGLE 
RADIAL IMMUNODIEEUSIO 
All equipment and materials used are described in 
Appendix G. 
Method 
The method described by Mancini et al (1965) was employed. 
0 
Single radial diffusion plates (Gl), reference sera (G2), and 
the sera to be tested were left, on the bench for at least 
15 minutes until they came to room temperature. The test 
serum samples used were fresh aliquots which had not been in- 
activated or frozen and thawed repeatedly. If moisture was 
present in the wells of the plates when the resealable 
plastic envelope was removed, they were allowed to stand a 
further 15 minutes uncovered to permit evaporation. Ten 
microlitre quantities oe each standard reference serum (high, 
mid-range and low) were pipetted into three separate wells 
on each plate. The test sera were pipetted in 10 ý_l quantities 
into the other wells. In doing this the wells were filled 
fronýthe botto-m upwards. The covers of the plates were re- 
placed and the plates allowed to stand 15 minutes before mov- 
ing. The plates were placed in resealable plastic envelopes 
and left at room temperature on a level area for four days to 
allow complete'diffusion. At the end of four days the diameter 
of the developed rings were measured to the nearest 0.1 mm, 
using a diameter measuring template (G4) placed over a' 
X-ray viewer (G5). A calibration curve was constructed 
using the readings given by the three standard sera. The 




as the X-coordinate. A straight line was 
drawn of best fit for all the points. The concentration 
of IgG or IgA of the test serum was read in iu/ml from the 
standard curve. A new standard curve-was prepared for each 
set of plates used. 
METHOD 
ASSAY FOR CARCINO EMBRYONIC 
ANTIGEN (CEA) 
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ASSAY FOR CARCINO EMBRYONIC ANTIGEN JCEA 
Serial samples of serum collected from British patients 
with invasive carcinoma and single samples of serum from 
matched controls were assayed for levels of CEA by Dr. 
Frances Searle, at the Department of Oncology, Charing Cross 
Hospital (Fulham), Fulham Palace Road, London. 
CEA was prepared by conventional perchloric acid ex- 
traction from liver metastases, of colonic carcinoma. This 
was further fractionated by Concanavalin A chromatography. 
The CEA fraction released by 2% methyl glucoside (termed the 
2B fraction) was labelled with 
1251 
using, a modification of 
0 
the chloramine-T method of Hunter and Greenwood (1962). 
Rabbit antiserum was raised against this 2B fraction. 
This antiserum. was absorbed against pooled normal human C> II 
plasma and bound to enzacryl The assay used was a solid phase 
direct competition assay. 50 0-1 of. enzacryl containing 
bound rabbit anti-CEA, serum was made to react at 37 
0C over- 
night with 100 ýxl, of the sample,. 50 JU of labelled CEA 
(2B fraction), and 100 ý1 of PBS. At the end of the over- 
night incubation, the reaction mixture was filtered on a rapid 
automated Kentek 3000 machine whichý directly estimated the CEA 
activity of the sample. The range of CEA activity recognised 
by the machine was 5 g/litre to 1000 -, g/litre. There was 








METHOD FOR-DETERMINING RUBELLA HAEMAGGLUTINATION INHIBITING 
All materials and equipment required for this test are- 
described in Appendix H. 
Pre-treatment-of sera 
1. Removal of heat labile inhibitors, 
A 1: 4 dilution of serum was prepared by diluting 0.2 ml 
of serum in 0.6 ml of haemaggluti7nation inhibition (HAI) 
diluent (H3) and heat inactivated at 560C for 30 minutes. 
2. Removal of B-lipoprotein, inhibitors of rubella haemagglutinin 
0.01 ml of heparin (5000 units/ml) and 0.1 ml of MnCl (1M) 2 
were added, the mixture shaken vigorously, and incubated at 
40C for 20 minutes. The, precipitate was removed by centrifuga- 
tion at 2000 rpm for 10 minutes. 
Removal of excess MnC1 2 which causes agglutination of 
red cells 
0-05 ml of Na 2CO3-(0-5 M) was added, shaken vigorously 
and, the precipitate removed by spinning at 2000 rpm for 
20 minutes. 
Antigen 
The antigen (H2) was dissolved in HAI'diluent (3-10 ml) 
and doubling dilutions made in duplicate using 0.025 volumes. 
0.025 ml of red cells were added to each dilution, incubated 
at 40C for one hour and used at a concentration of 8 units. 
One unit was the least amount of antigen that caused 100% 
agglutination of red cells. 
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One day old chick red cells were used which were 
washed in HAI diluent till the sppernate was clear. A 0.25% 
suspension of red cells in HAI diluent'was prepared. 
Plates 
V-shaped microtitre plates (H1) were used. 
1) 0.025 ml of HAI diluent was placed in all wells 
except the first well in each row. 
2) 0.025 ml of the treated serum samples were added 
to the first, second and last well of each row. 
3) Using standard microtitre loops which delivered 0.025 
volumes, two-fold dilutions of serum were obtained starting 
at the second well and leaving., out the last well. 
4) 0.025 ml of rubella HAI antigen (8 HAU/0-025 ml) was 
added to all wells except the last well which served as a 
serum control, 
5) An antigen titration was performed in each test. A low 
titre and high titre positive control serum and negative 
control serum were included in each test. A cell control 
too was set up. 
6) The plates were incubated at RT for one hour. 
7) 0.025 ml of 0.25% red cells was added to all wells. 
8) Plates were incubated at 40C for one hour. 
9) The rubella HAI titre of a serum sample was taken to be the 
highest dilution which provided a complete inhibition of rubella 
haemagglutinin. 
,I METHOD 8 
ýDETERMI , 





METHOD FOR DETERMINING MEASLES HAEMAGGLUTINATION INHIBITING 
ANTTBODTES 
These test were conducted by Dr. Mairin Clarke of the MRC 
National Institiute f, 'ar 13iological Standards and Controls. 
All materials and equipment used are described in-Appendix H. 
Pre-treatment of sera 
0.2_ml of serum was diluted in 0.2 ml of veronal buf- 
fer (VB) (H4) and adsorbed with 0.05 ml, of a 50% suspension 
of rhesus monkey RBC at 40C for one hour shaking frequently. 
The cells were removed by centrifugation at 2000 rpm for 
20 minutes on a bench centrifuge. 
kntip-en 
Measles haemagglutinih was titrated in 3X 21 inch tubes. 
0-7 ml of VB was added to the first of a series of 12 tubes 
and 0.4 mi of diluent into the rest. 0.1 ml of antigen was 
added to the first tube and doubling dilutions of antigen 
prepared. 
0.2 ml of 1.0% washed monkey RBC was added to each tube. 
A cell control was set up containing 0.4 ml, diluent and 0.2 ml 
Tubes were incubated at 37 0C for two*hours. 
One unit of antigen was considered to be the l. east amount of 
antigen which agglutinated 50% of red cells. 
Four units were used in testing serum samples. 
I 
V-shaped microtitre plates (HI) were used. 
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Method 
1) 0.025 ml of VB was added to all wells. 
2) 0.025 ml of adsorbed serum was added to the first well 
and the last well in the row. 
3) 0.025 ml of antigen was added to all wells except to the 
last which served as a serum control. 
4) The plates wer'e left at RT for one hour. 
5) 0.025 ml of-1% monkey RBC was added to all wells and 
shaken well. 
6) Plates were incubated at 370C for two hours approximately, 
until the cells settled. 
A positive and negative serum were included in each test. An 
antigen titration was done in every test and a cell control 
was also set up. 
7) The measles HAI titre of a serum sample was taken as the 




RESULTS. PART I. 
ANALYSIS OF AGE, SOCIAL CLASS, 
ETHNIC ORIGIN, AND SEX RELATED 
VARIABLES IN PATIENTS WITH 
CERVICAL ANAPLASIA, IN BRITAIN., 
MALAWI, SUDAN AND SRI LANKA. 
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PART I. 
ANALYSIS OF AGE, SOCIAL'CLASS, ETHNIC ORIGIN, AND SEX 
RELATEP. VARIABLES IN PATIENTS WITH CERVICAL ANAPLASIA, 
IN BRITAIN, MALAWI, SUDAN AND SRI LANKA. 
AGE DISTRIBUTION-OF PATIENTS WITH CERVICAL ANAPLASIA 
(dysplasia carcinoma in situ and invasive car6inoma)- 
AND STAGE OF DISEASE OF INVASIVE CARCINOMA PATIENTS 
WHEN FIRST DETECTED 
All three types of lesions were detected in a wide 
range of ages (Table 6.1). The age group showing max- 
imum incidence among patients with dysplasia, carcinoma 
in situ, and invasive carcinoma in Britain was 21-30, 
31-40 and 51-60 years respectively. 
Incidence of cervical anaplasia among Vounger women 
in Britain. 
Thirty-nine of 166 (23%) patients with cervical 
anaplasia Were aged 30 years or younger (Table 6.2). 
Of these, 23 had dysplasia, 11 had carcinoma in situ, 
and five had invasive carcinoma, i. e. 16 (14%) of a 
total of 114 patients requiring immediate'treatment 
(patients with carcinoma in situ and invasive carcinoma) 
were 30 years or younger. 
Incidence of cervical anaplasia among post menopausal 
women in Britain. 
Thirty-six of 70 patients (51%) with invasive car- 
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Table 6.1 
Age di-stribution of patients at time of detection of 
pre-malianant or malignant state 
Patient Dysplasias Ca in situ Inv. Ca Inv. Ca Inv. Ca Inv. Ca. 
Group Britain BrYit-a: i7-n Britain Sri Lanka Sudan Malawi 
No. 
_of 
52 44 70 32 27 27 
patients 
e. 20 yrs. 4% 
21-30 yrs. 40% 25% 7% 65f. 
31-40 yrs. 27% 37% 14% 16% 
41-50 yrs. 21% 27% 19% 22% 
51-60 yrs. 4% 9% 30% 
. 
41%1 
61-70 yrs. - 2% 21% 9% 
>70 yrs. 4% - 9% _6% 
Median 29 37 53 52.5 
Average 35 37.5 52.7 51 
Range 19-79 22-68 22-80 25-74 2 












cinoma were aged 50-70 years and seven of the 12 (58%) 
patients who died as a result of recurrence were also 
in this age group. 
Stage of disease at time of detection and maximum age 
of incidence in Sri Lankan, Malawian and-Sudanesepatients 
34% of British patients with. invasive carcinoma were 
detected in stage 1 of the disease. The proportion-of 
patients detected in stage 1 in Sri Lanka (6%), Malawi 
(4%)-and Sudan (none) were noticeably less (Table 6-3)- 
However, Table 6.1 shows that in spite of presenting at 
later stages, the Malawian and Sudanese patients had the 
youngest age of maximum incidence 01-40 and 41-50 
respectively). The maximum . age of incidence for Sri 
Lankan aild British patients with invasive carcinoma 
was 51-60 years. However, considering the age gr oup 
showing the next highest incidence, 41-50 for Sri Lankan 
patients and 61-70 for British patients, it is possible 
that the Sri Lankan patients present at a younger age. 
SOCIAL CLASS DISTRIBUTION OF-PATIENTS WITIt CERVICAL ANAPLASIA *0 
The majority of patients from Sudan, Malawi and Sri 
Lanka were from the low social classes. (Table 6.4). 
Social class analysis of the 166 British patients 
showed that a major proportion of patients with dysplasia 
(75%), 'carcinoma in, situ (73%) and invasive carcinoma (60%), 
were in social classes I-III. However, in comparison with 
the small proportion of patients with dysplasia (5%) and 
carcinoma in situ (20%) in social classes IV and V, there 
were more patients with invasive carcinoma (30%) in these 
two social classes. 
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Table 6.2 
Analysis of British patients below the age of 30 years in 
relation to the total number of patients presenting with 
dysplasia, 
_carcinoma 
in situ and invasive carcinoma 
do 
Patients with dysplasia, 
carcinoma in situ and 
invasive cTrcinoma- 
Patients with carcinoma 
in situ and invasive 
carcinoma. 
TOTAL NUMBER BELOW AGE 
OF 30 YEARS 
166 39 (23.4%) 
114 16 (14%) 
Table 6.3 
Analysis according to stage of disease-atýtime of detection. 
Invasive carcinoma patients from Britain, Sri Lanka, 
Malawi and Sudan 
No. of Stage-I Stage II Stage III Stage IV 
patients 
BRITAIN 64 22 (34%) 26 (41%) 13 (20%) 3 (5%) 
SRI LANKA 32 2 (6%) 16 ý50%) 14 (44%) 
MALAWI 27 1 (4%) 13 (48%) 4 (15%) 9 (33ýo) 
SUDAN 27 None Majority Few 
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Table 6.4 
Analysis according to social classof patients with 
cervical anaplasia from Britain, Sri Lanka, Malawi 
and Sudan 
SOCIAL CLASS 
Total no. I II IIIA IIIB IV V not 
of patients classified 
DYSPLASIA --52 4% 15% 23% 33% ý2 17% 
Britain 755%o 
Ca IN SITU 44 17% 7% 18% 41% 9% 11%. 7% 
Britain 73% 2 
INV. Ca 70 1% 14%' 16% 29% 1,1%0' 0 10% 
Britain - 30% 
SOCIAL CLASS 
Upper Middle Low 
INV. Ca 32 3% 97% 
SRI LANKA 
INV. Ca 27 21% 79% 
MALAWI 
INV. Ca 27 100% 
SUDAN 
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ETHNIC ORIGIN OF PATIENTS WITH CERVICAL ANAPLASIA 
Sri Lankan, Sudanese and Malawian patients 
10% of invasive carcinoma patients from Sri Lanka 
were Tamil. This proportion is similar to the propor- 
tion of Tamils in the general population. The Sudanese 
-and Malawian patients were homogeneous with regard to 
ethnic origin (Table 6.5). 
British patientS' 
19.6% of patients with dysplasia, 10% of patients 
0 with carcinoma in situ, and 10.5% of British patients 
with invasive carcinoma were negroid in origin (mainly 
West Indian) (Table 6.5). Of the 39 British patients 
with cervical anaplasia who were 30 years or younger, 
(21%) were West Indian (Table 6-6). Their socio- 
economic distribution was similar to that of caucasians 
in-this age group, i. e. approximately 80% of both 
caucasians and West Indians below the age of 30 years 
were in social classes I-III. In contrast with caucasians 
however, a higher proportion of West Indians had had 
a) previous venereal -infection (37% v 13%). b) spontane- 
--ous or therapeutic abortion (50% v 26%) and a lesser 
proportion of West Indians in this age group were 
married. 
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Tabl e 6.5 
Proportions of different ethnic groups among patients 
with abnormal cervical cytology in Britain, Sri Lanka, 
Malawi and Sudan 
BRITAIN 
bysplasia- Ca in situ Inv. Ca 
11N 7N 7N 
(21%) (16%) (10.5%) 
41 c 37C 61 c 
(79%) (84%) (89.5%) 
SRI LANKA MALAWI SUDAN. 
2T 32N 27 Sud. 
(10%) 100% 100% 
30S 
(90%) 




Social class and sex related variable analysis of British 




CA IN SITU CA IN SITU 
INVASIVE CA INVASIVE CA 
Caucasian Negroid Caucasian 
- -1 and Negroid 
Total 31 (79%) 8 (21%) 39 
Social Class 1 1 1 '2 
11 5 2 7 
IIIA 11 1 12 
IIIB 9 4 13 
IV 2 - 2ý 
V 2 2 
not known 1 1 2 
Married 19 (61%) 1 (13%) 20 (51%) 
Married more than 3 3 
once or divorced 
Number who had 16 (52%) 6 (75%) 22 (56%) 
become pregnant 
Number who had 8 (26%) 4 (50%) 12 (31%) 
TOP or abortion 
P. H. /O. 'venereal 4 (13%) 3 (37%) 7 (15%) 
infection . 
TOP - termination of pregnancy 
P. H. /O. - previous history of 
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AGE AT MARRIAGE OF PATIENTS WITH CERVICAL ANAPLASIA 
AND THEIR CONTROLS 
A high proportion of Malawian patients and con- 
trols (47% and 45% respectively) (Table 6-7) were 
married before the age of 18 years. Sri Lankan 
patients married earlier than controls. The averaý-_e 
age of marriage of all groups of-British patients 
with-cervical anaplasia was similar. Unfortunately, 
at the time British control sera were collected, the 




Analysis of age of marriage of patients with 
cervical anaplada from Britain, Sri Lanka and Malawi 





































married Age at married 
before 18 marriage before 18 
years years 
1 (3%) -NOT KNOWN 
53 
4 (10%) NOT KNOWN jq 
Z-51- NOT KNOWN 
Median 23 13- (48%) Average 23-5 -1 (6-7%) 27 Range 15-35 15 
9 Median 18 (47%) Average 18 4 (45%) 15 Range 14-2ý 
RESULTS. PART II. 
ON FIRST SERUM SAMPLES. 
IgG AND IgA ANTIBODIES TO THE 




PART II - FIRST SERUM SAMPLES. 
IgG AND IgA ANTIBODIES TO THE MEMBRANE ANTIGENS OF 
HSV-2 INFECTED CELLS. 
PROPORTION OF PATIENTS AND CONTROLS WITH IgG, AND IgA 
ANTIBODIES TO MEMBRANE ANTIGENS (MA) OF HSV-2 
INFECTED CELLS 
_A 
high proportion (87%-100%) of patients in all 
groups, as well as controls possessed IgG anti-MA anti- 
bodies (Figure 6.1). 
In contrast (Figure 6-2) a* siggni- 
ficantly higher proportion of patients with dysplasia, 
carcinoma in situ, and invasive carcinoma from Britain 
and Sri Lanka, had IgA-dnti-MA when compared with con- 
trols and with patients from Britain with other genital 
malignancies as well as those with extra-genital non- 
squamous malignancies. A high proportion of British 
patients with invasive carcinoma who had been treated 
1-12 years previously still possessed these antibodies. 0 
Similar proportions of Malawian patients and controls 
possessed IgA anti-MA. A high proportion of invasive 
carcinoma patients from Sudan for whom no controls could 
be obtained, also possessed these antibodies. However, 
the proportion of patients with non-genital squamous 
carcinomas ýrho possessed IgA anti-MA was similar to that 
of patients with cervical anaplasia (dysplasia, carcinoma 
in situ and invasive carcinoma). 
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Of 174 patients with cervical anaplasia from all 
countri6s, six (3%) -had no detectable IgG anti-MA, and 
35 (20%) had no-detectable IgA anti-MA (Table 6.8). 
Three Sri Lankan patients and three British patients 
had no detectable antibody by both the IgG and IgA 
assays. -Theýcorresponding number among-British controls 
was five. All the Sri Lankan controls had antibodies 





InG ANTILOBTES TO MEMBRANE ANTIGEN OF HSV-2 INFECTED 
CELLS IN PATIENTS WITH CERVICAL ANAPLASIA AND 
MATCHED CONTROLS 
PATIENT GROUP 1 10% 20% 30% 
40% 50% 60% 70% 80% 90% 
DYSPLASIA (BRITAIN) 
CONTROLS 
Ca IN SITU (BRITAI 
CONTROLS 
UNTREATED INV C . a. (BRITAIN) 
CONTROLS 
TREATED INV. Ca. 
(BRITAIN) 
CONTROLS 
INV. Ca. (SRI LAN 
CONTROLS 
(MALA-V. 'I) Ca INV . . 
CONTROLS 
INV. Ca. SUDAN) 
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'ý'I, G U -RE 2 1 
I2-A ANTIBODIES TO MEMBRANE ANTIGENS OF HSV-2 INFECTRn CRIL 
IN PATIENTS VITH-CEERVICAL ANAPLASIA. MATCHED CONTROLS AND 
12ATTENTS WTTH MALIGNANCIES OTHER THAN CERVICAL CARCINO 




P, ý. . 001 




UNTREATED INV. Ca 
(BRITAIN) 
CONTROLS 
P . 02c 












IN, IASIVE CA-, -ýCINOMA 
(S(. JDAN) I I 




IS- ý7 IT 4ALIGNANCIES-7-ýRITAIý I I 
EXTRA-GEN17=T7- 
T SQUAMOUS MAUIGNAN- 
CIES - -1-iITAIN I I A I 
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Table 
Number of patients with cervical anaplasia having. 
no detectable IgG or IgA antibody to membrane antigens of 
HSV-2 infected cell& 
Patients Controls 
-, Total Number Number with no with no 
number with IgG with IgA, detectable detectable 
of anti-MA anti-MA IgG anti-MA IgG anti-MA 
patients of< 1.. 8 of <1: 4 and IgA and IgA 
anti-MA anti-MA 
DYSPLASIA 30 4 
Britain 
CA IN SITU 29 92 
BritaTin 
INV - CA 29 2922 Britain 
INV. CA 32 373 
Sri Lanka 
INV. CA 27 2' 
Malawi 
INV. CA 27 4 
Sudan 




THE GEOMETRIC MEAN TITRES OF IgG and IgA ANTIBODIES TO 
MEMBRANE ANTIGENS (MA) OF HSV-2 INFECTED CELLS 
IgG anti-MA 
The geometric mean titres (GMTs) of IgG anti-MA 
in patients with cervical anaplasia did not differ, signifi- 
cantly from that of their controls (Table 6.9a, and Table 6.10a), 
with the exception of Malawian patients who had a tignifi- 
cantiy higher GMT compared with controls. There was no 
consistent pattern in the variation of titres of IgG anti- 
MA with advancing stage of disease (Table 6.11). The IgG 
anti-MA GMT (256) of six virologically confirmed cases of 
genital HSV-2 in, Britain was higher than the GMTs of IgG 
anti-MA of British patients with cervical anaplasia 
(Table 6.9c). 
IgA anti-MA 
All groups of patients with cervical anaplasia had 
significantly higher GMTs of IgA anti-MA than their con- 0 
trols (Table 6.9b and Table 6.10b). Iýn contrast with- 
the GMTs of IgG anti-MA,. IgA anti-MA GMT appeared to rise 
with advancing stage of disease (Table 6.11). Among 
British patients', the GMTs of IgA anii-MA in patients 
with cervical anaplasia, treated invasive carcinoma and 
non-genital squamous carcinoma resembled the GMT of IgA 
anti-MA of 16 patients with virologically confirmed 
genital herpes (HSV-2) (Table 6.9c). 
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Table 6.9 
GMTs of IgG and IgA antibodies to membrane antigens of 
HSV-2 infected cells - British patients 
a. IgG anti-MA 
Dysplasia 
Cases 185.2 (30) 
Controls 198.0 (27) 
p *1 X- 05 









CA in situ 
113.5 (29) 
73.8 (29) 
> . 05 













Genital Other genital Extra-genital Treated Non-gen. 
Herpes malignancies non-squamous inv. CA squamous 
malignancies carcinoma 
IgG 256 (6)* 2 79.4 (16) 
IgA 7.1 (16)*3 3.9 (33) 
*1 Paired t test -2 tailed 
() Number of patients 
*2 18 sera from 6 patients 
*3 52 sera. from 16 patients 
lo6.4 (30) 
3.4 (37) 7.3 (30) 8.3 (18) 
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Table 6.10 
GMTs of-IgG and IgA antibodies to membrane antiszens of HSV. -2 
infected cells, in -patients with invasive carcinoma, and 
matched controls from Britain, Sri Lanka, Malawi and Sudan 
a. ' IgG anti-MA 
Britain Sri Lanka Malawi 
Cases 108.2 (29) 120 (32) 692 (27) 
Controls 116.4 (22) 133 (17) 362 (18) 
. *1 
p ),. 05 >-05 '7-05 
b. IgA anti-MA 
Sudan 
331 (27) 
Britain Sri Lanka Malawi Sudan 
Cases 9 (29) 14 (32) 21.2 (27) 13 (27) 
Controls 4.2 (23) 4.7 (17) 7.7 (18) 
*2 p 4-05 4-02 4.025 
Paired t-test (2 tailed) 
*2 t-test for independent means. (P)-. 05 in a paired t-test) 
16S 
Table 6.11 
Analysis of GMTs of IgG anti-MA and IgA anti-MA 
according to the stage of disease 
,, G 
IgA 
Brit ain Sri Lanka Malawi Britain Sri Lanka Malawi 
Stage 1 149 (9) 256 (2) 256 (1) 11-3 (2) 3 (1) 
Stage 11 73.5 (10) 98.7 (16) 600.8 (13) 4.9 (10) 13,. 4 (16) 13.6 (1: 
Stage 111. 90-51 (8) 134.5 (14) 1024 (4) 13-45 (8) 14.5 (14) 38 (4) 
Stage IV 362 (2) 812-7 (9) 64 (2) 24.5 (9 
.b 
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A GEOGRAPHICAL VARIATION IN THE GMTS OF ANTIBODIES TO 
MEMBRANE ANTIGEN 
Patients and controls from Malawi possessed signifi- 
cantly higher IgG anti-MA GMTs than their counterparts 
from other countries. The IgG anti-MA GMT of patients 
and controls from Britain and Sri Lanka were similar, and 
were significantly lower than that of Sudanese patients* 
(Table 6.12a). 
A similar degree of geographical variation in GMTs 
was not observed when IgA anti-MA GMTs were compared 
(Table. 6-12b). Although there was a significant difference 
between the values of Malawian patients and British 
patients, the GMTs of Malawian, Sri Lankan and Sudanese 
patients did not differ significantly. Similarly, 
Malawian controls possessed a GMT of IgA anti-MA which 
was significantly higher than that of British controls, 
but similar to those of Sri Lankan controls. 
Text cut off in original 
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Table 6.12 
Geo, -raDhical variation of GMTs of IgG anti-MA and IaA 
anti-MA among patients with invasive carcinom a and controls 
a. CASES CONTROLS 
GMT of IgG P*1 GMT of IgA P 
*1 
anti-MA anti-MA 
Britain- 108.2 (29) 116.4 (22) 
Malawi 692 (27) -'-. 001 362 (18) =. 005 
Britain 108.2 (29) 116.4 (22) 
Sri Lanka 120 (32) ý>-05 133 (17) >. 05 
Sri Lanka 120 (32) 133 (17) 
Malawi 692 (27) /--001* 2 362 (1*8) 4.001 
Sudan 331 (27) - 
Malawi 692 (27) =. 001 
Sudan 331 (27) 
Britain 108.2 (29) L-001* 
2 
Sudan 331 (27) 
Sri Lanka 120 (32) 4.001* 2 
b. CASES CONTROLS 
GMT of IgG P*1 GMT of IgA P*1 
anti-MA anti-MA 
Britain 9 (29) 4.2 (23) 
Malawi 21.2 (27) 4.025 7.7 (18) 4.05 
Britain 9 (29) 4.2 (23) 
Sri Lanka 14 (32) >. 05 4.7 (17) >. 05 
Sri Lanka 14 (32) 4.7 (17) 
Malawi 21.2 (27) >-05 7.7 (18) >. 05 
Sudan 13 (27) 
Malawi 21.2 (27) >-05 
Sudan 13 (27) 
Britain 9 (29) '; ý-05 
Sudan 13 (27) 
Sri Lanka 14- (32) . 05 
*1 
t-test for jr dprp rdprt Tnpqn- , 
*2 IT +, no+ 
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RESULTS. PART III. 
I 
ON FIRST SERUM SAMPLES (cont. 
IgA ANTIBODIES TO VIRUS - 
CAPSID ANTIGENS OF HSV-2 
INFECTED CELLS IN PATIENTS 
WITH CERVICAL ANAPLASIA AND 
THEIR MATCHED CONTROLS. 
0 
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PART III FIRST SERUM SAMPLES (cont. ) 
- 
IgA ANTIBODY TO VIRUS CAPSID ANTIGEN (VCA) OF HSV-2 
INFECTED CELLS IN PATIENTS WITH CERVICAL ANAPLASIA AND 
THEIR MATCHED CONTROLS. 
In contrast with the results described in Part II 
on-IgA anti-MA antibodies to HSV-2 infected cells, similar 
proportions of patients with cervical anaplasia and con- 
trols possessed IgA anti-VCA, and in similar titres, 
with the except-ion of British patients with dysplasia 
(Table 6-13 and Figure 6-3)- 
The distribution of these antibodies also did not 
0 
differ significantly in patients with dysplasia who on 
follow up showed progressing'tcytology in contrast to 
others showing regressing cytology; nor in patients with 
invasive carcinoma who developed recurrence of their 




Proportion of patients rith cervical anaplasia possessing 
IgA anti-MA and IgA anti-VCA and the 
i- 
geometric mean titres of these antibodies 
IgA anti-MA IgA anti-VCA 
Proportions GMTs Proportions GMTs 
Dysplasias -'Britain 26 (86.6%) 8 (50%) 19 TO 30 
Controls 11 (42%) 3.8 5 (16%) 12 
26 __ 31 




ý 9 34 
Controls 1.3 (45%) 3.5 6 (17%) 14 
29 3'1ý 
Invasive CA- Britain 20 
- 




(39%) 4.2 7 (25%)"' 16 
23 28 
Invasive CA 21 (78%) 14 (15%) 18 







Invasive CA 25 (93%) 21.2 5 (20%) 14 
Malawi 27 25 








































































Distribution of IgA anti-VCA in serum 
samples of patients with cervical anaplasia 
analysed according to their follow up hist6ries 
Group and Number Sub-Group and Number 
DYSPLASIAS 
(30) 
CA in situ OF 
KNOWN FOLLOW UP 
CYTOLOGY 
(29) 
SRI LANKAN AND 
BRITISH INVAS. - 
IVE CARCINOMAS 
OF KNOWN FOLLOW 
UP HISTORIES 
(49) 
Who regressed to 
normal cytology. 
OA - N2) (15) 
Who had persistant 
3A smears or who 
progressed to 3B or 
Pos 4. (15) 
Normal smear after 
cone biopsy (22) 
3A smear after cone 
biopsy (5) 
Recurrence cases 
and terminal cases 
(16) 
Well patients (33) 









P> . 05 0 
5 
9%) 




RESULTS. PART IV 
ON FIRST SERUM SAMPLES (cont'd) 
HSV-1 AND HSV-2 SPECIFIC 
ANTIBODY. 
Iý7, 
Section 1 Prevalence of HSV-1 
and HSV-2 specific antibody in 
all groups of patients. 
Section 2 Type-specific nature 
of IgA anti-NIA response. 
11 
Section 3 Comparison of 
Complement-Fixation Testland 
ELISA for HSV-1 and HSV-2 
specific antibody. 
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RESULTS. PART IV. -SECTION 1.1 
THE PREVALENCE OF HSV-2 SPECIFIC ANTIBODIES IN PATIENTS WITH 
CERVICAL ANAPLASIA AND IN MATCHED CONTROLS IN ALL FOUR 
COUNTRIES (AS DETERMINED BY ELISA) 
A higher proportion of patients vrith cervical anaplasia 
from Britain, Sri Lanka and Malawi possessed HSV-2 specific 
antibodies when compared with controls matched for age, ethnic 
origin and social class (Table 6-15). This difference was 
significant except-for the group of British patients with 
dysplasia (0.1-?, P), 0-05). However, it is noteworthy that 
27-48% of these patients did not possess HSV-2 specific 
antibody. 
4p 
ANALYSIS OF RESULTS TO TEST THE HYPOTHESIS THAT PREVIOUS 
INFECTION WITH HSV-1 EXERTS A PROTECTIVE EFFECT ON THE 
SUBSEQUENT DEVELOPMENT OF CERVICAL ANAPLASIA 
a) Prevalence of antibodies to HSV-2 alone 
Among 82 patients with cervical anaplasia from Britain, 
Sri Lanka and-Malawi and 30 controls, who possessed. antibody 
to either HSV-1 or HSV-2 or both, there were four Sri Lankan 
patients and one Sri Lankan control with antibodies only to 
0 
HSV-2, i. e. the proportion of patients with antibody only to 
HSV-2 was 4.6% in comparison with 3% among controls (Table 6.16). 
b) The "inverted" case control prevalence of HSV-1 antibody 
alone 
A higher proportion of matched controls in each country 
possessed only HSV-1 specific antibody without HSV-2 
specific antibody when compared to patients with cervical 
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Table 6.15 Proportions of patients and controls having 
HSV-2_specific antibody as determined by ELISA 
PATIENT GROUP PROPORTION HAVING PROPORTION P 
HSV-2 S PECIFIC AMONG (X2 -- 2 ANTIBOD Y CONTROLS tailed) 
Dysplasias (Britain) 14 (63%) 11. (39%) >-05 22 28 
Ca in situ (Britain) 19 (67.9%) 11. (40%) 1, -05- 25 27 
Untreated Inv. Ca 13 (52%) - 
1 (12 
. 5%) 4.005 (Britain) 25 2 
Treated Inv. Ca 19- (65.5%) 0 
(Britain) 29 8 




(16%) <. 001 9 
Inv. Ca. (Malawi) 1 !L ý (73%) -ý! (30 -7%) 2 13 
Inv. Ca (Sudan) 12 
'(52%) 23 
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Table 6.16 Prevalence of antibody to HSV-2 alone among 
patients with cervical anaplasia from Britain, Sri Lanka 
and Malawi, and their matched controls (Type specific 
antibody by ELISA) 
NUMBER WITH NUMBER WITH NUMBER WITH 
ANTIBODY TO ANTIBODY TO ' ANTIBODY TO 
HSV-1 and HSV-2 HSV-2 ALONE HSV-2 
NUMBER WITH 
ANTIBODY TO 




Patients with cervical 
a4 anaplasia in Britain, 82 
Sri Lanka and Malawi 
controls from 
Britain, Sri Lanka 30 33 
and Malawi 
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anaplasia. This difference was significant in all groups 
except among British patients with dysplasia and controls 
and Sri Lankan patients with invasive carcinoma and controls. 
(Table 6.17). 
THE PROPORTION OF PATIENTS WITH CERVICAL ANAPLASIA AND 
CONTROLS WITH NO DETECTABLE ANTIBODY TO HSV-1 01ý HSV-2 
Of all patients with cervical anaplasia, in Britain, 
op 
Sri Lanka and Malawi, 3 of 175 (1.7%) had no detectable 
antibody to either HSV-1 or HSV-2 by both ELISA and the 
IgG and IgA membrane antibody test. The proportion among 
controls from these three countries was 3 of 113 (2.6%) 
(Table 6.18). 
ANALYSIS OF RESULTS TO TEST THE POSSIBILITY THAT CERVICAL 
ANAPLASIA DEVELOPING IN THE OLDER AGE GROUPS IS OF A 
DIFFERENT AETIOLOGY TO THAT DEVELOPING IN THE YOUNGER 
I AGE GROUPS 
In 102 British patients with cerVical anaplasia, the 
prevalence of HSV-2 specific antibody was examined accord- 
ing to the age at which the cervical lesion was detected 
(Table 6.19). Sixty-six to 80% of patients in whom non- 
malignant (dysplasia) and malignant (Ca in situ and invasive 
carcinoma) lesions were detected below the age of 60 years 
possessed HSV-2 antibodies. In contrast, onlY 37% of patients 
with invasive carcinoma above the age of 60 years possessed 
these antibodies. However, on comparing the prevalence of 
HSV-2 antibodies between patients and controls in the same 
age groups, a significantly higher proportion of the 
patients had HSV-2 antibodies. 
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Table 6.18 Proportion of patients. with cervical anaplasia 
and controls wi th no detectable antibodV to HSV-1 or HSV-2 
by ELISA and IgG and IgA membrane antibody assays 
NUMBER PROPORTION WITH NO ANTIBODY 
TO HSV-1 OR HSV-2 BY ELISA 
AS WELL AS IgG AND IgA 
MEMBRANE ANTIBODY ASSAY 
All patients with 
cervical anaplasia 175 from Britain, 
Sri Lanka and Malawi 
All controls from 
Britain, Sri Lanka 113 




113 x 100 = 2.6% 
Table 6.19 Prevalence of HSV-2 specific antibody in, British 
patients with cervical anaplasia a: nd controls according to the 
age at which the lesion was detected (Type specific antibody 
by ELISA) i. 
20 40 yr 4o 6o -yr 6o - 80 yrs 
Dysplasia 12 (80%) 2 (66%) A5 '5 1 
Ca in situ and 21 28 6 
invasive carcinoma 
5-0 (70%) (74%) (37%) 
Controls 18ý(49%) (1 0 (0%) 37 18 
;, X2 p. (2 tailed) <. 025 4.0005 4-05 
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There was a lower prevalence of HSV-. ý2 specific 
antibody in Malawian patients over, the age of 60 years 
in comparison with those below this age. However this same 
difference was not observed among Sri Lankanýpatients 
(Table 6.20). 
A COHORT ANALYSIS OF THE PREVALENCE OF HSV-ý-2 SPECICIFIC 
ANTIBODY (TYPE SPECIFIC ANTIBODY BY ELTSA). 
Figure 6.4 shows the prevalence of HSV-2 specific 
antibodies in cohorts of British patients with cervical 
anaplasia and controls. The controls in this analysis 
includea. gynaecological controls, as well as other British 
patients with malignancies other than cervical'anaplasia. 
A higher prevalence of HSV-2 specific antibodies is 
not seendn all cohorts of patients with cervical anaplasia 
when compared to cohorts of controls. The two cohorts of 
patients with'c'ervic'al 'anapias'ia'ý born be'tw`een-1, q'00 'and 
1920 have a similar prevalence of HSV-2 antibodies as 
cohorts of controls born in the same period. Also surpris- 
ingly, the cohort of patients with cervical anaplasia born 
between 1951 and 1960 has a lower prevalence of HSV-2 
antibodies than the cohort of controls born between 1951 
and--1960.. Among controls, a similar prevalence of HSV-2 
antibodies is seen among cohorts born from 1900 to 1950 
after which there is a steep rise in the prevalence from 
45% among the cohort of controls born between 1941 and 1950 
to 82% among the cohort of controls born between 1951 and 
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was seen between cohorts of controls born in 1900, to 1950 
suggests that there has been no loss of antibody in, cohorts. 
born in 1900 to 1920, i. e. it is an indication of there 
being no loss of HSV-2 specific antibody in the over-60 
year age group in this study. 
In contrast with the steep rise in prevalence of 
HSV-2 specific antibody seen among the cohorts of controls 
born between 1951 and 1960, the similar steep rise, in 
prevalence of HSV-2 specific antibody among patients' 
with cervical anaplasia is seen approkimatelY 30 years 
earlier in the cohort of patients born between 1921 and-1930. 
THE PREVALENCE OF HSV-2 SPECIFIC ANTIBODY IN BRITISH 
PATIENTS WITH MALIGNANCIES OTHER THAN CERVICAL CARCINOMA 
(TYPE SPECIFIC ANTIBODY BY ELISA) 
Sixty-five of 104 (63%) of British patients with cervical 
anaplasia possessed HSV-2 specific antibody. This proportion 
was higher than the proportion of a) patients with non- 
genital squamous carcinoma (43%), b) other genital malig- 
nancies (52%). and c) extra-genital non-squamous malignancies 
(31%) possessing HSV-2 specific antibodies (Table 6.21). 
However, this difference was. significant only for patients 
with extra-genital non-squamous malignancies. 
In 
185 
Table 6.20 Prevalence of HSV-2 specific antibody (ELISA) 
in Malawian and*Sri Lankan patients with invasive carcinoma 
according to age 
PATIENT GROUP <60 YEARS >60 YEARS 
Malawian patients 
L8- (78%) .2 (60%) 23 5 
Sri Lankan patients 
15 (65%) (83%) 
23 
Table 6.21 Prevalence of HSV-2 specific antibody in British 











PROPORTION HAVING PROPORTION OF 
ANTIBODY TO HSV-2 BRITISH PATIENTS 
WITH CERVICAL 
ANAPLASIA WITH 
ANTIBODY TO HSV-2 
9 (43%) 65 (63%) 21 104 
(5 --ýl (63% 104 




> . 05 
4.005 
4 
RESULTS. PART IV. SECTION 2 
Type-specific nature of IgA 
anti-MA response. 
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RESULTS. PART IV. -SECTION 2. 
TYPE-SPECIFIC NATURE OF THE IgA MEMBRANE ANTIBODY RESPONSE 
IN HSV INFECTION 
a) IgA anti-MA titres in 19 sera of known antibody tv-Pe 
Table 6.22 shows the IgA anti-MA and IgG anti-MA GMTs to 
HSV-2 infected cells, and the optical density readings (OD) 
by ELISA to HSV-1 specific antigen, and HSV-2 specific 
antigen of 19 sera. These 19 sera were tested for HSV-1 
and HSV-2 type specific antibody by both ELISA and CF tests. 
By both assays 4 were found to contain no herpes antibody, 
ft 
5 possessed only HSV-1 type specific antibody, and 11 
Possessed both HSV-1 and HSV-2 type specific antibody. The 
11 sera containing HSV-2 antibody had a 4-fold higher IgA 
anti-MA GMT as well as an OD to HSV-2 specific antigen 
which was 19 times higher. This demonstrated the greater 
type specific nature of the IgA anti-MA assay because 
the GMT of IgG anti-MA was only 2-fold higher in the sera 
whichpossessed HSV-1 and HSV-2 specific antibody in comparison 
with those that possessed only HSV-1 specific antibody. -Further- 
more, in the 19 sera there was correlation between IgA anti-MA 0 
titres and OD readings to HSV-2 specific antigen (P<-05), whereas 
there was no similar correlation between the IgG anti-MA titres 
and the*OD readings to HSV-2 type specific antigen. IgA anti-MA 
titres did'not correlate with OD readings to HSV-1 specific antigen 
b) IgA anti-MA in convalescent sera of HSV infected patients 
Figure 6. % shows the IgA ant nd Figure 6.5b the 
. 
i-MA titres a 
IgG anti-MA titres to HSV-1 and HSV-2 infected cells'in 
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confirmed HSV-1 and five patients with virologically con- 
firmed HSV-2 infection. Although the IgG anti MA titres 
in all these 9 sera were higher to HSV-1 infected cells 
than to HSV-2 infected cells, the IgA anti-MA titres 
were in all 9 sera higher to test cells infected by the 
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Figure 6.5 L, 0g0 snti -TVIA ti t-rp-ctn HSV-1 infpcted c3lls and HSV-2 in ected 
cells (%), of convalescent sera from 4 HSV-1 
infected patients and 5 HSV-2 infected patient! 3. 
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THE RELIABILITY OF THE IgA-MEMBRANE FLUORESCENCE ASSAY OF IgA 
ANTIBODY TO HSV-2 INFECTED CELLS AS A TEST OF THE PRESENCE OF 
HSV-2 ANTIBODY 
The results in a) and b) above show that the IgA anti-MA 
response is'more type specific than the IgG anti-MA response. 
Týerefore, in order to determine the reliability of the'IgA 
anti-MA assay as a test of the presence of HSV-2 - specific 
antibody, the IgA anti-MA titres of 43 sera whose, type 
specific antibody type was established by ELISA were examined. 
21 of these sera (Figure 6-50possessed only HSV-1 specific 
antibody. 22 (Figure 6-5d) possessed both HSV-1 and HSV-2- 
specific antibody. " 
4D 
Assuming that a thre of >1: 8 indicated the presence 
of HSV-2 specific antibody: 19 of the 21 sera which possessed 
only HSV-1 specific-antibody had an IgA anti-MA, titre, of 
< 1: 8 and two of 21 had an IgA anti7MA titre of >, 1: 8. 
Thus two of 21 were false positives. 
Fifteen of the 22 sera which possessed HSV-1 and HSV-2 
specific antibody had IgA anti-MA titres of: ý1: 8 and seven 
of 22 had IgA anti-MA titres of< 1: 8. Thus, the proportion 
of false negatives among ., 
these 22 sera was seven of 22. 
Therefore as a test of the presence of HSV-2 specific anti- 
body the total false result rate was nine of 43, i. e. 20%. 
The corresponding proportion of false results by CF 
was 34% and by ELISA 17% (? +2). However by the IgA membrane 
192 
a 








Ifiti- <4 16 
ý2. ý4 12'8' 2ý6--- 
Figure 6-5r- Ereauency distribution of IgA anti-MA to HSV- 
infected cells in 21 British sera conta3*. n3*. 
HSV-1 s-Decifi6 antibo by ELISA.. 
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I-A Ultl <4 1.6 32 64 128 256 
Fig-ure 6.5d Frequency distribution of IgA anti-MA to 
HSV-2 infected cells in 22 British sera 
containing HSV-1 and HSV-2 specific antibod 
by ELISA. 
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fluorescence assay it is not possible to differentiate 
patients who have only HSV-2 specific antibodies from 
those who possess HSV-1 and HSV-2 specific antibody. 
Considering that in this series the proportion of patients 
with HSV-2 specific antibody alone was extremely small 
(none among British, Malawian and Sudanese patients and con- 
trols and 4 among patients and controls from Sri Lanka by 
ELISA), this does not appear to be such a disadvantage. Thus 
a British patient with an IgA anti-MA titre of > 1: 8 would be 
more likely to possess both HSV-1 specific and HSV-2 specific 
antibodies. 
Among Sri Lankan patients and controls too, an IgA anti- 
-W MA titrd of > 1: 8 differentiated patients who possessed HSV-2 
specific antibody (by ELISA) fýom patients who did not, With 
a false result rate of 25%- 
Among Malawian patients the corresponding differentiating 
titre was 1: 16 with a false result rate of 17%- 
A significantly higher proportion of Malavdan patients 
with invasive-carcinoma had IgA anti-MA ti-Lres of.; 5ti: 16 in 
contrast with controls, i. e'. 18 of 27 (66%) Malawian patients 
with invasive carcinoma possessed IgA anti-MA titres of>1: 16 
in contrast with 7 of 18 (38%) of controls (P<. 05). This 
contrasts with the picture in Fig. 6.2 where a titre of 
1: 4 did not differentiate Malawian patients from controls. 
THE PREVALENCE OF TgA ANTI-MA AT A TITRE OF5ý1: 8 IN BRITISH 
PATIENTS WITH CERVICAL ANAPLASIA, CONTROLS, AND BRITISH 
PATI RNTS WITH MALIGNANCIES OTHER THAN CERVICAL CARCINOMA 
Employing the IgA anti-MA titre of 1: 8 which was 
195 
established as explained above, it was found that a signif- 
icantly higher proportion of British patients with cervical 
anaplasia had IgA anti-MA titres of > 1: 8 compared with 
matched controls and with patients having other genital 
malignancies and extra-genital non-squamous malignancies 
(Table 6.23). However a higher proportion of patients with 
non-genital squamous carcinoma possessed IgA anti-MA titres 
of; ý1: 8 compared with patients with cervical anaplasia. 
This difference was not significant. 
0 
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Table 6.23 The prevalence of IgA anti-MA at a titre of 
>1: 8 in British patients with cervical anaplasia, in controls, 
and in British patients with malignancies other than cervical 
carcinoma 
GROUPS BEING COMPARED PROPORTION WITH p 
IgA A NTI -MA >1 
Cervical anaplasia 47/88 (53%) 4.01 
Controls 24/78 (30%) 
Non-genital squamous 16/24 (66%)' 
carcinomas 
>-05 
Cervical anaplasia 47/88 (53%) 
Other genital 9/33 (27%) 
malignancies 4.025 
Cervical anaplasia 47/88 (53%) 
Extra-genital non- 8/37 (21%) 
squamous malignancies 4-005 
Cervical anaplasia 47/88 (53%) 
ESULTS. PART IV. SECTION 3 
omparison of CF test and ELISA 
or HSV-1 and HSV-2 type 
pecific antibody. 
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RESULTS. PART IV. SECTION-3. 
COMPARISON ON 58 SERA BY THE CF TEST AND ELISA, AS 
METHODS OF DETECTING PREVIOUS INFECTION BY HSV-1 AND HSV-2 
In 20 (37%) sera (Box A. M and Y, Table 6.24) 
comparable results-were obtained-by-the CF test and ELISA. 
However of the 4 sera in box Y-which were classified as 
being seronegati-sive, i. e. as having no type co=on or-type 
specific antibodies by-both assays, -3 contained IgG. anti-MA 
and were therefore false seronegatives, by, -, both CF and 
ELISA. The 38 sera in which discordant results were 
obtained were reassessed-in the light. of IgG and IgA 
membrane antibody results, and the optical density (OD) 
results by ELISA to HSV-1 and HSV-2 type specific antigen. 
They were then reclassified according. to the estimated 
HSV-1 and HSV-2 specific antibody. The-aim of this 
exercise was: 
a) to estimate--the, approximate false negative result 
rate by CF and ELISA, and 
b) to estimate the distribution of HSV-1 and HSV-2 specific an-Ubody 
in British patients with cervical anaplasia and controls on 
the basis of the comb! 'n-ed results'. ' 
THE 38 SERA ON WHICH DISCORDANT RESULTS WERE OBTAINED BY THE 
CF TEST AND ELISA 
HSV-1 specific antibody by CF and HSV-1 and HSV-2 
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Patient No. 1 and 2 (Table 6.25) had no detectable 
dr 
IgA anti-MA, and also had. very low OD values to HSV-2 
type specific antigen. It is possible therefore that they 
wem false positives for HSV-2 specific antibody by 
ELISA. Th--yhave been considered as possessing only 
HSV-1 specific antibody. Numbers 3 to 7 have been considered 
to p9ssess. both HSV-1 and HSV-2 specific antibody, as 
demonstrated by ELISA and may therefore be-false negatives 
for-HSV-2-specific antibody by the CF test. ' 
HSV-1 specif ic antibody by , 
CF. seronegative by ELISA 
SB6x E, Table 6.24) 
Of the two patients in this category (Patient No. 
and 9, Table 6.25), 
- 
patient 8 had noldetectable 
antibodies by the IgG membrane antibody assay. This was 
considered a false negative by the IgG membrane antibody 
assay and ELISA. Patient No. 9 had an IgG anti-MA titre 
of 1/128 and was considered to be a false negative by ELISA. 
HSV-2 specific antibody by CF, HSV-1 and HSV-2 specific anti=_ 
body by ELISA (Box H. Table 6.24) 
In these three patients (No. 10,11 and-1-2, Table 6.25), 
the OD with HSV-l'type specific antigen by ELISA were all reason- 
ably high. Therefore, results by ELISA have, been considered 
as correct, i. e. these were three false negatives for HSV-1 
specific antibody by complement fixation. 
HSV-1 and HSV-2 specific antibody by OF and-HSV-1 
specific antibody by ELISA (Box K, Table 6.24) 
Of these five patients, two-(No. 15 and no. 17, Table 6.25)- 
200 
I did not have detectable levels of Ig A anti-MA. However, 
among the 11 patients (Box M, Table 6.24) in whom 
HSV-1 specific and HSV-2 specific antibody were detected 
by both CF and ELISA there was one who did not have detect- 
able levels of IgA anti-MA antibody. 
Therefore these five sera have been considered-to be 
five false negativesfor HSV-2 specific antibody by ELISA. 
No type specific antibody bv CF, but HSV-1 specific 
antibody by ELISA (Box P. T able 6.24) 
These 10 patients (No. 18 to 27, Table 6.25) had a 
similar GMT. of IgG anti-MA and mean OD to HSV-1 type specific 
antigen and mean OD to HSV-2 type specific antigen as the patientsin! 
Box A, Table 6.24, who had HSV-j specific antibody by 
both CF and ELISA. Therefore these 10 patients have been 
considered as false negatives for HSV-1 specific antibody 
by CF - 
No type specific antibody by CF, but HSV-1 and HSV-2 
specific antibody by ELISA (Box R, Table 6.24) 
a 
These tvýo sera (No. 28 and 29, Table 6.25) have beerr 
considered as possessing HSV-1 and HSV-2 specifi6*antibody 
although ser= no. 29 was a doubtful positive for HSV-2 
specific antibody as there was no detecýable IgA anti-ýMA, 
and the OD to HSV-2 type specific antigen was low. 
No tviDe sT)ecific antibodv by CF, and seronegative bv ELISA 
(Box T, Table 6.24) 
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IgG anti-MA antibody. This serum was therefore considered a 
false seronegative by'ELISA. 
ýeronegative by CF, HSV-1 specific antibody bV ELISA 
(Box U. Table 6.24) 
All these five patients (No's 31-35,. Table 6.25) had 
0 
IgG anti-MA antibodies. They were therefore considered as 
false seronegatives by CF. 
Seronegative by CF, HSV-1 and HSV-2 specific antibody by ELISA 
(Box W, Table 6.24) 
All three patients in this category (No's 26-29, Table 
6.25) had IgG anti-MA antibody. They were therefore con- 
sidered false seronegatives by CF. 
EFFICIENCY OF THE THREE ASSAYS (CF, ELISA. AND'MEMBRANE 
ANTIBODY) IN DETECTING HSV-1 AND HSV-2 TYPE COMMON AND 
TYPE SPECIFIC ANTIBODY 
Table 6-26A shows the final classification of the 58 
sera compared, according to the presence or absence of 
HSV-1 and HSV72 specific antibody following corrections 
made as explained in Table 6.25. Table 6.26B is an 
estimate of false negative rates per 100 sera by each assay. 
1. As a method of determining antibody to the antigen 
common to HSV-1 and HSV-2 
The IgG membrane antibody was the most sensitive (false 
negative rate of 1.7%). The CF test and the ELISA gave 




A. ' Final classification of the 58 sera compared. according to 
HSV-1 and HSV-2 specific antibody (based on corrections 
made in Table 6.25). 
No. of sera with HSV-1 specific antibody 24 
No. of sera with HSV-1 and HSV-2 specific antibody 29 
Total no. of sera with HSV-1 specific antibody 
11 
53 
No. of sera with no type specific antibody 4 
No. of seronegative sera C) 1 
B. Assessment of "false" results* by CF and ELISA assay (based 
on corrections made in Table 6.25 
FALSE SERONEGATIVES 
(HSV-1 AND HSV-2) 


















23/53 (43%) 10/29 (34%) 
2/53 (3.7%) 5/29 (17%) 
+? 2/58 (3%) 
(false 
positive) 
A seronegative serum lky one assay was classified as false 
seronegative as well as false negative for HSV-1 
specific antibody, if by the results of the-other assay 
as well as the membrane antibody assays it was estimated 
that the serum contained HSV-1 specific antibody. 
I 
2o6 
2. As a method of estimating HSV-1 specific antibody. 
ELISA was the most sensitive (false negative rate of 3.7%). 
The CF test was much less sensitive (false negative rate 
of 43%) - 
3- As a method of estimating HSV-2 specific antibody 
ELISA was more sensitive (17% false negative and ? 3% 
false positive). The CF test had a false negative rate 
of 34%. 
0 
A comparison of the distribution of HSV-1 and HSV. -2 specific 
antibody in 36. British patients with cervical anaplasia and 
22 controls by A) the complement fixation test, B) ELISA, 
and C) a combined assessment based on results by CF. ELIS 
and IgG and_IgA membrane antibody assavs 
A significantly higher proportion of patients with 
cervical anaplasia possessed HSV-2 specific antibody com- 
pared with. controls, by both the CF test (Column A, Table 6.27) 
and ELISA (Column B, Table 6.27). However, when the results 
I by both assays and the IgG and IgA membrane antibody results 
on these sera were made use of to make a more accurate assess- 
ment of the herpes antibody type in each serum as explained 
above, the following observations were made: 
A) *The proportion of seronegatives among patients fell to 
1/36 (3%) and among controls to none. 
B) Fewer patients were classified as not possessing type 
specific antibody in comparison with the proportion obtained 
by the CF test (3% and 14% respectively). 
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C) There were no patients with only HSV-2 specific antibody. 
D) A higher proportion (72%) of patients with cervical 
anaplasia had HSV-2 specific antibody in contrast to 50% 
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RESULTS. PART V., 
0 J*ON FIRST SERUM SAMPLES (cont'd) 
LEVELS OF SERUM IgG AND IgA IN 
PATIENTS WITH CERVICAL CARCIN- 
OMA, CONTROLS, AND PATIENTS 
WITH OTHER GENITAL MALIGNANCIES 
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PART V 
RESULTS ON, FIRST SERUM SAMPLES (cont'd)_ 
GEOMETRIC MEAN LEVELS (GMLs) OF TOTAL IgG AND IgA IN FIRST 
SERUM SAMPLES OF PATIENTS WITH INVASIVE CARCINOMA AND CON- 
TROLS IN BRITAIN, SRI LANKA, MALAWI AND SUDAN; AND OF TOTAL 
IgA IN BRITISH PATIENTS WITH OTHER GENITAL MALIGNANCIES. 
Geographical variation in levels of total IgG and total IgA. 
, The levels of total IgG of patients from Sri Lanka, 
Malawi and Sudan and controls from Sri Lanka and Malawi were 
similar and significantly higher than levels in patients and 
controls iri*Britain (Table 6.28). 
-Although within, e . ach country patients had higher IgA 
levels than their matched controls (Table 6-30b), these 
levels did not differ significantly with those of their 
counterparts in the other countries (Table 6.29). 
These findings in the British, Malawian and Sri Lankan sd"ra 
were confirmed by a multi-way analysis of.. variance (Appendix J, 3&4)ý 
which controlled for the separate influence on the levels 
of. total IgG and_IgA by age and stage 6. f disease. 
Comparison of GMLs of total IgG and total IgA between 
patients with invasive carcinoma and controls within 
the same country. 
Patients with invasive carcinoma from Britain, Sri 
Lanka and Malawi had GMLS of IgG which were similar to those 
of their controls (Table 6-30a). In contrast British and 
Sri Lankan patients had significantly higher GMLs of IgA 




Statistical comparison of IgG levels among_ 
patients from Sudan,, - Sri Lanka, Malawi and Britain and 
controls from Sri Lanka, Malawi and Britain 
COUNTRY QML OF I, --G IN p GML OF. IgG IN P* 
PATIENTS_ CONTROL 
Britain 140.7 131.8 
Sri Lanka 247 
< 
. 001 241 < . 001 
Britain 14o-7 131.8 
Malawi 256 
<-001 
277 < . 001 
Sri Lanka 247 241 
Malawi 256 -05 277 NS 
Brit 
, 
ain 14o. 7 
Sudan 217.6 < . 001 
Sudan 217.6 
Malawi 256 > . 05 
. 
Sudan 217.6 
Sri Lanka 247 >-05 
t-test 
-(2 
tailed) for Independent Means 
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Tablp, 6.29 -- 
Statistical comparison of IgA levels among 
patients from Britain, Sri Lanka. Ylalawi- and Sudan, an 














GML'OF TOTAL GML OF TOTAL P* 
LgA IZI DrA IN CON- 
PATIENTS, TROLS 
101.7 83.2 
116.9 >. 05 88.9 >. 
05 
101.7 83.2 
101.1 05 86_. 7 
>. 05 
116.9 88.9 >. 05 
101.1 >. 05 86.7 
157.14 
101.7 >. 05 
157.14 
101.18 > . 05 
157.14 
116.9 ),. 05 
0 
212. 
Table 6.30 Geometric mean levels of total immunoglobulin 
(IgG and IgA) in first serum samples of invasive carcinoma 
patients in Britain, Sri Lanka and Malawi, and matched controls. 
a) 
0 
COUNTRY BRITAIN SRI LANKA MALAWI SUDAN 
Cases 140-7 (28) 247 (31) 256 (25) 217.6 
Controls 131.8 (27) 241 (17) 277 (16) 
ProbEibffity: '11. P>. 05 P *-- 05 P-7-05 
b) 
GEOMETRIC M EAN LEVELS OF TOTAL IgA 
COUNTRY BRITAIN SRI LANKA MALAWI SUDAN BRITAIN 
(untreated (treated .2 C ) cases) a Inv. 
Cases 101-7 (29) 116.9 (32) 101.18 (25) 157.14 (23) 68-26 (1ý1 
Controls 83.2 (27) 88.9 (77) 86-7 (18) 69.28 (15)1 
Prcbability P 4.01 p 4.01 P>-05 
*1 Paired t-test (2 tailed) 
Serum samples collected 1-12 years after treatment 
No. of patients 
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patients had higher GMLs of IgA than their controls, but 
this difference was not significant. The GML of IgA in 
the treated group of British patients withcervical carcinoma 
was similar to that of controls (Table 6.30b). 
Analysis of GMLs of IgG and IgA according to stage of disease 
GMLS of both IgG'and IgA showed a tendency'to increase 
with progress of the. disease. (Table 6-31 and 6,., 32). 
In a multi-way -analysis, of variance which omt: 'aled Rr tte sepza-te 
effects of race and age, the increase of-total'IgG with pro- 
gress of disease was riot significant, but the increase of 
total IgA with progress of disease was (P< . 01) - see 
Appendix J-3 and 4. 
The inverse relationship of total IgA and IgA-anti-MA in 
invasive carcinoma patients in Britain, 'Malawi and Sri Lanka. 
By the same multi-way 'analysis of milVice which. contrcUed Jbr the ef f ects 
of race, age and stage of disease, IgA anti-MA titres were 
invetsely re-lated to total IgA. When total IgA was 
doubled, IgA anti-MA was multiplied by a factor of 0.6461 
(Appendix J5)., 
Variations in levels of total IgG and total IgA with. 
increasing age. 
The total IgG and total IgA results of 27 controls 
showed a tendency for IgA levels to increase with age, but 
after the age_of 60 years, IgG levels did not show a con- 
sistent change with increasing age (Table 6-33). In con- 
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trast by computer analysis, levels of total IgA in 
patients with invasive carcinoma in Britain, Sri Lanka 
and Malawi decreased with age, but this effect was not 
significant at the . 05 level (P=1). 
N 
Comparison of GML of IgA in British patients with invasive 
carcinoma and British patients with other maliknancies. 
The levels of total IgA in the pre-treatment serum 
samples of British patients with squamous carcinoma of the 
cervix was shown to be significantly higher than those of 
matched controls (Table 6.30b). In contrast seven patients 
with adenocarcinoma of the cervix, 10 patients with endo- 
metrial, cancer and five'patients with malignancies of the 
ovai, y had levels similar to that'of controls matched for 
age, sex and social class (Table 6.34). Although there 
were only three British patients with non-cervical squamous 
genital carcinoma (vulval squamous carcinoma), it is of 
interest that these patients had levels of total IgA which 
were similar to those'in pre-treatment sera of British 
patients with squamous cervical carcinoma. Matched controls 
for these three patients with vulval carcinoma had levels 
of total, IgA which were similar to those of controls for 
the patients with squamous carcinoma of the cervix. ' 
S 
215 
Table 6.31 Variation in levels of IgA with progressing 
stage of disease 
BRITAIN SRI LANKA MALAWI 
Stage 1 82.44 (9) 109.9 (2) 65 (1) 
Stage 11 101-58 (10) 109.6 (16) 93.8 (13) 
Stage 111 115.6 (8) 127.8 (14) 72-12 (3) 
Stage IV 146.1 (2) - 138, (8) 
Table 6.32 Variation in levels of IgG with progressing 
stage of disease 
BRITAIN SRI LANKA' MALAWI 
Stage 1 1.26.1 (9) 120 (1) 158 (1) 
Stage 11 1.38.7 (10) 258.6 (16) 256.2 (13) 
Stage 111 149.1 (8) 273-8 (14) 246-o (3) 
Stage IV 176.2 (2) - 321.7 (8) 
Table 6-33 
_Analysis 
according to age. of th 
levels of IgG and IgA in 27 British controls 
AGE GROUP IgG iu/ml IgA iu/ml 
21 - 30 (3) 171 78 
31 - 40 (3) 162 78 
41 - 50 (3) 142 76 
51 - 60 (7) 128 69.4 
61, - 70 (6) 100 82.4 
70 (5) 14o 125-01 
Table 6.34 Geometric mean levels of IgA in pre-treatment sera of 
British patients with invasive carcinoma and other malignancies 
(mainly genital), and their matched controls 
DIAGNOSIS Inv. Ca Adeno. Ca. Endometrial Carcinoma Carcinoma 
Untreated of cervix Cancer of ovary of vulva 
PATIENTS 101.7 (29) 88.04 (7) 95.12 (10) 93-01 (5) 127.0 (3) 
CONTROLS 83.2 (27) 108-07 (5) 93.68 (8) 61.11 (4) 84-68 (3)1: 
PROBABILITY Pý-Ol Pý-05 P>-05 P7.05 P)-05 
S. PART VI. 
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ON SERIAL SAMPLES. 
IgA ANTIBODIES TO MEMBRANE 
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ANTIGENS OF HSV-2 INFECTED 





PART VI. ON SERIAL SAMPLES 
IgA ANTIBODIES TO MEMBRANE ANTIGENS AND VIRUS CAPSID ANTIGENS 
OF HSV-2 INFECTED CELLS, IN PATIENTS WITH GENITAL HERPES. 
IgA. anti-VCA (virus capsid antigen) antibodies and IgA anti-MA 
antibodies to HSV-2 infected cells in serial samples of serum 
from cases of genital herpes 
Figure 6.6 is a representation on a time scale of the 
presence of IgA anti-MA antibodies and IgA anti-VCA anti- 
bodies in serial samples of serum from 16 patients with 
genital herpes. In each case the first serum was collected 
within one to two months of a clinical attack during which 
HSV-2 virus was isolated from the cervix or vulva. 
IgA anti-VCA was found to be transient, i. e. present 
for two to three months after clinical infection except in 
patient number 4 who continued to have these antibodies 
10 months after the first clinical attack, and patient 
number 8 ih whom IgA anti-VCA was first detected one year 
and three months after the initial clinical infection. These I 
two patients had no recurrent attacks which were-clinically 
apparent or which caused symptoms during this-period. -Also 
during this time attempts to isolate virus from these 
patients was unsuccessful. 
In contrast, IgA anti-MA was found in every serial 
sample of serumfor the duration of follow up studies in all 
patients. This extended to one year and three months in 
patients numbers 7,8 and 9. These patients also had no 
clinical attacks during this period. 
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IgA anti-VCA antibodies in serial samples of serum from 
11 patients with abnormal cervical cytology. 
Figure 6-7 is a representation on a time scale of the 
presence or absence of IgA-anti-VCA and IgA anti-MA antibodies 
in serial samples of-serum from 11 patients with abnormal 
cervical cytology. All but two (No's 4 and 9) of these 11 
patients possessed IgA anti-VCA antibodies in their first 
serum samples. 
IgA anti-VCA antibodies were found to persist in 5/9 
patients (No's 2.3,5,6 and 11) for-a period ranging from 
four months to 9 months. This is longer than in the 15116 
patients with genital herpes (Figure 6.9). 
The two patients who were seronegative for IgA anti-VCA 
antibodies in their first serum samples did not have these 
antibodies in subsequent samples. I 
a 
Age analysis of 20 British Datients who presented with their 
i 
first clinical attack of genital herpes. 
The age. range of these 20 pati*ents was 18 - 39 yý-, ars- 
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RESULTS, PART VII. 
ON SERIAL. SAMPLES OF SERUM(cont! Z 
RESULTS OF TOTAL IgG, AND IgA, 
AND IgG AND IgA ANTIBODIES TO 
MEMBRANE-ANTIGENS OF HSV-2 
INFECTED`CELLS IN SERIAL SAMPLB: ýý 
OF SERUM OF BRITISH. AND SRI 
LANKAN PATIENTS WITH -INVASIVE 
CARCINOMA. 
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RESULTS. PART VII. 
ON SERIAL SAMPLES OF SERUM (cont'd) 
CHANGING LEVELS OF TOTAL SERUM IgG ANDýIgA AND OF IgG AND IgA 
ANTIBODIES TO THE MEMBRANE ANTIGENS OF HSV-2 INFECTED CELLS 
IN BRITISH PATIENTS WITH INVASIVE CARCINOMA. 
Levels of total IgG, total IgA, IgG anti-MA and IgA 
anti-MA were estimated in serial samples of serum of British 
and Sri Lankan patients with invasive carcinoma. The reasons 
for doing this were as follows: Firstly, - in the three 
studies on immunoglobulins in cervical darcinoma-described 
in the introduction, there was some suggestion that they 
were of prognostic, value. Secondly, it has been claimed 
that certain HSV-2 related antibodies are also of prognostic 
value in cervical carcinoma, and'it wasýtherefore important 
to determine the prognostic value of IgG'and IgA anti-MA. 
Thus changing trends of both total immunoglobulins and of" 
HSV-2 related antibodies have been compared in patients who 
developed tumor recurrences and in those who-remained well. 
Figures 6.8 and 6.9 and figures 6.10 and 6.11 show 
the changes in levels of total IgG and IgA respectively 
among British patients, as determined by single radial 
immunodiffusion and plotted on a time scale. The number 
on each plot corresponds to the patient number on Tables-6.35 
and 6.38. A change of 10% or more above or: below the 
previous serum level was considered a rise (R) or fall(F). 
A change of less than 10% was classified as no change (NC). 
The course of radiotherapy usually lasted for seven to 
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eight weeks. 1 
It was therefore assumed that by 1'0 weeks 
from the onset of treatment, any alteration in immunoglobulin 
levels or antibody titres which might have resulted from 
the effects of radiotherapy would by then have been stabilised. 
Thus the changes were assessed at two stages during the 
period of follow up. 
a) At 10 weeks from the onset of treatment, and 
b) At the end of the period of follow up. 
The overall changes up to the end of the period of follow 
up has been referred to as gross change. 
Method of determining gross change. 
The gross change up to the time of collecting the 
last serum was determined as follows. 
a) A fall in level of immunoglobulin or titre of antibody 
up to a period of 10 weeks from the onset of treatment 
which persisted at this level in subsequent sera was con- 
sidered a gross fall (patient No. 10 on Table 6.35)- 
b) A rise in level of immunoglobulin or titre of antibody 
up to a period of 10 weeks from the onset of treatment 
which persisted at this level in subsequent sera was consid- 
ered a gross rise . (patient No. 14 on Taýb_le 6.38). 
c) A rise in level of immunoglobulin or titre of antibody 
up to 10 weeks from the onset of treatment followed-by a 
fall thereafter was considered a gross fall, i. e. the patient 
was beginning to demonstrate a falling trend in the level 
of immunoglobulin or in titre'of antibody (patient No. 7 
on Table 6-35)- 
d) Similarly a fall in level of immunoglobulin or titre 
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of antibody up to a period of 10 weeks from the onset of 
treatment followed by a rise was considered a gross rise, 
i. e. the patient was beginning to show a rising trend in 
the level of immunoglobulin or the titre of antibody 
(patient No. 22 on Table 6-35). 
CHANGES IN LEVEL OF TOTAL IgG 
Rising levels of total IgG tended to be associated with 
recurrences. Thus by the end of 10 weeks from the onset 
of treatment 3', of 7 (42%) patients Who developed recurrences 
showed rising levels, in-comparison with 4 of 20 (20%) 
patients who-have remained well (P> . 05) (Table 
6.36). 
This association was even more striking when sera collected 
after 10 weeks from theý'onset of-treatment were tested fP 
since 5 of 5 (100%) patients who developed recurrences 
demonstrated rising levels in contrast with 5 of 15 (33%) 
who remained well (P<ý01) (Table 6.37)- 
CHANGES IN LEVEL OF TOTAL Igý 
The association between a rise in total IgA and 
tumor recurrences was less clearcut than between total 
qo 
IgG and tumor recurrences. Thus up to 10 weeks following 
treatment there was no significant difference in changes 
in IgA level in patients who developed recurrences and 
those who remained well (Table 6.39). However after 10 
weeks from the onset of treatment, 4 of 5 (30%) patients 
who'developed recurrencEs demonstrated a rise in level. 
This contrasts with 6 of 15 (40%) who remained well 
(P >-05) (Table 6.40). 
Fiaure 6.8 Chanaes in level of Total IgG in 15 British patientp 
ýA,, ýith invasive carcinoma, re-presented on a time scale. -223- 
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Figure 6.9 Changes in level of Total IgG in 12 British -patients 
with invasive carcinoma. relDresented on a time scale. --224- 
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Table 6.35 Changes in level of IgG observed in British 
_patients with 
invasive carcinoma I 
PATTENT - CHANGZa-IP CHANGES AFTER GROSS FOLLOW UP 
& NAME TO 10 WEEKS 10 WEEKS CHANGE IýISTORY 
A. Sera available up to approx. 10 weeks after onset of treatment 
19 M- G-. ý F Well 
11 L. B. F Well 
13 L. W. F Rec. 
21 J. B. F Well 
8 F. A. F Well 
12 M. E. NC, Well 
20 V. C. R Rec. 
B. Sera available beyond 10 weeks after onset of treatment 
10 A. G. ý F NC F Well 
1 G*P. F NC F Well 
2 J. W. F NC F Well 
6 V. F. NC NC NC Well 
5 S. D. NC NC NC Well 
26 W. M. NC NC NC Well 
23 A. S. NC F'r F. I:, Well 
16 N. L. NC NC NC Well 
25 B. T. R R R Rec. 
15 J. D. R R R Well 
7 E. H. R F F Well 
18 E. N. R R R Well 
24 E. C. R R R- Well 
17 H. M. R R R Rec. 
27 L. J. NC R, F F- Well 
4 R. S. NC F, R R Rec. 
14 J. F. NC R R Rec. 
3 P. K. NC R R Well 
22 G. V. F R R Rec. 
9 I. D. F R R Well 
NC No variation in level over or above 10% of the level 
observed in the previous serum. 
F Fall in level over 10% of that observed in previous serum. 
R Rise in level over 10% of that observed in previous serum. 
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Table 6.36 Changes in level of totaL IgG u p to 10 weeks after the 
onset of treatment, in British patients with invasive carcinoma. 
TOTAL- BECURRENCE WELL I p2 
ýPATIENTS - ý'PATIENTS -(X --ý2 talle `, ý 
Total 27 7 20 1. I 
Rise in level 7 3 (42%) 4 (20%) > . 05 
. 
Fall in level 
ý10 
2. (29%) 8 (40%) 
Unchanging. 10 2 (29%) 3 (40%) 
levels 
Table 6.37 Changes in levels of total IgG after 10 weeks from 
the onset of treatment, ' in British patients with invasiVe carcinoyna. 
_ 
Total 
Rise in level 










PATIENTS (X2 -2 tc-iled) 
15 
5 (33%) 4 . 01 
6 
4 
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Table 6.38 Changes in level of total IgA observed in British 
_patients with 
invasive carcinoma 
PAT TFNT - CHANGES UP CHANGES AFTER GROSS FOLLOW UP 
NUM BER A ND NAME TO*10 WEEKS 10 WEEK CHANGE- HISTOR 
A. Sera available up to approx. 10 weeks after onset of treatment. 
19 M. G. NC Well 
1.1 L. B. F Well 
13 L. W. F Rec. 
'21 J. B. F Well 
F. A. F Well 
12 M. E. R Well 
20 V. C. F Rec. 
B. Sera available beyond 10 weeks after onset-of treatment. 
10 A. G. R F F Well 
I G. P. NC NC NC Well 
J. W. NC F F Well 
6 V. F. R R R Well 
5 S. D. NC NC NC Well 
26 W. M., F F F Well 
23 A. S. NC F F Well 
16 N. L. R R, F F Well 
25 B. T. R R R 'Rec. 
1'5 J. D. F F F Well 
7 E. H. R NC R Well 
18 E. N. R R R Well 
24 E. C. F R R Well 
17 H. M. NC NC NC Rec. 
27 L. J. NC F F Well 
4 R. S. NC F, R R Rec. 
14 J. F. R NC R- Rec. 
3 P. K. NC R R Well 
22 G. V. NC R R Rec. 
9 I. D. NC F, R R' Well 
NC No variation in level over or above 10% of the level 
observed in the previous serum. 
F Fall in level over 10% of that observed in previous serum. 
R Rise in level over 10% of that-observed in previous serum. 
-1 
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Table 6.39 Changes in levels of total IgA up to 10 weeks 
after the onset of treatment, in patients with invasive 
carcinoma from Britain 
TOTAL RECURRENCE PATIENTS WELL PATIENTS 
Total 27 7 20 
Rise in level 2 (29%) 6 (30%) 
Fall in level 2 (29%) 6 (30%) 
Unchanging levels 11 3 (42%) 8 (40%) 
Table 6.40 
-Changges-in 
levels of total IgA after 10 weeks 
from the"onset of treatment in patients with invasive 
carcinoma from Britain 
TOTAL RECURRENCE PATTENTS 
Total 
Rise in level 
Fall in level 
Unchanging levels 
20 5 
10 4 (80%) 
70 
31 
WEID P (X 
2- 
PI 
2 PATIEUTS lrtailec: jý 
15 




It is noteworthy that none of the patients who 
developed recurrences demonstrated a gross fall in level 
of total IgG or total IgA. 
CHANGES IN TITRE OF IgG AND IgA ANTIBODY TO MEMBRANE ANTIGENS 
(MA) OF HSV-2 INFECTED CELLS, IN SERIAL SAMPLES OF SERUM 
FROM BRITISH -PATIENTS WITH INVASIVE CARCINOMA. 
Figures 6.12 and 6.13 and figure 6.14 show the changes 
If in titre of IgG anti-MA and IgA anti-MA respectively in 
serial samples of serum from British patients with invasive 
carcinoma. plotted against a time scale. The number on 
each plot corresponds to the patient numl5er in Table 6.41 
and Table 6.44 
CHANGES IN TITRE OF IgG ANTI-MA 
Rising titres of IgG anti-MA were associated with 
recurrences. Although this was observed in sera collected 
up to a period of 10 weeks from the onset of treatment, 
after this interval there was a greater difference in the 
incidence-of rising titres among patients with recurrences 
then those who remained well. Thus up to 10 weeks from'the 
onset of treatment, 6 of 7 (86%) patients who developed 
recurrences demonstrated rising titres of IgG anti-MA 
in comparison with 11 of 20 (55%) of patients who remained 
I. - 
well (P> . 05)(Table 6.42). In the sera collected after 
this period,. 4 of 5 (80%) patients. who developed recur- 
rences had rising titres in contrast with 5 of 15 (33%) 
of the patients who remained well (P<-05) (Table 6.43)- 
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However it must be emphasised that these rising titres were 
not dramatic ones; often the rise in titre was only a 
two- to four-fold difference. However on testing these 
sera repeatedly and testing them under code these dif- 
ferences were consistently. detected. 
CHANGES IN TITRE OF IgA ANTI-MA 
In pre-treatment serum samples it was IgA anti-MA 
titres that clearly distinguished patients with invasive 
carcinoma from controls. These týtres also increased 
with the stage of disease. Despite this, attempts-to 
detect trends of changing levels of IgA anti MA did not 
help in distinguishing between patients who developed 
recurrences and those who remained well. This is seen from 
Table 6.45 which shows the changes up to 10 weeks from the 
onset of treatment and Table 6.46 which shows the gross 
changes in titre thereafter. It is however relevant to * 
other findings in this study which are discussed later 
that of the patients who remained well, 9 of 20 (45%) 
showed a fall in titre of IgA anti-MA up to 10 weeks from 
the onset of treatment but only 4 of 15 (27%) showed a fall 
in titre by the end of the period of follow up, i. e. in 
some of the patients who remained well, the IgA anti-MA 
titres had reverted to their original levels. 
SUMMARY OF THE GROSS CHANGES IN TOTAL IgG AND IgA ANTI-MA 
IN BRITISH PATIENTS WITH INVASIVE CARCINOMA 
Table 6-47A summarises details of patients who developed 
recurrences and those who remained-well or who showed 
FiFure 6.12 Changes in titre of IgG- anti-MA in 12 British - 
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GMT of C- GMT of I. -, S anti-MA in controls 
patients with invasive carcinoma, represented on a time scale. 
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Tabl: e 6.41 Changes in titre of IgG anti-MA in British 
patients with invasive carcinoma. 
I 
PATIENT CHANGES UP CHANGES AFTER GROSS FOLLOW UP 
NUMBER & NAME TO LO WEEKS 10 WEEKS CHANGE HISTORY 
A. Sera available up to approx. 10 weeks after onset of treatment. 
19 M. G. R Well 
11 L. B. R Well' 
13 L. W. R Rec. 
21 J. B. F Well 
8 P. A. R Well- 
12 A. E. NC Well 
20 V. C. R Rec. 
B. Sera available beyond 10 weeks after onset of treatment. 
10 A. G. R R R Well 
1, G. P. R F F Well 
2 J. W. NC F F Well 
6 V. F. R R R Well 
5 S. D. NC F F Well 
26 W. M. R R R Well 
23 A. S. R F F Well 
16 N. L. NC NC NC liýTell 
25 B. T. R R R Rec. 
15 J. D. NC NC NC Well 
7 E. H. NC NC NC Well 
18 E. N. NC NC NC Well 
24 E. C. NC F F Well 
17 H. M. R R R Rec. 
27 L. J. R F. R R Well 
4 R. S. R R R Rec. 
14 J. F. R F F Rec. 
3 P. K. R F F Well 
22 G. V. NC R R Rec. 
9 1. D. R NC R Well 
NC Same titre as the serum before. 
F Fall in titre (2-fold fall in titre inclusive). 
R Rise in titre (2-fold rise in titre inclusive). 
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Table 6.42 Changes in titre of IgG anti-MA up to 10 weeks 
after the onset of treatment in British patients with 
invasive carcinoma 
L RECURRENCE WELL p 
PATIENTS PATIENTS 2_ (X 2 tailed) 
Total 27 7 20 
Rise in titre 17 6 (86%) 11 (55%) >-05 
Fall in titre- 1 0 1 
Unchanging titre 9 1 8 
Table 6.43 Gross changes in titre of IgG anti-MA in British 
patients with invasive carcinoma 
TOTAL RECURRENCE WELL p2 
PATIENTS PATIENTS -2 taileo (X 
Total 20 5 15 
Rise in titre 9 4 (80%) 5 (33%) K. 05- 
Fall in titre 7 1 6 
Unchanging levels 4 0 4 
Fi! 2: ure 6.14 Changes in titre of IgA anti-MA in 27 British -237 
]ýatients with invasive carcinoma, relDresented on a time scale. 
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Table 6.44 Changes in titre of IgA anti-MA in 
British patients with invasive carcinoma. 
PATIENT - CHANGES U CHANGES AFTER FINAL FOLLOW UP 
NUMBER & NAME TO 10 WEEKS 10 WEEKS CHANGE HISTORY 
A. Sera available up to approx. 10 weeks after onset of treatment., 
19 M. G. NO Well 
11 L. B. F Well 
13 L. W. NO Rec. 
21 J. B. NO Well 
8 F. A. F Well 
12 M. E. " NO Well 
20 V. C. NO Rec. 
B. Sera available beyond 10 weeks after onset of treatment. 
10 A. G. F NO F Well 
G. P. NO NO NO Well 
2 J, W. FRR Well 
6 V. F. NO NO NO Well 
5 S. D. FRR Well 
26 W. M. NO NO NO Well 
23 A. S. R NO R jJell 
16 N. L. NO NO NO Well 
25 -B. T. NO NO NO Rec. 
15 J. D. NO NO NO Well 
7 E. H. FFF Well 
18 E. N. NO NO NO Well 
'24 E. C. FFF Well 
17 H. M. NO NO NO Rec. 
27 L. J. F R, NC R Well 
4 R. S. NO RR Rec. 
14 J. F. RRR Rec. 
3 P. K. F R, NC R Well 
22 G. V. NO NO NO Rec. 
9 I. D. RFF Well 
NO Same titre as the serum before. 
F Fall in titre (2-fold fall in titre inclusive). 
R Rise in titre (2-fold rise in-titre inclusive). 
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Table 6.45 Changes in titre of IgA anti-MA up to 
10 weeks after the onset of treatment in British patients 
with invasive carcinoma 
Total 
Rise in titre 
Fall in titre 
Unchanging titre 
TOTAL RECURRENCE JELL 
PATIENTS PATIENTS 
27 7 '20 
3 1 (14%) 2 (10%) 
9 0 9 (45%) l 
90% 
15 6 (86%) 9 (45%) 
Table 6.46 Gross changes in titre of IgA anti-MA in British 
patients with invasive carcinoma 
'I 
TOTA RECURRENCE hTjjl 
PATIENTS PATIENTS 
Total 20 5 15 
Rise in titre 7 2 (40%) 5 (33%) 
Fall in titre 4 0 4 (27%) 
Unchanging titre 9 3 (60%) 6 (40%) 
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Table 6.47 , Gross change in IgG anti--MA and total immuno- 
globulin observed in British patients with invasive carcinoma 
A. 
RISE IN IgG 
ANTI-MA- 
Recurrence patients, ý4/5 (80%) 
Well. patients 5A 5 (33%) 
B. 
RISE IN TOTAL RISE IN TOTALý 
19G 19A 
515 (100%) -4/5 (80%) 




119G ANT NA I ýI - TIgG ANTI -MA 
IIEG AU- ap 
ITOTAL I9A I'MOT.. ILG TTQT. IgA ITOTAL IRG 
tTOTAL DrA 
Recurrence patients 315 (60%) 4/5 (80% 4/5 (80%) 315 (60%) 
Well patients, 2/15 (13%) 1115 (6%) 4/15 (26%)-1/15 (6%) 





a) a ris'e in total IgG, b) a rise in total IgA and 
0a rise in IgG anti-MA. 
In Table'6.47B the. proportion of these two groups of 
patients who showed all possible combinations of the 
changes discussed above have been examined. A combina- 
tion of*a rise of IgG anti7MA and rise in total IgG gave 
the best distinction between patients who developed recur- 
rences andýthose who remained well. - 
CHANGES IN LEVELS OF TOTAL IgG AND IgA ANTIBODY TO THE 
MEMBRANE ANTIGENS OF HSV-2 INFECTED CELLS'IN SRI LANKAN 
PATIENTS WITH CERVICAL CARCINOMA -4 A COMPARISON WITH 
RESULTS ON BRITISH PATIENTS WITH INVASIVE CARCINOMA 
The changes in immunoglobulin levels and antibody 
titres in Sri Lankan patients with invasive carcinoma con- 
firmed, the results observed among British patients. Follow 
up histories were available on 20 of 29 Sri Lankan patients 
from whoiý serial samples were'obtained. From 12 of these 
20 patients, serial samples were obtained up to a period 
of 10 weeks. from the onset of treatment and from eight up 
to a period of approximately 20 weeks. Unfortunately'six 
patients who developed recurrences were among the 12 from 
whom sera were collected for an interval of 10 weeks from 
the onset of treatment. Therefore a study of'how well 
changes in level of immunoglobulin and titre of antibody 
distinguished patients who developed recurrences from those 
who remained well, could be dcne only on sera- collected 
up to a period of 10-weeks from the onset of treatment. 
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These results have been compared below to the results on 
British sera collected up to the same period. 
Later on page; 50changes in level of immunoglobulin 
and titre of antibody have been compared between: 
a) Eight Sri Lankan patients who did not develop recur- 
rences and who were followed up for longer than 10 weeks 
from the onset of treatment, and 
b) 15 British patients who similarly did not develop 
recurrences and who were followed up for a longer period 
than 10 weeks from the onset of treatment. 
Tables 6.43,6.49,6.51 and 6.52 give details of the 
follow up histories on Sri Lankan patients and details of 
the changes observed in level of'immunoglobulin and antibody 
titre as for British patients. 
CHANGES IN LEVEL OF TOTAL IgG 
-10 
Up to a period of 10 weeks from the onset of treat- 
ment (Table 6.50A) a rise in level of total IgG'was seen 
more frequently in Sri Lankan patients who developed recur- 
rences (4 of 6= 67%) than among patients who remained well 
(3 of 13 = 28%) (P <. 05). These results are simllar to those 
obtained in British patients with invasive carcinoma (Table r: ). 36). 
CHANGES IN LEVEL OF TOTAL IýTA 
Up to a period of 10 weeks from the onset of treatment, 
the changes in level of total IgA were similar among patients 
who developed recurrences and those who remained well. These 
results are compatible with those observed up to 10 weeks from 
i 
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the onset of treatment in British patients with invasive 
carcinoma (Table 6.39). 1. -I 
CHANGES IN TITRE_OF IgG ANTI-NIA 
Three of six Srl, Lankan patients who developed recur- 
rences had no-detectablb IgG anti-IIIA (Table 6.51). However 
of the three in whom IgG anti-MA was detected, two (66%) showed 
a rise in IgG anti-MA by 10 weeks from the onset of treatment. 
It In contrast onlY 5 Of 13 
(38%) of patients who remained well 
showed a similar rise of IgG anti-MA (Table 6.53). The 
equivalent proportions among British patients was 86% and 55% 
repectively (Table 6.42). 
CHANGES IN TITRE OF IgA ANTI-MA 
il 
Although a significantly higher proportion of Sri Lankan 
patients possessed IgA anti-MA in comparison with controls, 
5 of 6 patients who developed recurrences had no detectable 
IgA anti-MA (Table 6.52). However 6 of 13 (46%) Sri Lankan 
patients who remained well showed a fall in titre of IgA anti-MA 
or had stable titres (Table 6.54). Among British-patients this 
proportion was 9 of 20 (45%) (Table 6.45). 
CHANGES AFTER 10 WEEKS FROM TREATMENT OF LEVELS -OF TOTAL 
IgGAND TOTAL IgG ANTI-MA AND IgA ANTIýMIA IN SRI LANKAN 
PATIENTS WITH INVASIVE CARCINOMA 
Eight Sri Lankan patients from whom serial samples of 
serumwere. collected for a period-of 20 weeks from the onset 
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Table 6.48 Changes in level of total IgG observed in Sri Lankan 
patients with invasive carcinoma 
PAT TFNT - CHANGES UP CHANGES UP FOLLOW UP 
NUMBER-61 NAME TO 10 WTEKS TO 20 WEEKS HISTORY 
11 H. R. N. R Well 
12 S. W. F Well 
13 A. A. NC Well 
28 J. M. J. F Well 
31 K. A. B. F Sera not available Well 
7 W. C. H. R ar 10 weeks. Rec. 
9 M. G. R. R Rec. 
17 V-deS. F Rec. 
18 D. M. R Rec. 
22 B. G. S. NC Terminal 
23 M. E. R Rec. 
26 K. R. F Rec. 
1 P. D. R R R Well 
6 D. A. F F F Well 
8 U. G. P. F F F Well 
15 P. N. F F F Well 
19 K. T. N. R F F Well 
20 A. D. F R R, Vell 
25 S. H. F F F Well 
30 M. A. F R R Well 
3 W. L. F F F-7 
16 T. K. F F F 
21 V. P. L. NC 
24 M. M. R 
27 G. G. R. NC Not known 
29 B. M. R 
32 M. H. NC 
2 P. D. R F F 
10 J. R. F F F 
NC No change. 
F Fall in level over 10% of that observed in previous serum. 
R. Rise in level over 10% of that observed in previous serum., 
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Table 6.49 Changes in level of total IgA observed in Sri Lankan 
_patients with 
invasive carcinoma 
PATTENT - CHANGE U CHANGE UP FOLLOW UP 
NUMBER & NA E TO 10 WEEKS TO 20 WEEKS, ESTORY 
11 H. R. N. NC Well 
12 S. W. R Well 
13 A. A. F Well 
28 J. M. J. NC Well 
21 -K. A. B. NC Well 
7 W. C. H. R sera not available Rec. 
9 M. G. R. R after 10 weeks Rec. 
17 V. deS. NC Rec. 
18 D. M. NC Rec. 
22 B. G. S. NC Terminal 
23 M. E. F Rec. 
26 K. R. FJ Rec. 
1 P. D. NC NC NC Well 
6 D. A. NC NC NC Well 
8 U. G. P. R R R Well. 
15 -P. N. F R R Well 
19 K. T. N. 
ýNC 
F F Well 
20 A. D. NC NC NC Well 
25 S. H. F R R Well 
30 M. A. F NC F Well 
3 , W. L. F 
16, T. K. R 
21 V. P. L. R 
24' M. M. R 
27 G. G. R. F Not known 
29 B. M. R 
32 M. H. NC 
2 P. D. R F F 
10 J. R. F F F 
NC No change. 
F Fall in level over 10% of that observed in previous serum. 
R Rise in level over 10% of that observed in previous serum. 
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Table 6-50 Changes in level of total IgG and IgA up to 
10 weeks from the onset of treatment in Sri Lankan patients 
with invasive carcinoma with known follow up histories 
A. IgG 
TOTA RECURRENCE TERMINAL WELL 
PATIENT CASES PATIENTS 
Total 20 6 1, 13 
Rise in level 7 4 (67%) 3 (28%) 
Fall in level 11 2 (33%) 9 (69%) 
Unchanging levels 2 0 1 1 
B- IgA 
TOTA RECURRENCE TERMINAL WELL 
PATIENTS CASES PATIENTS 
Total 20 6 1 13 
Rise in level 4 2 (33-3%) 2 (15%) 
Fall in level 6 2 (33-3%) 4 (31%) 
Unchanging levels 10 2 (33.3%) 1. 7 (54%) 
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Table 6.51 Changes in titre of IgG anti-MA in 29 Sri 
Lankanpatients with invasive carcinoma. 
PATIENT - CHANGES UP CHANGES UP FINAL FOLLOW UP 
NUMBER & NAME TO 10 WEEK5 To 20 WEEK CHANG HISTORY 
11 . H. R. N. F Well 
12 S. W. R Well 
13 A. A. R Well 
28 J. M-J. ' R Well 
31 - K. A. B. NO Sera not ava ilable Well 
7 W. C. H. 
, 
R after 10 wee ks. Rec. 
9 M. G. R. NO Rec. 
17 V. deS. R Rec. 
18 D. M. NO (SN) Rec. 
22 B. G. S. NO Terminal 
23 M. E. NO (SN) Rec. 
26 K. R. NO (SN)-I Rec. 
1 P. D. R NO R Well 
6 D. A. NO NO NO Well 
8 U. G. P. 
' 
NO NO NO Well 
15 P'. N. 
. 
NO NO NO Well 
19 K. T. N. NO R R Well 
20 A. D. R NO R Well 
25 S. H. NO R R Well 
30 M. A. NO F Well 
3 W. L. R 
16 T. K. NO 
21 V. P. L. NO 
24 M. M. R 
27 G. G. R. NO Not known 
29 B. M. NO 
32 M. H. F- 
2' P. D. R F F 
10 J. R. R F F 
SN Seronegatiye F Fall in titre 
NO No'change in titre R Rise in titre 
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Table 6.52 Changes in titre of IgA anti-MA in 29 Sri- 
Lankan patients with invasive carcinoma. 
PAT TENT - CHANGES UP CHANGES U FINAL FOLLOW UP 
NUM BER & NAME TO 10 WEEK TO 20 WEEK CHANGE HISTORY 
11 H. R. N. NC (SN) Well 
12 S. W. F Well 
13 A. A. NC Well 
28 J. M. J. F Well 
31 K. A. B. NC (SN) Sera not available Well 
7 W. C. H. NC (SN) after 10 weeks Rec. 
9 M. G. R. NC Rec. 
17 V. deS. NC (SN) Rec. 
18 D. M. NC (SN) Rec. 
22 B. G. S. F Terminal 
23 M. E. NC (SN) Rec. 
26 NC (SN) Rec. Rec. 
1 P. D. R F F Well 
6 D. A. NC NC NC Well 
8 U. G. P. NC NC NC Well 
15 P. N. F NC F Well 
19 K. T. N. NC NC NC Well 
20 A. D. F NC F 611 
' ý5 S. H. F F F Well 
30 M. A. F NC F Well 
3 W. L. NC 
16 T. K. NC 
21. V. P. L. R 
24 M. M. NG 
27 G. G. R. F Not known 
29 B. M. F 
32 M. H. F 
2. P, D. NC 
10 J. R. NC 
SN Seronegative F Fall in titre 
NC No change in tiýre R Rise in titre 
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Table 6.53 Changes in titre of IgG anti-MA up to 10 weeks 
from the onset of treatment in Sri Lankanpatients with 
invasive carcinoma with known follow up hisýories 
Total 
Rise in titre 
Fall in titre 
Unchanging titre 
Seronegatives 
TOTA_ RECURRENCE TERMINAL WELL 
PATIENTS CASES PATIENTS 
20 6 .1 13 
7 2 (33%) 5 (38%), 
2 0 2 (15%)l 
8 1 (16%) 1 6 (46%)' 
3 3 (50%) 
Table 6.54 Changes in titre of IgA anti-MA up to 10 weeks 
from the onset of treatment in Sri Lankan patients with 
invasive carcinoma with known follow up histories 
T-(= RECURRENC TERMINA WELL 
UTIENTS CASES PATIENTS 
Total 20 6 1 13 
Rise in titre 0 0 0 
Fall in titre 7 6 (46%) 
Unchanging titre 6 5 (38%) 





Table 6.55 Immunoglobulin (IgG and IgA) and membrane antibody 
(IgG and IgA) in 8 Sri Lankan well patients after 10 weeks from 
treatment - comparison with British well ratients and British 
recurrence patients 
TOTAL Ig TOTAL IaA IgG ANTI-MA IgA *ANTI-MA 
Proportion of Sri (38%) (38%) 4 (50%) 0 Lankan well 8 8 8 
patients showing 













rise in level or 
titre 
fIgG ANTI-MA AlIgG ANTI-MA TTOT. ^jIgG ANTI-MA 
TTOTAL IRA tTOTAL IgG tTQ2. I G ITOTAL IgG 
TTOTAL IgA 
Sri Lankan well 
patients 











(26%) --1- 15 
(6%) 
Sri Lankan and 2 (13%) (13%) (1*7%) 1 (4%) 




itish recurrence (60%) (86%) (80%) 3- (60%) 
patients 5 5 5 5 
Rise in 
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of treatment have remained well up till now. In Table -. 55A 6 
a comparison has been made of the changes in total IgG and 
total IgA and IgG anti-MA and Io,, A anti-MA observed after a 
period of 10 weeks in these patients and in British patients 
who have remained well. The changes are similar... Further- 
more on grouping the Sri Lankan and British patients who 
have remained well together (row 3 of Table 6.55B), and 
comparing the combined results with those of British patients 
who developed recurrences, a rise intotal IgG and a rise 
in IgG anti-MA gives the best differentiation between 
patients who developed recurrences and those who remained 
well. 
TOTAL IMMUNOGLOBULINS (IgG AND IgA) AND IgG AND IgA ANTI- 
BODIES TO ANTIGENS OF HSV-2 INFECTED CELLS IN THREE BRITISH 
PATIENTS WHO DIED FOLLOWING RECURRENCE OF CARCINOMA 
Table 6.56 shows the levels of total IgG, total IgA, 
IgG anti-MA and IgA anti-MA antibody in three patients who 
died following recurrence of carcinoma. First-serum samples 
from these patients had been collected at varying intervals 
of time after initial therapy, i. e.. it was not possible to 
determine pre-treatment levels of immunoglobulin and titres 
of antibody. 
Patient N6.1 appeared to be progressing well by 
clinical examination on 28/2/77. In her first serum 
sample which was'collected 40 months after initial treat- 
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ment, she had levels of total IgG (186 
IgA (179 iu/ml) which were higher than 
(132 iu/ml and 83 iu/ml respectively). 
was suspected on 25/7/77 and confirmed 
these two visits she showed a rise in 
The patient died one year later. 
iu/ml) and total 
the GML of controls 
A tumor recurrence 
on 25/8/77. Between 
level of total IgG. 
Patient No. 2 had a stage III carcinoma and her 
first sample of serum was taken one month after start of 
treatment when levels of IgG and IgA above normal levels 
was detected (211 iu/ml and 157 iu/ml, respectively). She 
showed a rise in level of IgG and titre of IgG anti-MA 
on 4/7/77 after 
on 21/11/77. A 
which there was 
Total IgA level 
high. She also 
on 3.4.78. The 
was collected. 
which recurrence of carcinoma was noticed 
pelvic clearance was done on, 13/1/78 after 
a fall in level of IgG noticed on 13/4/78. 
s rose after pelvic clearance and remained 
showed a rise in titre of IgG anti-MA 
patient died one year after her last serilm 
Patient No. 3 had levels of IgA (79 iu/ml) within normal 
limits and showed no clinical signs of recurrence up to 
17/10/77. She showed a rise in titre of IgG anti-MA 
between 21/2/77 and 17/10/77 and a progressive rise of 
total IgA from 21/2/77 to 16/1/78. A recurrence was sus- 
pected on 22/12/77. The patient died six months later on 
11/6/78. 
In all three patients an elevated total IgG level appeared 
to drop at the time recurrence of the carcinoma was develop- 
ing, e. g. patient No. 1 on 25/7/77- patient No. 2 on 5/12/77 
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and patient No. 3 on 16/1/78. 
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RESULTS. PART VIII. 
A. PREVALENCE OF ANTIBODIES TO 
HERPES SIMPLEX, RUBELLA AND 
MEASLES IN BRITISH, SRI LANKAN 
AND MALAWIAN SUBJECTS. 
B. CHANGES IN TITRE OF ANTI- 
BODIES TO 3 VIRUSES FOLLOWING 
TREATMENT OF PATIENTS WITH 




PREVALENCE OF HERPES, RUBELLA AND MEASLES VIRUSES AMONG 
POST-PUBERTAL FEMALES IN BRITIAN, MALAWI AND SRI LANKA 
Only the, serum of controls . -was' used 
in estimat-, 
I 
ing the prevalence of herpes antibodies. However, the sera 
of both - -: pati6nts and . controls was used in estimating 
the prevalence of rubella and measles antibodies. 
A high prevalence of herpes and measles antibodies 
was found in all three populations, and of rubella in 
Britain and Malawi. The prevalence of rubella antibody 
among the Sri Lankan subjects, however, was significantly 
lower (X2 , P<. 01) than among the British and Malawian 
subjects. (Table 6.57). 
CHANGES IN TITRE OF IgG ANTI-MA AND RUBELLA AND MEASLES 
HAEMAGGLUTINATION INHIBITION (HI) ANTIBODIES IN PATIENTS 
WITH INVASIVE CARCINOMA-FOLLOWING RADIOTHERAPY 
Many British and Sri Lankan patients with invasive 
carcinoma showed a rise in titre of IgG anti-MA immediately 
following radiotherapy. Therefore rubella and measles HI 
titres were tested in these same sera in order to ascertain 
if the rise in antibody was herpes specific or part of a 
more general phenomenon due to the effects of radiotherapy. 
Ten of 47 (21%) British and Sri Lankan patients with 
cervical carcinoma showed 4-fold rises in titre of IgG 
anti-MA compared with 3 of 41 (7%) who showed rises in 
rubella HI titres (Table 6.58). This difference was not 
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significant (P <-05). The difference however was highly 
significant on including in the comparison tNo-fold rises 
in titre as well. Twenty-seven of 47 (57%) of British and 
Sri Lankan patients then showed rises in titre of IgG 
anti-MA in comparison with 9 of 41 (22%) who showed rises 
in titre of measles HI antibody and 5 of 33 (15%) who 
showed rises in titre of rubella HI antibody (P<.. 0005) 
(Table 6.59). 
On testing sucrose gradient fractions of the serum of 
one of the patients who showed a four-fold rise of both 
measles HI antibody and rubella HI antibody, antibody to 
measlesantigen was detected only in the IgG fractions. 
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Table 6.57 Prevalence of measles, rubella and herpes simplex 
antibody in British, Sri Lankan and Malawian subjects. 
BRITAI 5RI LANKA MV. IALAWI--. - 
e 
Measles 43 (96%) 45 
Rubella 45 (100%) 45 




22 (M) 4f 1 
1-7- (100%) 17 17 
23 (100%) 
28 




Table 6.58 Proportion of British and Sri Lankan patients 
with invasive carcinoma showing a 4-fold rise in'herpes IgG 
anti-MA antibody and rubella and measles HI antibody up to 
-20 weeks from the onset of radiotherap 
HERPES DrG MEASLES HI RUBELLA H 
ANTI-MA 
British Inv. Ca. 1 
patients showing 23 23 23 
4-fold rises 
Sri Lankan Inv. Ca. 7 4 2 
ýatients showing 24 19 10 
-fold rises 
Total 10 (21%) (7%) -2 (9%) British and Sri 47 33 
Lankan 
P >. 05 (x 22 tailed) 




of British and Sri Lankan patients 
with invasive carcinoma showing a 2-fold and 4-fold rise in 
. 
herpes IgG anti-MA antibody and rubella and measles HI anti- 
body up to 20 weeks from the onset of radiotherapy 
HERPES Ig MEASLES HI RUBELLA HI 
ANTI-MA 
British Inv. Ca. patients ý14 -5- -3- showing 2-fold rises and 23 22 23 
4-fold rises 
Sri Lankan Inv. Ca. 13 4 2 
patients showing 2-fold 24 19 10 
rises and 4-fold rises 
Total 2 
British and Sri Lankan -477- 
(57%) (22%) 53 (15%) 33 
2 P <-0005 (X 2 tailed) 
I 
IRESULTS. PART IX: 
I 
LEVELS OF CARCINOEMBRYONIC 
ANTIGEN IN THE SERA C-F BRITISH 
PATIENTS WITH INVASIVE CARCINOMP, 
AND OF MATCHED CONTROLS. 
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RESULTS PART TX 
LEVELS OE CARCTNOEMBRYONIC ANTIGEN IN THE SERA OF BRTTIS 
PATIENTS WITH INVASIVE CARCINOMA AND OF MATCHED CONTROLS. 
Levels of carcinoembryonic antigen (CEA) were assayed 
in pre-treatment serum samples of 29 British patients with 
invasive carcinoma, and of 13 matched controls, In addition 
levels were assayed in serial post-treatment samples of 27 
of these patients. Patients had higher pre-treatment levels 
(mea I n, '13.5 pg/litre) than controls (8tig/litre), but this 
difference v-as not. significant. 
The purpose of estimating levels in serial samples was 
to observe if rising levels were an index of tumor recurrences. 
However it was founq that similar proportions of patients who 
still remain well (63%) showed rising levels as patients who 
developed recurrences (57%) (Table 6.60).,, 
Table 6.60 Changing levels of CEA in sgrial samples Qf serim 
of 27 British patients with invasive carninoma, 
T DTAIL RECURRENCE WELL 
PATIENTS PATIENTS 
Total 23 7 16 
Rise in level 14 4 (57%) 10 (63%) 
Fall in level 8 3 (43%) -'5 
(31%) 









SCREENING FOR CERVICAL CANCER IN THE U. K. 
The mortality trends in countries which have introduced 
widesj; ýea'd cervical screening leave no doubt that it saves 
lives (Cervical Cancer Screening Program, 1976). A recent 
study by Clarke and Anderson (1979) in Ontario, Canada has 
provided convincing evidence of the efficacy of Papapicolaou 
smear screening in reducing the incidence of invasive cervical 
cancer. In Britain, the age at which screening should begin 
0 sitill remains debatable (Lancet, 1978). However, the age at 
wýich screening is, begun is obviously a variable. which every 
cpuntry. must decide for itself depending on the epidemiological 
features and trends of the disease, and the resources available. 
Trends in Trortality from cervical carcinoma (England and 
Wales', 1957-19? 5) 
In a cohort,, analysis accordingto year of birth (Fig. 7-1) 
mortality was generally-decreasing in cohorts born up to the 
turn of the century, after which there was an increasereach- 
ing a peak in those born around 1921. This peak is attributed 
to a period of disturbed sexual relationships during the 1939- 
1945 war when this cohort of'women reached their, young adult 
life (Hill and Adelstein, 1967). There. was a subsequent de- 
cline in mortality'lasting approximately fifteen years after 
which there has' been an increase in . mortality affecting young 
women born inthe 1940's or later. -Thi ,6 difference is believed 
, to be related to an increasing exposure to sexually trans- 
O_pqý_p! ýFessýrilyý, c mitted infection, althou 'ausally (Beral,, 
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decreasing use of barrier contraception (Lancet, 1978). In 
fact the number of deaths among women between the ages of 
twenty-five and thirty-four have more than doubled between 
1966 and 1976 from twenty-nine to sixty-nine. (Lancet, 1978). 
This has caused the present screening policy of the Depart- 
ment of Health and Social Security (DHSS) to be questioned 
and there have been calls to reduce the age at which routine 
screening should begin (Lancet, 1978). At present the recom- 
mended age for routine screening is thirty-five years. One 
of the-arguments that has been brought forward against alter- 
ing the present screening policy is that although there has 
been a Hse in mortality among younger women, the deaths in 
this age group still account for only a small number of the 
total deaths from cervical carcinoma, 'i. e. the sixty-nine deaths 
in 1576. were only 3% of the total number of deaths from cervical 
carcinoma for that year. Thus it has been argued (Spriggs and 
Husein, 1978) that many millions of smears would have to be 
screened in order to save one life. However, in the study 
reported in this thesis it was found that the incidence of 
cervical anaplasia was high in this age group. Thirty-nine 
of one hundred sixty-six (23%), patients with cervical ana- 
plasia were aged thirty years or. younger. Of-these, twenty! - 
three had dysplasia, eleven had carcinoma in situ and-five, 
had invasive carcinoma, i. e. sixteen (44%) of a total of 
one hundred fourteen patients requiring immediate treatment 
(patients with carcinoma in situ and invasive carcinoma) were 
thirty years'or younger.. Since it was felt that age specific 
incidence or morbidity information rather than mortality 
information was a better criterion of assessing the problem 
I? 
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Prc por-61oniof a ti ts bel w tl ea e of 








1 1 1 1 
Year ---- ý 164 165i 166 167 179. 169 168 
1172 -73 174 -171 175 
4 
Start of screenin-g programme in England and Wales. 
Proportion of women below the age of 35 years among 
all women. presenting with cervical carcinoma 
England and Walýes (1964 - 1975). 
Based-oh figures in the Hospital In-Patieni Enquiry. 
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of cervical carcinoma in the younger age group an attempt was 
made while writing this thesis to obtain these figures for 
England and Wales. It was discovered that comprehensive 
information on age specific incidence is not readily-. available. 
Therefore an approximate estimate was. made from the Hospital 
In-Patient Enquiry (HIPE) published by the Office of Popula- 
tion Censuses and Surveys (OPCS) which contains statistical 
analysis of one in ten, discharges and deaths occurring in all 
hospitals in England and Wales. Information was available only 
for*patients with invasive carcinoma, and not for patients 
with dysplasia and carcinoma in situ, and these figures con- 
firm the findings in this study. In 1964,6.1% of all patients 
admitted with invasive car I cinoma were below the age of thirty- 
five years. By 1975, this proportion had doubled to 12% 
(Fig- 7-2). The estimated number of patients under the age of 
thirty-five admitted with invasive carcinoma in 1964 was seven 
hundred twenty-eight. By 1976 this number had risen to one 
thousand four hundred fifty-nine. In this study, the ratio of 
patients below thirty years with invasive carcinoma, to those 
with dysplasia and carcinoma in situ was one to seven. Thus 
the figures quoted above on the incidence of cervical carcin- 
oma among the young women probably represents-the tip of the 
iceberg as regards the incidence of all forms of cervical 
anaplasia (dysplasia, carcinoma in situ'and invasive carcinoma) 
in this age group. '' 
Screening for cervical cancer in-post-menopausal-woM 
Thirty-six of seventy patients with invasive carcinoma 
in this study were aged fifty to seventy years and of the 
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twelve patients who died as a result of recurrences, seven 
were also in this age group. The fact that over 50% of all 
women with cervical carcinoma in this study were post-menopausal 
women implies that the screening programme is, not sufficieritly 
made available to and promoted in this age group. 
Implications of the social class analysis of British patignts 
with cervical anaplasia 
0A major proportion of patients with 
dysplasia (75%), 
carcinoma in situ (73%) and invasive carcinoma (66%) were in 
social classes I III. While this may be a reflection of 
the social class distribution of tAe population served by 
St. Thomas', it is sýill a finding contrary to the accepted 
belief that cervical carcinoma is associated with lower social 
class. Thus it may reflect a change in the epidemiology of 
the disease which has been brought about by the change in 
sexual mores and habits of the people. Thirty per cent of 
patients with invasive carcinoma were in the lower social 
classes (IV and V) in contrast with 8% of patients with dys- 
plasia and 20% of patients with carcinoma in situ. This 
probably reflects the fact that women in the lower socio- 
economic groups present less frequently for cervical smears 
and are therefore seen when they develop symptoms caused by 
invasive carcinoma. This is a commonly encountered-problem 
in cytology. screening. 
The efficiency of the screening programme. 
Figure-7.3 shows the mortality rates for cervical carcin- 
oma, per-one hundred thousand of-the population in England and 
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Wales between the years 1964 and 1976. In Figure 7.4, an 
approximate estimate of incidence has been made up to 1975 
from information obtained from the HIPE. The estimated num- 
ber of total admissions with invasive carcinoma have been 
related to the estimated mid-year home population in England 
and Wales for that year, according to sex and age. It is 
seen that the screening programme which began in 1968 has not 
had any impact on either. 
The success of a screening programme depends 6n such 
factors as: 
a) The population of women at risk who are screened 
b) The taking of smears by the correct method 
c) The correct reading of smears 
d) The efficient follow up of patients with abnormal smears. 
'While the proportion at risk who are . being screened in 
Britain has not been estimated, this, proportion has been high 
in areas of the world where screening programmes have achieved 
good results. In British Columbia, where-all sexually active 
women above'the"dge of twenty were screened'#- a 33% reduction 
in incidence rate was achieved in seventeen ypars (Worth, 1973). 
In Toledo, USA over a period of nineteen years the proportion 
being screened was stepped up gradually from 15-90% of those 
at risk. A 66% reduction in the incidence rate was achieved 
(Kim et al, 1978). Similarly in Louisville, Kentucky where 
screening began in 1956,94% of the population. at risk ýA, ere 
being screened by 1967. - 
A 57% decrease in incidence rates 




































f all -fall 
Start of screening programmeýin Eng,, land, and Wales. 
Fiaure 7-3 Death rates from cervical carcinoma -'England and Walezq 
(1963 - 1976). From mortality statistics by cause, 
Office of the Population Censuses and Surveys. 
268 
Figuire 
Start of screen-in'r programme ir Enc. -l. a-. d and 1,1-ales. 
Ircidence ra7es fo--,, cervical car-. inoma - E-&; ý-l-ý;,. -Ad 
and Waless (19'53 - 1975) ýased on figures in -6he 
Enquiry. Hospital In-Patient 
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In contrast, in Auckland where approximately only 20% of the 
women at risk were being screened, the incidence and mortality 
rates which were already falling prior to the campaign did not 
show an accellerated response (Green, 1970). 
There are basically two criteria by which the cost bene- 
fit of widespread cervical screening and thEreby the detection 
of early cervical lesions may be assessed: a) the benefit to 
the patient and b) the benefit to the Health Services. The 
treatment of early invasive carcinoma invol-. 4res extensive opera- 
tive or radiotherapeutic procedtires which are often debilitat- 
ing and. which always castrate. Thus, though the cure rates 
in early cervical carcinoma are good, the price is high. Com- 
pared with this, the benefit to the patient of a comparatively 
simple curative pr6cedure applied to pre-invasive lesions 
which involves the removal of selected areas of abnormal 
cervical epithelium, are only too obvious. In terms of the 
expenses incurred by the Health Services in treating the more 
advanced lesions, it was estimated in the U. S. A. that for every 
dollar spent, nine were saved (Christopherson, 1976). 
Ethnic or igin of i)atients with cervical anaplasia 
Studies which showed varying incidence of cervical car- 
cinoma bet--; oeen women sharing the same ervdronment but belong- 
ing to different ethnic groups were described previously in 
the Introduction (pagel9 ). In the studies reported in this 
thesis 21% of British patients - below the age of thirty years 
with cervical'anaplasia were West Indian in origin. Although 
their socio-economic-distributioný, was similar to that of the 
Caucasians, a higher proportionof them had had previous 
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venereal infection or had a history of previous spontaneous 
or therapeutic abortion. In addition a smaller proportion of 
West Indians in this age group were married. Although numbers 
are small, they may imply that different ethnic groups in 
Britain carry varying degrees of risk of developing cervical 
carcinoma. Ethnic group associated incidence has not been 
adequately established in the U. K. It is of interest that in 
a study conducted in the genito-urinary department of St. Thomas' 
Hospital, it was noticed that dysplasia was nearly twice as 
common among Negroids with genital herpes than among Caucasians 
with genital herpes (Carrol, 1977). 
AGE OF DEVELOPING CERVICAL CARCINOMA IN SRI LANKAN. MALAWIAN 
AND SUDANESE WOMEN 
In contrast with British women with invasive'cervical 
carcinoma, only a low proportion (6%) of Sri Lankan women pre- 
sented in stage one of the disease. Despite this the age group 
showing the maximum incidence of malignancy was younger (forty- 
one to sixty) among Sri Lankan than British women f if ty-ýOm-'ý 01 
to seventy). The age group showing maximum incidence of the 
tumor was even younger among Malawian and Sudanese women 
(thirty-one to fifty). Furthermore, like Sri Lankan patients 
Sudanese and Malawian patients presented in the later stages 
(Stages II and III) of the disease. It is apparent from the 
results on age incidence and on considering the stage of dis- 
ease that they presented in, that the tumor develops well 
within the-child-bearing age in a high proportion of Sri 
Lankan, Malawian and Sudanese_ women. Thus there is seen an 
obvious need to screen these women for cervical cancer at least 
at the antenatal clinics, more so because cervical carcinoma is 
one of the commonest female tumors in all these three countries. 
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In the historical survey seven criteria were layed down 
which if, fulfilled would provide evidence that HSV-2 was 
aetiologically related to carcinoma of, the cervix, (page, a, + 
Clearly, this study could not contribute further evidence to 
criterion number five and six. However it contributes towards 
the other five criteria, and this is discussed below. 
CRITERION NUMBER 1 
THE EPIDEMIOLOGICAL CHARACTERISTICS OF WOMEN WITH CERVICA 
CARCINOMA AND. GENITAL HERPES SHOULD BE SIMILAa. 
As many studies have demonstrated before (page 
in this study too early initiation of sexual intercourse was 
a noticeable'feature among patients from all four countries, e. g. 
Sri Lankan patients. 
The, date of marriage is usually the date of first coitus 
among Sri Lankan women. In this-study the average age of- 
patients with invasive carcinoma was seventeen years in con- 
trast with controls who had married at an average age of 
twenty-two years. 
Malawian patients. 
ApproximatelY 50% of Malawian patients and controls had 
married before the age of eighteen years. One patient had 
married before menarche at the age of eleven years and two 
at the ages of fourteen and fifteen. Such early initiation 
of young girls into marital relationships shortly after menarche 
is a cultural feature among many African communities such as 
in Uganda, Zambia and Malawi(S. PalanLVpan , Personal communication). 
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Sudanese patients 
Although the date of marriage of patients in the study 
could not be obtained (see Materials and Methods pagelfZ), 
independent information obtAined about, marriage customs among 
Sudanese (M. Kambal and M. O. A. Malik, Personal communication) 
revealed that marriages are often arranged for Sudanese females 
between the ages of fifteen and nineteen years.. 
0 
British patients 
Unfortunately the gynaecologists at St. Thomas' were not 
willing that their patients should be questioned about the age 
of initiation of coitus. The average - age of marriage of British 
patients was twenty to twenty-one years., Table 7.1 was com- 
piled by Chamberlain and Dewhurst (1977) from two studies con- 
ducted by Michael Schofield. One of these studies (Schofield, 
1965) aimed to measure the sexual experience of British males 
and females between the ages of fifteen and nineteen. His 
research was conducted on random samples drawn from seven 
areas in London which were representative of all socio-economic 
groups. He found that 17% of females had experienced sexual 
intercourse by the age of eighteen years.: From another study 
by Schofield,. Chamberlain and Dewhurst quote 70% of British 
females as being sexually experienced before marriage. 
Table 7.1 Sexual experience of young adults in Britain by age 
(from Chamberlain and Dewhurst, 1977), based on two studie 
Michael Schofield . 
PROPORTION, SEXUALLY F , XPERIENCED 
By 16 years 
By 18 years 
By 21' years 









By'extrapolating from this indirect evidence it-is likely 
that many of the British patients in this study who had mar- 
ried between the ages of twe-I-Ity and twenty-one years had had 
sexual intercourse in early adolescence. Thus how does the 
herpes hypothesis fit in with the constant epidemiological 
finding that women with cervical anaplasiaýbegin sexual activity 
at an early age? Two possibilities have already been briefly 
mentioned in the historical survey, (pages 25 & 26). 
Firstly Coppleson and Reid (1967) suggested that the meta- C> 
plastic adolescent-cervical epithelium is more likely to be 
transformed by a sexually transmitted agent into cells possessing 
neoplastic potential, 'than the non-metaplastic epithelium in 
later life. Is HSV-2 infection then acquired in early adolescence, 
thus fulfilling the triad of events represented in Figure 7.5? 
Coitus in early adolescence 
Cervical anaplasia 
HSV-2 inýfection in early adolescence , 
Figure 7.5 A suggested triad of events leading to cervical 
ana, plasia if-the, herpes hypothesis is to fit the observed 
epidemiological features of cervical carcinoma. 
The average age of twenty. patients with genital herpes 
in this study was 23.5, the nedian 21.5 and the rancýe 18-39 c) 
years. In the study conducted by Naib et al (1969) the aver- 
age age was 20 years. In a study conducted at the genito- 
urinary department at St. Thomas', 32% of three hundred thirteen 
patients with, genital herpes-presented between the ages of 
thirteen years and nineteen years*(Carrol, 1977). over 50% 
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of cases of genital herpes seen recently at the venereal 
disease clinic, of the General Hospital in Birmingham, has 
been in patients under the age of twenty-one years (Skinner 
et al,. -1978). This provides evidence that a reasonable pro- 
portion of HSV-2 genital infection does in fact occur in 
early adolescence. It also leads to the possibility that the 
selective factor which operates is the age at wh ich HSV-2, 
genital infection occurs, i. e. it could be that of patients 
of all ages who acquire HSV-2 genital infection only those 
acquiring it during early adolescence progress to develop 
cervical anaplasia. This possibility has so far not been 
explored adequately but if established would explain the dis- 
crepancy between the calculated risk of a woman developing 
genital herpes which is 0-80% (average 20%) and the calculated 
risk of a woman developing cervical anaplasia which is 1-2% 
(Nahmias et al, 1978). An explanation-for this discrepancy 
is indeed essential if-a causal relationship in cervical ana- 
plasia was attributed to the virus. What evidence then may 
confirm or'strengthen this possibility? If it could be shown 
by coloscopy that of all patients suffering from HSV-2 genital 
herpes only those infected before the age of nineteen years - 
develop colpose4pically abnormal transformation zonesj the 
association between early-age of coitus,. HSV-2 infection 
and cervical anaplasia would-be strengthened. However, two 
factors have to be borne in mind: a) that the cervi cal 
epithelium also undergoes metaplasia following first pregnancy 
and b) that it has been observed that recurrent attacks of 
genital-herpes are'more common in pregnancy (Naib, 1966; 
Yen et al, 1965). 
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Thus colposcopic examination of the cervices of women 
with a previous history of genital herpes or those with 
HSV-2-specific antibodies after first pregnancy would yield 
evidence for the second possible triad of events. 




Post partum metaplastic epithelium 
Since both metaplastic periods in the epithelium are transient 
this hypothesis takes into account the selective factors of 
exact timing in acquýring a genital herpes infection, i. e. 
infection and metaplasia must be concurrent*. 
The second, suggestion attempting to link early initiation 
of coitus with the herpes hypothesis (Rawls et al, 1976) is 
that women who begin sexual activityat an early age also have, 
multiple sexual partners. This is possibly true of more sexual- 
ly liberated Western societies but is not strictly true of more 
conservative Asian communities such as those in India, and Sri 
Lanka or such Muslim communities as in The Sudan, whe re the 
tumor is one. of, the commonest inýwomen., However, in this. 
study, a high proportion, of patients-, vy. ith invasive carcinoma 
from-both Sri Lanka and Sudan possessed IgA anti-MA to HSV-2 
infected cells (73%, and 85% respectively) and HSV-2 specific 
antibodies by ELISA (65% and 52% respectively), Thus while 
the investigation into the social habits of these two study 
groups is. not in, keeping with the suggestion of Rawls and his 
colleagues, an alternative explanation must be considered 
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which may possibly operate in these more conservative 
societies. This relates to recent evidence focusing on the 
importance of the high risk male. Kessler (1977) identified 
men who were married to-women with confirmed cervical cancer 
at'a time prior to the date of cancer diagnosis, and subsequent- 
ly traced one thousand eight-seven other wives of these men. 
The incidence of abnormal cervical cytology in-these one 
thousand eighty-seven women was 14% and this contrasts with an 
incidenceýof 8% in six hundred fifty-nine control wives. 
4 
Twenty-nine "marital clusters" were identified in which two 
women married to the same man had developed cervical neoplasia. 
The expected number of such "marital clusters" was 11.6. 
Centifanto et al (1972) isolated HSV-2 from the urethral dis- 
charge of 15% of one hundred ninety male patient's seen at a 
urology clinic none of-whom had a known history of genital 
herpes. Similar isolation rates have been reported by others 
fIn both (Goodwin et al, -1970;, Jeansson and, Molin, 19704 - 
Sri Lankan and Sudanese societies, pre-marital, and extra-marital 
sexual activity, although generally uncommont is a more likely C: ) 
feature among the males in the community with a, restricted 
population of willing females. Thus in these communities 
HSV-2 could well have been transmittedýto a cloistered, sexually, 
inexperienced, monogamous young female by an older more exper- 
ienced male whom she marriedý Unfortunately, -well designed 
epidemiological studies in such communities are sadly lacking, 
although these communities provide interesting epidemiological 
groups in whom both-the-role of the male as well as the 
mechanism of acquiring HSV-2 genital infection at an early 
age may be studied. - 
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CRITERION NUMBER 
WOMEN WITH CERVICAL CARCINOMA WOULD BE EXPECTED TO HAVE A 
HIGHER FREQUENCY OR HIGHER TITRES OF ANTIBODY TO VIRUS---SPECIFIED 
ANTIGENS AND ASSAYS OF'CELL MEDIATED IMMUNITY SHOULD SHOW A 
POSITIVE OR NEGATIVE CORRELATION 
The antibodies to three types of viral antigens were 
examined in this study: 
A. The membrane antigens on the surface of HSV-2 infected cells. 
B. The virus capsid antigens in the cytoplasm and nucleus-of 
HSV-2 infected cells. 
C. Antigens which are type-specific to HSV-1 and HSV-2. 
A. & B. ANTIBODIES TO MEMBRANE ANTIGENS AND VIRUS CAPSID ANTI- 
GENS OF HSV-2 INFECTED CELLS. 
Sir MacFarlane Burnet coined the term immune surveillance 
when. he elaborated a theory expounded by Lewis Thomas that the 
immune system is the basic natural machanism against neoplasia, 
and that cancer cells differ from normal cells and are recog- 
nised by the immune system as being foreign. The tumor anti- 
gens-that the immune system can most effectively-respond to 
and themfore reject are those located on the--cell membrane 
rather than in the cell interior. In the Introduction of 
this thesis, studies were quoted which had demonstrated HSV 
related antigens on the cell membranes of squamous carcinoma 
cells, on cells transformed by HSV, and cells infected by 
HSV. Also in the Introduction, new non-virion antigens, Fc 
-. receptors, lectin receptors, unmasked fetal antigens and histo- 
compatibility antigens were described, as Possible new antigens- 




of adenoviruses, a non-virion antigen has been demonstratea 
which is common to cells undergoing lytic infection by the virus 
as well as an tumors induced by the virus Thus, the basis for 
employing HSV-2 infected cell membranes as the antibody trap C$ pping 
test system in this study was that the antigens of these membranes 
would at least partly represent the antigens on a cervical carcin- 
oma cell, if the virus was aetiologically related to the tumor. 
In the studies reported in this thesis the results of 
the IgG and IgA membrane fluorescent assays showed that 
whereas both the frequency of IgG anti-MA and the titres 
were similar among patients with cervical anaplasia and 
controls, both the frequency 'of IgA anti-MA and 
- 
their_titres 
differed. A higher proportion of British and Sri Lankan 
patients with cervical anaplasia possessed IgA anti-MA to 
HSV-2 infected cells and in significantly higher titres 
than controls and all other patients with malignancies except 
patients with, squamous carcinomas at other sites of the body. 
All patients with genital herpes had persisitent IgA anti-ýA 
and their titres were, similar to; those seen in patients with 
cervical anaplasia and with squamous carcinoma. IgA anti-MA 
persisted in a high proportion of British patients with invas- 
ive carcinoma who had been treated one to twelve years pre- 
viously. The titres of IgA anti-MA in these patients were 
similar -to those observed among untreated patients with 
cervical anaplasia, squamous carcinoma and patients who had 
had genitaI herpes. 
.,,. As in. studies. reported by El Falaky and Vestergaard (1977), 
, ý, Similar proportion of patients with cervical anaplasia and 
ýontrols possessed IgA anti-VCA, antibodies and in similar. titres 
Titres of IgA anti-MA increased vrith increasing stage of 'disease 
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The questions which arise from these results are as follows: 
1. Against which antigens on the surface of the HSV-2 infected 
cell are these IgA anti-MA antibodies directed? 
2. Why is there a high prevalence and a high titre of IgA 
anti-MA in patients with squamous carcinoma? 
Why do these antibodies persist in high titre in patients 
with invasive carcinoma who had been previously treated? 
How do these results relate to the hypothesis that HSV-2 
causes cervical carcinoma? 
Antigensagainst which the IgA anti-MA antibodies could 
'Qe directed. 
Current experimental work where attempts have been made 
to characterise the glycoproteins of HSV infected cells are 
I 
relevant to the above questions. 
Vestergaard et al (1977a),, Vesterzaard and Grauballe (1975), 
and Norrild and Ve. stergaard'(1977) have by immunoelectrophoretic 
studies characterised some antigens on the ce. 11 membranes of 
HSV-1 and HSV-2 infected cells. 
18 and Ag'll are two major HSV type common membrane Ag 
bound glycoproteins each composed of several polypeptides of 
which at least one is glycoselated. Monospecific antisera 
raised against these. glycoproteins neutralised both HSV-1 and 
HSV-2 (Table 7-2). They were shown to contain Polypeptides 
belonging to the high molecular weight region of the glycoselated 
polypeptides. found in purified virions which were designated 
7/8 byýSpear and Roizman (1972), and 2/3 by Powell and W-atson 
2 1? 0 
(1975). Recent work suggests that both Ag-8 and Ag 11 from 
HSV-1 infected cells contain HSV-1 type specific determinants 
in addition to type common determinants but Ag-8 and Ag-11 from 
HSV-2 infected cells contain only type common determinants 
(Vestergaard and Grauballe, 1977; Vestergaard, 1979). Vester- 
gaard (1979) using crossed immunoelectrophoresis with inter- 
mediate gel, estimated semiquantitatively the antibody against 
eight herpes simplex virus proteins in one hundred human sera. 
These sera possessed higher antibody titres to Ag-8 and Ag-11 
than to other proteins. There was also a high degree of cor- 
relation between neutralising antibody titre and titre of anti- 
body to Ag-8 and Ag-11. It is deduced therfore that most sero- 
logical cross reactivity between HSV-1 and HSV-2 in human sera 
is caused by antibody to Ag-8 and Ag-11. 
A9-4, and to a smaller extent Ag-9 contain HSV-2 type 
N 
specific determinants but also some type common determinants. 
Thus monospecific sera-raised against these glycoproteins 
neutralise not only HSV-2 but to a smaller degree HSV-1 as 
well. Antibody against Ag-4 and Ag-9 were present in the 
one hundred human sera referred to above. The major part of 
antibodies directed against these two antigens are believed 
to represent HSV-2 specific antibodies. Ag-1 is totally 
HSV-2 type specific. However it does not appear to-play a 
role in the human immune response (Vestergaard, Personal 
communication). 
Ag-3 is a water soluble non-glycoselated type common 
antigen. Antibodies to Ag-3 were detected in human sera but 
in smaller quantities than antibodies to Ag-8 or Ag-11. 




'2 Immunological data*of HSV antigens extracted from infected. 
gell membranes by non-ionic detergents (Adapted from-Vestergaard etal 
1977). 
e 
ANTIGE VIRUS, ANTIGEN SOLUBILIT MEMBRAN VIRUS. 
-NEUTRD -SIMILAR ýPRESEN_T IN WATER BOUN BY MONOSPEC- ANTIGENS 
FIC EERUM TO ýCRIBED BY 
OTHER 
WORKERS 
8 HSV-1 & HSV-2 + HSV-1 & HSV-2 7/3 SpearsA 
Roizman, 
11 HSV-1 & HSV-2 + HSV-1 & HSV-2 1972 and 2/ý 
of Powell & 
Watson, 197.5 
3 HSV-1 & HSV-2 + Weak neutr'n. 
of HSV-1 and 
HSV-2 
1 HSV-2 + Does not neut- 
ralise either. 
9 HSV-2' + Greater neut- ? VP 119 3 ralizing Courtney 4 HSV-2 + potency 
against HSV-2 
than HSV-1 
6 HSV-1 + Neutralises ? VP 123 
HSV-1 Courtney 
Powell 1975 
Table 7.3 Proportion of patients with different-malignancies'ýho 
Possessed antibody to NVA-TAA - results of 2 studies, 
DIAGNOSI NUMBER REACTING I 
CF TEST TO NVA-TAA 
3 
Carcinoma of the larynx 36ý8 (95%) 
Controls for CA of the larynx 2 36 (5%) 
Squamous carcinoma 48/57 (84%) 
Cases cured of sq. carcinoma 20/28 (71%) 
Carcinoma of the cervix 21/24 (87%) 
Non-squamous carcinomas 2/24 (8%) 
Sq. cancer of head and neck 15/24 (62%) 
other than larynx 
Carcinoma of the cervix 13/16 (81%) 
Squamous cell cancer of 6/8 (75%) 
head, neck and vulva 
Non-squamous carcinoma 3/11 (27%) 
REFERENCE AND TES 
Complement fixation 
test 








major capsid antigen (Vestergaard, 1979)- CO 
Ag-6 is an HSV-1 type specific virion glycoprotein. 
Monospecific antibodies against Ag-6 neutralise HSV-1 only. 
Antibody to Ag-6 was detected in human sera. Together with 
the HSV-1 specific determinants on Ag-8 and Ag-11, Ag-6 is 
credited with eliciting HSV-1 specific antibody in human sera. 
Vestergaard et al (1977a) have suggested, that Ag-6 of 
molecular weight 131,000 is identical to the major virion 
P envelope glycoprotein reported by Spear and Roizman (1972) 
and Courtney and Powell (1975). 
Courtney and Powell termed this major virion envelope 
glycoprotein of HSV-1 infected cells, VP 123. In a later 
study (presented at the herpes workshop, Cambridge, England 
in 1978, not yet published) antiserum was prepared to VP 123 
and to VP 119, the major glycoprotein region of HSV-2 infected 
cells, which were found to react type specifically with HSVý-l 
and HSV-2 infected and transformed cells in a membrane 
fluorescence test performed on live cells. 
The other antigen of relevance to this study is the 
NVA-TAA (non-virion antigen - tumor-associated antigen) 
which was first described by Hollinshead et al (1972). This 
is a soluble membrane antigen which was first isolated from 
the supernate of, sonicated vaginal, vulval, cervical and lip 
cancer cells in one of the fractions separated by sephadex 
gel filtration (Hollinshead et, al, 1972; and Hollinshead and 
Tarro, 1973). It cross reacted in a complement fixation test 
7 
with antiserum prepared in guinea pigs against semi-purified 
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HSV-2. 'The antigen was later prepared)by polyacrylamide gel 
separation, of the supernate obtained by stepwise*disruption 
and sonication of HSV-2 infected cells (Hollinshead et al, 1973). 
Table 7-3 shows the proportion of sera from groups of'patients 
with various malignancies that reacted with NVA-TAA. These 
results were repýated by Notter and Docherty (1976) and 
Hollinshead et al (1976). 
Most sera reacted with antigen prepared from HSV-1 as 
0 well as from HSV-2 infected cells. Eighteen per cent reacted 
only with HSV-1 antigen and 5% only with HSV-2 antigen. 
The presence of*antibody to the NVA-TAA does not simply 
represent-past infection with the herpes virus. Four sera 
from cervical cancer patients with no detectable antibody to 
herpes virus reacted with NVA-TAA (Hollinshead and Tarro, 1973). 
Similar proportions of the two groups of patients marked with 
an asterisk in Table 7.3 possessed HSV neutralising antibody 0 
and complement fixing antibody although they differed in the 
proportions possessing antibody to NVA-TAA. 
Thus in su=ary, NVA-TAA is an antigen on HSV-1 and HSV-2 
infected cells which cross reacts with an antigen on many 
squamous cell carcinomas. 
The possible antigens that IgA anti-MA is directed against 
could thus be one or more of the membrane associated glyco- 
proteins described by Vestergaard or VP 119 described by 
Courtney, or an antigen similar to NVA-TAA, i. e. 
To an antigen common to HSV-1 infected cells and HSV-2 
infected cells denoted CM 1 and 2 (common 1 and 2). 
t 
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2. To antigens specific for HSI 
-TS-2 (type specific-2). 
3. To a cross reacting antigen 
Cr (cross reacting antigen) 
similar antigen on squamous 
V-2 infected, cells, denoted 
similar to NVA-TAA denoted 
which cross reacts with a 
carcinoma cells. 
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Evidence for detection of a cross reacting antigen between 
squamous cell carcinomas and HSV-2 infected cells by the IgA 
membrane fluorescence test on HSV-2 infected cells. 
In addition to CM 1 and 2, TS-2 and Cr above, let TS-1 
denote type specific antigen on HSV-1 infected cells. Patients- 
who have had previous HSV-1 infection would possess anti CM 1 
and 2 and anti TS-1. Patients who have had previous HSV-2 
infection would possess anti CM 1 and 2 and anti TS-2, and 
patients who have had previous HSV-1 and HSV-2 infection 
would possess anti CM 1 and 2 and anti TS-1 and anti TS-2. 
In Table 7.4 each group of patients in the study have 
been divided into two classes: 
a) Those possessing type specific antibody to HSV-1 as determined 
by ELISA, and 
b) Those possessing type specific antibody to HSV-1 and HSV-2- 
Two groups of antigen on RK 13 cells infected with'H['. oV-2 
which were employed in the membrane fluorescence assay would' 
be CM 1 and 2 and TS-2. Therefore among the Group 1 (British 
controls) class (a) patients only anti-CM 1 and 2 antibodies 
would attach onto -, the test cells, whereas both anti CM 1 and 2 
antibodies and anti TS-2 antibodies in Group 1 class (b) 
patients would attach onto the test cells. This explains the 
higher IgA: anti-MA GMT of Group 1 class (b) patients, 'in con- 
trast to that observed among the Group 1 class (a) patients. 
When one examines the-'IgA anti-MA GMT's of class (a) 
patients in Group 1, Group 2 (dysplasias), Group 3 (carcinomas 
in situ) and Group 4 (British untreated invasive carcinomas), 
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the class (a) carcinoma in situ patients and the class (a) 
untreated invasive carcinoma patients have a higher IgA anti-MA 
GMT than the class (a) controls or class (a) patients with 
dysplasia. Similarly, class (b) untreated invasive carcinoma 
patients have a higher GMT of IgA anti-MA than class (b) con- 
clqsplas; oý 
trols, class (b); patients, or class (b) carcinoma in situ 
patients. Both class (a) and class (b) patients with non- 
genital squamous carcinoma (GrouP 5) had higher titres of 
IgA anti-MA than the class (a) and (b) controls respectively. 
Suppose patients with squamous carcinomas possessed a 
Cr antigen, the groups of patients in Table 7.4 who would 
possess this antigen would be the patients with carcinoma in 
situ, invasive carcinoma (untreated) and non-genital squamous 
carcinoma, i. e. these patients would possess Cr, antibodies 
which would attach t-o the test cells. This provides an ex- 
planation for the'observation, made before that'class (a) and 
cl . ass, (b) carcinoma in situ, untreated inva6ive carcinoma0and 
non-genital squamous carcinoma patients had higher IgA anti-MA 
compared to class, (a) and (b) dysplasias and controls. The, 
class (b) carcinomas in situ patients do not strictly follow 
-this pattern. 
If the higher titres of IgA anti-MA in these patients 
was caused by the presence of anti Cr antibodies, one could 
predict that these levels would fall following treatment of 
the carcinoma and the destruction of Cr antigen by radiotherapy. 
This is seen among the class (b) treated invasive carcinoma 
patients. (Group 6) who have'a lower GMT of IgA anti-MA than 
the class (b)__untreated invasive carcinoma patients. Once 
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the class (a) treated invasive carcinomas do not have a GMT 
which strictly falls into the pattern. This is to be expected 
in any biological system, and does not necessarily detract 
from the argument. However, in support of the above hypothesis 
is the fact that among the Group 4 patients, none of the seven 
patients who later developed recurrence of their malignancy 
showed a decline in titre of IgA anti-MA within ten weeks 
from the onset of treatment whereas nine of trenty (45%) 
patients who progressed without recurrence did' (Table 6.45) C> 
Class (a) and (b) patients with non-squamous genital 
malignancies (Group 7) and non-genital non-squamous malignan- 
cies (Group 8) had IgA anti-MA GMT's similar to class (a) 
and (b) controls (Group 1). This would have been expected 
on the hypothesis, that Cr antigen is present only on squamous 
carcinoma cells. 
0i 
A similar picture is seen among class (a) and (b) 
patients among Sri Iankan and Malawian controls, and invasive 
carcinoma patients (Table 7.5). The group (b) Sri Lankan 
and Malawian invasive carcinoma patients possess much higher 
titres of IgA anti-MA than their respective class (b) controls 
If one postulates a cross reacting antigen between HSV 
infected*cells and squamous carcinoma cells, one must also 
consider that during an episode of herpetic infection the 
infected cells in vivo may express such an antigen. It is 
possible even so that the amount of cross reacting antigen 
is extremely small and not sufficient an antigenic stimulus 
compared to the quantity expressed_on a malignant cell. 
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This would also explain the reason why the difference in 
antibody titre between squamous cancer bearing patients and 
non-tumor bearing patients is present, but not remarkably 
large. Nevertheless, this preliminary evidence for a cross 
reacting antigen carries an important. implication. In 
pati. ents with invasive cervical carcinoma, antibody to a:, Css reacting 
antigen may contribute towards a false result 'of elevatqd antibody 
titres to HSV antigens. It may therefore be of value to identify 
which of the antibody assays employing herpes simplex antigens 
are able to detect such anti-Cr antibodies. This may in 
particular be relevant to assays which, test for antibody to 
surface antigens of HSV infected cells., Thus patients with 
non-genital squamous carcinomas should form an important con- 
trol group in such studies.. 
49 
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Persistence of IgA anti-MA in patients after treatment for 
qarcinoma of the cervix. 
The key to the reason for this persistence lies in the 
prevalence of these antibodies observed among patients with 
genital herpes. In contrast with IgA anti-VCA aritibodies 
which were present for two to three months after clinical in- 
fection, IgA anti-MA persisted in every serial sample of serum 
from these sixteen patients with genital herpes. This period 
of follow up extended to one year and three months in three 
patients who during that period had no apparent recurrences. 
Furthermore, attempts to isolate virus from these patients 
during the period of follow up were unsuccessful. The cur- 
rent concepts-and unknown factors, concerning herpes simplex 
virus latency were described in Chapter 2, page 66 , and the 
serial, sequential formation of a, B and r polypeptides during 
viral infection were, also explained. 
a 
Herpes simplex virus has been isolated from the tri- 
geminal ganglia and sacral ganglia of human cadavers (Lons- 
dale-et al, 1979)- HSV-2 was isolated_from the sacrosciatic 
ganglia of mice infected with HSV-2 via their f oot pads 
(Stevens and Cooke, 1973)- Possibly the neural ganglion has 
evolved as the most advantageous site for viral survival as 
a means of escape, from the immune system. The interesting 
question then which arises is which antigenic stimulus is 
responsible for maintaining levels of IgA anti-MA over ex- 
tended periods at. levels similar to. those observed during 
convalescence. It is known that IgA is catabolised at a 
higher rate than IgG (Tomasi, 1972) and that the half-life 
of IgA is six days (Fenner and Blanden, 1975). Thus it would 
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be expected that continuous stimulation of the immune system 
is required for the maintenance of IgA levels over long periods. 
This antigenic stimulus could come from one of two sources: 
1. From low grade viral production, 'or 
2. From viral expression which falls short of production of 
viral progeny, at a site which is available to the immune Cý 
system. 
If the first possibility had been correct, it could be 
expected that IgA anti-VCA antibodies, i. e. antibodies direct- 
ed against the late viral proteins (Ypolypeptides) too would 
persist 
.- 
which was not the finding in this study. It there- 
fore appears that the second possibility is the more likely 
one. By viral expression which falls short of production of 
viral proge-ny is meant a state in which: 
a)- There is. no DNA, replication 
b), , There is no inhibition of host cells' macromolecular syn- 
thesis,. i. e. translation. of -viral DNA. is arrested before 
its a polypeptides are formed., This is necessary for the 
-long-term survival of the virus in this state 
Therefore, by a process of elimination, viral DNA could 
be - translated up to the stage of forming a polypeptides or 
early polypeptides. From the experiments summarised in 
Table 4.8 of the Introduction (page 90) it was seen that at 
least some of the membrane antigens on HSV infected cells were 
not dependent on DNA replication for their formation. Further- 
more, the experiments of Courtney (page 94 ) demonstrated mem- 
brane antigens on the surface of transformed cells in which 
it is'known that viral expression is arrested before DNA 
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replication occurs. Thus it seems plausible to suggest that 
the virus lies expressing its a polypeptides in an apparently 
healthy host cell which unlike the cells within the nerve 
ganglion are freely available to the immune system. In this 
manner the early viral proteins which are expressed on the 
cell surface would be able to stimulate the immune system. 
This leads to the next important question which is the site 
at which these cells carrying "latent" virus lie. It is pos- 
sible that they lie at the site of original infection, which 
is the external genitalia, vagina and the cervical epithelium. 
The evidence from this study on the effects of radiotherapy 
on antibody levels supports the possibility of... the virus 
lying in the cervical epithelium. A significantly higher pro- 
portion of the patients with cervical carcinoma showed a rise 
in IgG-anti-MA to HSV-2 infected cells following radiotherapy. 
This contrasted with the proportion who demonstrated rise 
in haemagglutination-inhibition antibody to two other common 
viruses - rubella and measles, i. e. this-., comparison suggested 
that the rise in titre of IgG anti-MA was caused by release 
of viral antigen following radiotherapy and was not due to a 
non-specific general stimulus to antibody levels. Thus. the 
herpes specific IgA antibody results on patients with genital 
herpes may be interpreted as follows: That whereas IgA anti- 
VCA antibodies are markers of recent productive infection, 
IgA anti-MA antibody is a marker of latent viral expression 
in cells available to the immune system. It is therfore sug- 
gested that the virus lies latent at two sites: the nerve 
ganglion and a local site possibly the cervical epithelium. 
Sri lankan and British patients with cervical carcinoma were 
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I treated by radiotherapy. Even if radiotherapy is responsible 
for the destruction of virus and viral antigens at the local 
sites, some patients may harbour a reservoir of virus in the 
sacral ganglia which could re-infect local sites. The initial 
destruction of virus and viral antigen at local sites could 
explain the initial fall in level of IgA anti-MA observed 
directly following radiotherapy in patients who did not develop 
recurrences. From Table 6.45, although nine of twenty (45%) 
showed a fall in level of IgA anti-MA up to ten weeks after 
the onset of treatment, only four of fifteen (25%) demonstrated 
a fall in level at the end of the period of follow up. It may 
therefore be deduced that in some patients local sites were 




The high prevalence of IgA anti-MA in patients -ith cervical 
ana-plasia 
The high prevalence of IgA anti-MA antibody in patients 
with cervical anaplasia must be interpreted in the face of 
evidende that: 
a) the IgA anti-MA response is more type specific than the' 
IgG anti-MA response 
b) IgA anti-MA may be a marker of the presence of latent virus 
expressing part of its genome 
0) IgA anti-MA may be in part directed against an antigen(s) 
common to HSV-2 infected cells and squamous carcinoma cells. 
Thus, the reason for the high prevalence of-IgA anti-MA 
in patients with cervical anaplasia may be in part an indica- 
tion of a higher incidence of HSV-2 infection in patients rith 
cervical anaplasia. --This is supported by the prevalence of 
HSV-2 specific antibody -detected by ELISA in a signif icartly 
higher proportion of; patients than in controls. Furthermore, 
it is-tempting to speculate that patients in whom an IgA anti- 
MA'response'was detected not only were-previously infected 
with HSV-2 but concurrently harboured latent virus which was 
expressing some of its genome. The increased'IgA anti-MA titres 
with. disease progress may either be a reflection'of_increased- 
expression of HSV-2 related antigens or-a reflection. of, IgA 
anti-MA directed against the antigen common to HSV-ý2 infected 
cells and squamous carcinoma cells. Such a tumor specific 
cross reacting antigen would be expressed in larger quantity 
as the tumor increased in mass. 
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IgA anti-MA in British patients withmalignancies other than 
squamous carcinoma of the cervix. 
Few studies have examined the prevalence of HSV-2 anti- 
bodies in patients with malignancies other than cervical car- 
cinoma. In those which have, either the numbers have been 
small (Rawls et al, 1968 and 1969; Aurelian et al, 1973) or 
the type of neoplasm has been unspecified by the authors 
(Freymouth et al, 1975; Sprecher-Goldberger et al, 1970; Aurelian 
et al , 1973) . In this study, patients with malignant disease 
other than squamous carcinoma of the cervix were classified 
into three separate groups, these being a) patients with other 
genital malignant disease, b)'patients with extra-genital non- 
squamous"malignant disease, and c) patients with non-genital 
squamous malignancies. ' 







of forty-three British 
patients whose HSV-1, and HSV-2'type specific antibody had. been 
tested by ELISA it was found that a-titre of IgA anti-MA greater 
than-orequal to 1: 8 provided evidence of"previous HSV-2 in- 
fection'(page-191). ' It was'also suggested above that the 
presbnce of IgA-anti-MA may signify the presence of latent 
HSV-2 virus; --Table 7.6 contrasts the-prevalence, of HSV-2 
specific antibody (ELISA) and IgA anti-MA at a titre of great- 
er than or equal to 138 in British patients with cervical ana- 
plasia and British patients with malignancies other than 
cervical anaplasia. 
Although similar proportions of patients with other 
genital malignancies possessed HSV-2 specific antibody by 
ELISA, a significantly higher proportion of patients with 
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cervical anaplasia possessed IgA anti-MA at tires of greater 
than or equal to 1: 8. This finding implies that whereas 
evidence for previous HSV-2 infection does not distinguish 
these two groups of patients, evidence for current expression 
of latent HSV-2 does. It must however be born in mind that if 
a cross reacting antigen exists between squamous carcinoma 
cells and HSV-2 infected cells, antibody to such an antigen 
may confuse the results of IgA anti-MA in patients with car- 
cinoma in situ and invasive carcinoma, but not in patients 
with dysplasia. 
Compared with patients with cervical anaplasia, a 
significantly I6wer proportion of patients with extra-genital 
non-squamous malignancies had been previously infected with'' 
HSV-2. ý An even lower proportion of -these patients showed 
evidence of expression of latent HSV-2 virus. 
-, gpnital . -_-_Although a smaller proportion of patients with non 
squamous carcinoma had been previously infected with HSV-2 in 
comparison with patients ',, orith cervical anaplasia, 
this differ- 
ence was not significant. However a higher proportion of 
patients with non-genital squamous carcinoma had IgA anti-MA 
greater than or equal to 1: 8 when compared with patients with 
cervical anaplasia This discrepancy may be due to IgA anti- 
MA being in part formed against an antigen(s) common to HSV-2 
infected cells and squamous carcinoma cells. 
Thus the subdivision of patients with malignancies other 
than cervical carcinoma into three broad groups provided re- 
vealing results. If a causal relationship between the virus 
and cervical anaplasia is to be upheld, it is necessary to 
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Table 7.6- Previous infection by HSV-2 (ELISA), and'concurrent 
infection by latent HSV-2 (IgA anti-MA'ýN> 1/8), in British' patients 
with malignancies other than squamous cervical carcinoma. 
PATTFNT GROI QON CURRENT-EXP RESSION OF PREVIOUS INFECTION BY 
LAT ENT HSV-2 ( IgA ANTI- HSV-2 (ELISA) 
ýAA : $ý 1 /8_)_ 
Other genital 9 (27%) 11 (52%) 
malignancies 33 21 
P e,. 025 P >. 05 
Cervical 47 (53%) 6 4 (63%) 
anaplasia 88 10 
Extra-genital 8 
- (21%) 
9 (31%) non-squamous 57 29 
malignancies 
P-C-005 P< . 005 
Cervical'ý, ) 








P> . 05, P >. 05 
Cervical 





identify an HSV-2 related variable which distinguishes patients 
with cervical anaplasia not only from matched controls, but 
from patients with other malignancies and from patients who 
have previously had genital herpes but who continue to possess 
healthy cervices. It is therefore significant that evidence 
for the presence of concurrent infection by latent HSV-2 dis- 
tinguishes patients with cervical anaplasia from patients with 
other genital malignancies. It is also significant and worthy 
of further investigation that patients with other squamous 
carcinoma are not distinguished from patients with cervical 
anaplasia by either evidence for previous or concurrent infec- 
tion by HSV-2- 
It is of, interest that in contrast to Aurelian et al (1973) 
who did not detect AG-4 antibodies in a small number of patients 
with other malignancies (mostly unspecified), Notter and Docher- 
tY (1976) detected AG-4 antibodies in five of eight (63%) patients 
with non-genital squamous malignancies. In the context of 
results in the study reported in this thesis, this finding a8- 
sumes greater significance, for according to Aurelian et al 
(1977) AG-4 antigen is detected on the surface as well as 
cytoplasm of HSV-2 infected cells. Could the AG-4 assay also 
be detecting antibody to cross reacting antigen? In contrast 
in the study by Notter and Docherty only four of twelve (33%) 
patients with extra-genital non-squamous malignancies possessed 
AG-4 antibodies. These results are very similar to those in 
the present study. 
Both AG-4 and VP 134 (Anzai et al, 1975) are antigens 
, produced early in the infectious cycle and may them-fore 
belong 
I to the group of a polypeptides. Antibodies to both these anti- 
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gens distinguish patients with cervical anaplasia from controls. 
However it is unfortunate that the prevalence of antibody to 
AG-4 and VP 134 have not been studied in patients with genital 
I 
herpes. 
In the studies reported in this thesis, the prevalence of, 
IgA anti-MA in patients with cervical anaplasia and patients 
with genital herpes was similar up to the period that these 
patients were followed up. IbAever if a longer prospective 
study of patients'with genital herpes shows that IgA anti-MA 
persists only in. women who later develop cervical anaplasia, 
this finding would strongly support the hypothesis that HSV-2 
is causally related to cervical anaplasia. 
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C. ANTIBODIES TO HSV-2 TYPE SPECIFIC ANTIGEN BY ELISA 
Of all the antibody assays that were employed in this 
study, the most sensitive for assaying previous infection by 
I HSV-2 was ELISA. Although the IgA anti-MA assay was more 
type specific thanixthe IgG anti-MA, assay, the interpretation 
of antibody titres in patients with cervical anaplasia is con- 
fused by the finding that the assay may be recognising anti- 
bodies directed against an antigen which is common to HSV-2 
&. infected cells and squamous carcinoma cells. Compared with 
the ELISA technique, the CF test for HSV-1 and HSV-2 specific 
antibody gave more false negative readings. 
By ELISA, a'higher proportion of patients with cervical 
anaplasia from Britain, Sri Lanka and Malawi had 
ýSV-2 specific 
antibodies -than matched controls. This difference was' statist: - 
ically, patients with dysplasia. , significantýexcept among'British 
These 'results -are simil-ar- to thoýe-obtained in the retros. Pective 
studies on-'patients with cervical anaplasia in the USA, West 
Indies, Europe, India and South Africa (Table 1.4). The 
studies reported in this thesis confirm the results of two 
previous studies conducted in Britain by Skinner et al showing an 
association betwe'en HSV-2'and cervical carcinoma. -Furthermore, the 
results -show the virus 'As associated' with ý cervical carcinorpa 
'in Sri 
Lanka and Malawi where no previous studies had been conducted. 
Patients with cervical anaDlasi6 who had no detectable HSV-2 
si)ecific antibodies. 
Approximately 2? -48% of all patients with cervical ana- 
plasia had no detectable HSV-2 specific antibodies by ELISA, 
the proportion being highest among patients from Sudan 
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(Table 6.15). The view was expressed by Rawls et al in 1977 
that HSV-2 specific antibody had been underestimated among 
women with cervical anaplasia. This was believed in part to 
be due to techniques employed at the time not being suf- 
ficiently sensitive. Since then ELISA for HSV-2 specific anti- 
body has been developed which in addition employs type specific 
antigen. From a comparison of fifty-eight sera in this study 
which were tested by both CF and ELISA, it was estimated that 
i 
ELISA gave a false negative rate for HSV-2 specific, antibody 
of 17%. Thus, even if for the sake of argument the benefit 
of this 17% error is given to the proportion of patients 
with no detectable HSV-2 specific antibodies, there are still 
10-31% of patients with cervical anaplasia with no HSV-2 spec- 
ific antibodies. It is likely that this is a real lack of 
HSV-2 -antibodies and not attributable to the insenstivity of 
laboratory technique" v Of the studies cited in Table 1.4 
those 
conducted in Taiwan, Japan, New Zealand, Colombia, and Israel 
didnot show an ass - ociation betwe - en HSV 1 -2 and carcinoma of 
the cervix. However even in those which did, most showed as 
in this study, a proportion in which HSV-2 antibodies were not 
detectable. The proportion of British, Sri Lankan and Malawian 
patients who lacked both HSV-1 and HSV-2 specific antibodY 
was only 1.7%, i. e. a high proportion of patients with ceriical 
anaplasia in this series, possessed HSV-1 specific antibody. 
This presents the possibility that in the aetiology of cervical 
carcinoma: 
HSV-1 too is . causally related, 
2. Agents other than HSV-1 and HSV-2 are causally related, or 
That aetiology could vary with age or geographic distribution. 
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1. HSV-1 as an aetiologic agent 6f cervical carcinoma. 
HSV-1 has been shown to possess as much oncogenic poten- 
tial as HSV-2 as demonstrated by transformation experiments 
and the oncogenicity of HSV-1 transformed cells in animals 
(Table 1-5). Wyburn-Mas= (1957) reported six patients 
between the ages of sixty and seventy in whom oral carcinoma de- 
velo_ped at sites at which recurrent herpetic lesions occurred. 
It was proposed as a possible causative agent of cervical car- 
cinoma in Japanese by Kawana et al (1976), when a much lower 
prevalence of AG-4 antibodies was detected in Japanese sera 
than in American sera. Fifty per cent of genital herpes simplex 
isolates made in Japan were HSV-1. The predominant virus of 
genital infections in Sri Lanka and Malawi is not known. 
However in the Department of Virology at St. Thomas', of nine 
hundred forty genital isolates made over a two year period, 
only six (0.6%) were HSV-1. This provides clear evidence 
that HSV-2 is by far the commonest virus of genital infe(Aion 
in the population from which the British patients with cervical 
anaplasia in this study were drawn. It therefore does not ap- 
pear likely that HSV-1 could be causally related to the 
tumor in the British patients in this study. 
p 
Agents other than HSV-1 or HSV-2 which could be aetiologically. 
related to cervical carcinoma. 
Countries in which no association between HSV-2 and 
cervical carcinoma was demonstrated were cited in Table 1.4. 
Yet the epidemiological features of the malignancy strongly 
suggest-that it is related to a sexually transmitted agent. 
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It is possible therefore that there are mulitple aetiologic 
agents and that they play roles of varying importance in dif- 
ferent geographic areas. Thus while in a single geographic 
area, one agent may be responsible for the majority of cases 
of cervical carcinoma, other agents may be resp*onsible for a 
small proportion of tumors in that area., An analogous situ- 
ation is seen in the case of Burkitt's lymphoma (BL). BL 
occurs sporadically but rarely in areas outside the endemic 
areas of Africa and New Guinea. These non-endemic cases dif- 
& fer slightly in age distribution and tumor sites, but are in- 
distinguishable in histology, cytology and their clinical, 
response to chemotherapy, from endemic BL seen in. Africa and New 
Guinea. The majority of, these non-endemic BL do not show an associ- 
ation with the-Epstein-Barr virus (EBV), but a small proportion 
(8-17%) dd (Epstein and Achong, 1977). No agent-has been found up 
to. date which is aetiologically related to these non-EBV related BL-,,! 
The possibility also exists that another agent is the 
real. aetiologic agent-of cervical carcinoma and that HSV-2 is 
one of its co-variables. There is some evidence from the 
studies reported in this thesis to support this., possibility. 
In the cohort'analysis on British patients and controls which 
examined the prevalence of HSV-2 specific antibody in cohorts 
born during ten year periods, from 1900 to, 1960, a higher 
prevalence of1HSV-2 specific antibody was not observed in all 
cohorts of patients in comparison with controls. If the 
, virus was 
causally. related, such a constant higher prevalence 
would ýe expected regardless of the year of birth.. A steep 
rise in the prevalence of HSV-2 specific antibody . Alas observed 
among cohorts of patients born between 1921 and 1930, thirty 
3o6 
lp 
years before a_similar rise in prevalence was observed in the 
cohort of controls born between 1951 and 1960. This could well 
be interpreted as being a marker of greater promiscuity-among 
patients with cervical anaplasia compared, with controls, and 
that HSV-2 was a co-variable of another sexually transmitted 
agent. Were it possible to determine antibody to this agent, 
there may have been a higher prevalence of such antibody in all 
cohorts of patients in the study compared with controls. 
1 
On, 
the other hand, a high prevalence of HSV-2 specific antibodies 
was detected in both patients and controls born between 1951 
and 1960. This coincides rith the higher incidence of genital 
herpes observed recently in venereal diseases clinics in 
England (Skinner et al, 1978). If - HSV-2 is causally related 
to cervical carcinoma, it may'then be predicted that this, would 
result in a similar rise in the incidence of cervical anaplasia, - 
I, The, cross" sectional'--, studies cited in the Historical Sur- 
vey-of this'thesis indicate that chlamydiae, mycoplasma, gono- 
cocci, cytomegalovirus and human papilloma virus may, be as- 
sociated with cervical anaplasia (pages 49-59) The 
association may be of a causal, co-factor or a synergistic 
nature. 
-IA 
noticeable deficiency in cervical carcinoma_ 
studies is that researchers have not takdn adequate notice of 
this possibility. It is therefore suggested in this thesis 
thatIfuture studies should examine evidence for all'such aetio- 
logic agents in a single groups of patients and controls, 
preferably drawn from different geographic areas. Such 
longitudinal studies would provide more information than 
isolated cross sectional-studies. 
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ý. The possibilitV that the aetiology of cervical carcinoma 
could vary according to geographic area or age. 
British patients with cervical anaplasia who were above 
sixty years when the lesion was detected had a noticeably 
lower prevalence of HSV-2 specific antibody (37%) than those 
who were younger (66-8o%). This difference is unlikely to 
be due to a loss of antibody with age, since in the above co- 
hort analysis, cohorts of controls born between the years 1900- 
1910 and 1941-1950 had a similar prevalence of HSV-2 specific 
antibody. This suggested that controls in this study who were 
over the age of sixty years had not suffered loss of antibody 
as detected by ELISA. Malawian patients too, who were over 
sixty years at the time of tumor detection had a lower pre- 
valence of HSV-2 spe, cific antibodies (60%), in contrast with 
those in whom the tumor was detected. at an earlier age (78%). 
However this difference was not observed among Sri Lankan pat- 
ients (83% and 65% respectively). 
The pathological changes supposedly induced by EBV are- 
among other factors age dependent. BL develops usually fol- 
lowing childhood infection by EBV, and infection mononucleosis C> 
from primary EBV infection in young adults (Epstein and Achong, 
1977). In addition there is a difference in the age. distribu- 
tion of pateints with EBV related and EBV unrelated BL. In 
New Zealand where no association was observed between HSV-2 
and cervical carcinoma, only 13% of patients were aged forty 
years or younger. In contrast in Houston, where an association 
was detected between the virus and the malignancy, 22% of 
patients were forty years or-younger (Rawls et al, 1970). 
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It io possible that at the time in New Zealand the majority of 
cases of cervical carcinoma occurred in older women and were 
aetiologically related to an agent other than HSV-2. This 
may also be true of populations in other countries. Unfortun- 
ately few studies on HSV-2 antibodies in patients with cer- 
vical anaplasia state the age distribution of patients in the 
study. Thus, this information could not be derived from 
studies conducted on populations in Formosa, Colombia, Taiwan, 
Japan and Israel. In all these countries no association was 
detected betweon the virus and the tumor. For this reason, 
these populations would be ideal for the study of other pos- 
sible aetiologic agents in cervical carcinoma, as well as a 







TO CAUSE CERYICAL -LEST 
ONS VMICH SHOULD- 
QCr. IIR IýTT. T. T; FFORF THE ONSET OF NEnPTARTTr- CHAMP, AUT) A HTr. HER 
INMENCE OF THE TUMOR SHOULD BE OBSERVED TH THESE WOMEN 
Indirect evidence for this criterion is provided in the 
studies reported in this thesis as it confirmed previous find- 
ings that the average age of patients presenting with genital 
herpes (23)vxmpxi3r than that of patients presenting with dysplasia 
(35), carcinoma An. Ritu (37) and invasive carcinoma (52). 
Catalano and Johnson (1971) demonstrated by kinetic 
neutral i natiop, HSV- 2 specific antibody in the sera of five of 
fourteen women who developed carcinoma j,. n situ one to eight 
years after that particular sample of serum had been collected. 
Although such retrospective studies are possible in instances 
where banks of serum are maintained, the studies of Sogbetun 
. et al 
(1979) question the validity of concluding the HSV-2 
specific antibody always results from a previous cervical 
infection. These workers examined four hundred twenty-two 
sera from children and young adults living in Ibaden, Nigeria. 
Eleven per cent of children in the three to five year age 
group and 14% of children in the six to ten year age group 
possessed HSV-2 specific antibody. A microneutralisation 
test was employed. The authors were of the opinion that those 
HSV-2 antibodies were acquired by non-venereally transmitted 
HSV-2 infection. The mechanism of such transmission they sus- 
pected wan by means of shared towels. bed clothes and beds, 
among people living in poor socio-economic conditions. Similar 
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studies had been previously reported by Osoba and Alausa 
(1974) who found that gonococcal vulvo-vaginitis in young 
girls in Ibaden was relatively frequent. and not caused by 
sexual contact. Gonococci like HSV are extremely labile 
organisms. They demonstrated that they survived long enough 
for such transmission to be possible when deposited on cloth 
exposed to humid air during the rainy season in Nigeria. Since 
sera for studies reported in this thesis were drawn from low 
socio-economic groups in three third world countries, it is 
recognised that in a small proportion of patients the presence 
of HSV-2 specific antibody may not have been an accurate index 
of previous cervical infection by HSV-2. In contrast to the 
Ibaden study, Nahmias et al (1970c) found in an American popula- 
tion that 11SV-2 specific antibodies were acquired after the 
age of fourteen years, and coincided with the onset of sexual 
activity. It is likely that in Britain HSV-2 antibodies are 
acquired similarly and therefore yield more accurate lnforma- 
tion as to previous cervical infection by HSV-2- Nevertheless, 
the most concrete proof of cervical HSV-2 infection is from 
the isolation of virus from clinical lesions or from apparently 
healthy cervices* Hence the most reliable evidence for this 
criterion must be sought in prospective rather than retro- 
Opective studies. Had more adequately controlled and prolonged 
prospective studies been conducted over the last thirteen 
Years following establishment of the relationship between the 
virus and the tumor, more progress may have been made as to 





RUSES OF THE HERPES GROUP SHOULD CAUSP NATURATJX 
OCCIJBRTNC; MALTrNANCTES IN-OTHER ANTMALS. 
Thera is no malignancy in animals of viral or non-viral 
aetiology which is analogous to squamous carcinoma of the cer- 
vix. However, other members of the herpes group of viruses 
induce malignancies in animals, and the Epstein-Barr virus 
(EBV) has been strongly linked to two human malignancies - 
Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC). 
Those herpes induced malignancies have been described in 
the Historical Survey (page 32-351 It is appropriate that 
cervical carcinoma should be compared and contrasted with them. 
Among the known herpes virus induced malignancies in 
animals, none occur in epithelial cells and in this respect 
nasopahryngeal carcinoma is the closest analoge to squamous 
carcinoma of the cervix. Studies in patients with NPC SITOW 
that approximately 90% possess IgA antibody to VCA of EBV and 
73% possess IgA to the diffuse component of early antigen 
(Henle and Henle, 19761 Ho et al. 1976). IgA anti-VCA titres 
in both studies ranged from IslO to it640. These titres in- 
creased with progress of the tumor and declined after treat- 
ment. The only EBV related antibody which did not show de- 
cline following treatment was antibody to Epstein-Barr virus 
nuclear antigen (EBNA). In contrast to patients with NPC, 
only 28% of patients with BL possessed IgA anti-VCA to EBV. 
Thus, of the two human malignancies associated with EBV, 
NPC a tumor of epithelial cells rather than BL a tumor of the 
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lymphoproliferative system, elicits a marked IgA host response. 
However, a parallel IgA response to VCA of HSV-2 was not ob- 
served among patients with cervical anaplasia in either this 
study or that conducted by El Falaky and Vestergaard (1977). Never- 
theless, a significantly higher proportion of patients with 
cervical anaplasia in this study had IgA antibodies to the 
membrane antigen (MA) of HSV-2 infected cells, 'in titres com- 
parable with those observed in convalescent sera of patients 
infected with HSV-2. Thus these results are similar to'the 
IgA results of patients with NPC, but not identical. The 
prevalence of IgA antibody to membrane antigens of EBV in- 
fected cells have not been studied in patients with NPC. 
Desgranges et al (1977) detected IgA anti-VCA to EBV in 
the saliva of 50% of patients with NPC. They also detqcted 
IgA anti-VCA to EBV in the plasma cells surrounding the 
epithelial, tumor cells. Similar studies on HSV-2. specific 
IgA anti-VCA or anti-MA in the cervical mucus of patients with 
cervical carcinoma have not been carried out. However, 
patients with cervical anaplasia possessed significantly 
higher levels of total IgA in their cervical mucus (Coughlan 
and Skinner, 1977). Thus both the humoral and local IgA mech- 
anism are stimulated by both NPC and carcinoma of the cervix. 
The presence of IgA anti-MA to HSV-2 infected cells-in the sera 
of patients with cervical carcinoma is indirect evidence that 
the antigenic stimulus originates from an epithelial surface, 
i. e. the cervical epithelium. 
, Although viral antigens have not been demonstrated in 
cervical carcinoma tissue, both Pacsa et al (1977) and Royston 
ana Aureli; a: n (1970b) claim to have-demonstrated herpes antigens 
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in the exfoliated cervical cells of patients with cervical car- 
cinoma (pages 42 and 43). In the study by Pacsa', these antigens 
were detected in the exfoliated cells of forty-five of forty-nine 
(92%) of, women with cervical carcinoma. It is possible that 
some environmental factor within the milieu of the cervix, 
stressed the virus in these cells to express more polypeptides. 
Malignant lymphoma in monkeys provides a similar example of a 
herpes virus induced tumor in which no viral'a: ntigens can be 
demonstrated"in cells obtained directly from the tumor. But a 
small proportion of these cells express viral antigens when 
transplanted into tissue culture. " Similarly, a small proportion 
of EBV transformed cells which usually express only nuclear neo- 
antigen EBNA and the membrane antigen LYDMA', 'are stressed into 
producing membrane'antigen, early antigen and VCA on being 
treated with halogenated pyrimidines (Hampar et al, 1972), EBV 
genome has been detected in all NPC and all endemic tumors. 
Similarly the genome of herpes virus siamiri, and herpes virus 
ateles have'been detected in malignant lymphomas in monkeys. 
HSV-2 DNA has so far been demonstrated only in the tumor tissue 
from one cervical carcinoma (Frenkel et al, 1972). They used 
DNA-DNA hybridisation which measured the rate of reassociation 
between radioactively Jabelled HSV-2 DNA and a surgically re- 
moved, cervical carcinoma cell DNA. The segment of DNA detected 
represented 39% of the HSV-2 genome. Attempts made by other 
workers to repeat these findings were unsuccessful. Thus 
zur Hausen et al (1974) used a technique of cRNA-DNA hybridisa- 
tion and searched for HSV-2 DNA in ten human cervical carcinomas. 
This technique'was estimated to be adequate to detect one genome 
equivalentýper cell. Schulte-Holthausen (1975) used a similar 
technique which', was sufficiently sensitive 
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to detect 20% of a genome equivalent per cell but failed to 
detect HSV-2 DNA in forty-six cervical carcinoma biopsies., 
Pagano (1975) used DNA-DNA renaturation kinetics which he 
estimated were sufficiently sýnsitive to demonstrate 25% of 
the HSV-2 genome. Considering that in SV-40 transformed cells 
as little as one-third of a genome (2.6 x 10 
6) 
is sufficient 
to, maintain the transformed state, if the port-ion of the HSV-2 
genome in cervical carcinoma cells is as, -little as this-, a 
technique ten times more sensitive than present techniques,: 
would be required to detect one-hundredth part of the HSV-2 
genome. It is noteworthy that by the same techniques as used 
by zur Hausen et al (1974), four to one, hundred thirteen genome 
equivalents of EBV'have been demonstrated in Burkitt's 
lymphoma cells (Pagano, 1974). However, at the herpes virus 
worksho. p held at Cambridge, England in 1978, J. K. McDougal 
presented encouraging preliminary work, where by a technique 
of in situ hybridisation he was able to demonstrate HSV RNA 
in 60% of biopsies of cells undergoing prb-malignant change. 
This work has not yet been published. 
ctepen4aAce The temperature^of -. the Lucke virus and the geographical 
prevalence of BL and NPC demonstrate-the extent to which the 
expression of oncogenic herpes viruses are governed by host, 
environmental and other co-factors. Although cervical car- 
cinoma is a widespread tumor, it'is possible that such 
selective factors may operate within the milieu of the cervix. 
Although in areas where BL is common, antibodies to EBV 
--are acquired at a very young age and nearly 50% of individuals 
are doubly infected with both malaria and EBV, the number 
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developing, tumors is small. Suggested reasons for this include 
genetic predisposition, very early infection or a particular 
sequence in the timing of infection in relation to acquisi 
tion of malaria (Epstein, 1978b). The recent Ugandan pro- 
spective study (de The et al, 1978) showed that children with 
anti-EBV-VCA antibodies of two doubling dilutions or higher 
than control levels carried a thirty times higher risk of 
developing the tumor, i. e. some host factor made these child- 
ren respond to the virus in a different manner. Similarly 
host factors such as the state of the cervical epithelium 
(metaplastic or non-metaplastic), HLA type, concurrent infection 
with other organisms, and the immune status of the patient may 
be of importance in the development of cervical car'cinoma. 
The association of the guinea pig herpes virus with an 
RNA virus, and the activation of leukaemia virus-by the 
Marek's disease virus is of interest as Duff and Rapp (1975) 
observed that C-type virus was released from HSV-2 transf; rmed 
3Y3 cells after serial passage in culture. Similarly, in- 
fection of Balb/C mouse cells with UV irradiated HSV-1 and 
HSV-2 resulted in activation of an endogenous C-type virus (Hampar 
et al, 1976). This presents the possibility that'induction of C-type 
virus synthesis may be a step in the'induction of oncogenic trans- 
formation (Huebner and Todaro., 1969). 
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CRITERION NUMBER 
INDIVIDUALS PROTECTED FROM DEVELOPING GENITAL HERPES TNFECTION 
SHOULD DEMONSTRATE A LOWER TNCIDENCE OF CERVICAL ANAPLASTA T 
LATER YEARS 
One of the aims of this study was to determine whether 
previous infection with HSV-1 protected from cervical ana- 
plasia. The answer to this question is important as such 
evidence may provide a basis for attempts. at immunprophylaxis. 
The evidence was examined from two different angles: 
A. By attempting to determine where there is an inverted case 
control prevalence of HSV-1 specific antibody, i*. e. do more 
controls than patients with cervical anaplasia possess, onlY 
HSV-1 specific antibody without HSV-2 specific antibody as a 
result of them being protected from subsequent HSV-2, infection? 
B. If previous HSV-1 infection does not protect from subsequent 
HSV-2 infection, does it protect from malignant transformation 
by HSV-2. If this occurs then one would expect the proportion 
of patients with cervical anaplasia who had only HSV-2. spec- 
ific antibody to be greater than the corresponding proportion 
in the general population. 
A. The inverted case control prevalence of HSV-1 specific antibod 
When compared with patients with cervical anaplasia from 
Britain, Sri Lanka and Malawi, a higher proportion of matched 
controls possessed only HSV-1 specific antibody-without HSV-2 
specific antibody. This difference was significant in the 
comparison between Malawian and British patients with invasive 
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carcinoma and British patients with carcinoma in situ and 
their respective controls. These findings confirm those of 
Skinner et al (1977). If this inverted case-control pre- 
valence of HSV-1 antibody alone is to be interpreted as being 
a significant one from the view-point of the protective effect 
of previous HSV-1 infection, certain assumptions need to be 
made. That patients and controls are equally exposed to HSV-2 
infection and that more patients possess both HSV-1 and HSV-2 
specific antibody because more of them succumbed to HSV-2 in- 
fection. The greater susceptibility to HSV-2 infection among 
patients would then presumably be due to: 
a) being infected by HSV-1 after they were infected by HSV-2, 
which is possible'but unlikely, and 
lb 
b) the inability of the immune mechanism of the patients to 
mount a response during previous HSV-1 infection which was 
sufficient to protect from subsequent HSV-2 infection. 
The alternative explanation for the inverted case control 
prevalence of only'HSV-1 specific antibody is that the control 
population comprises one which is less exposed to HSV-2 than 
the patient population. This explanation negates the signifi- 
cance of finding that more controls possess only HSV-1 antibody. 
Neither the patients and controls in the present study, 
nor in the study conducted by Skinner et al (1977) were 
matched for sex related variables. This hypothesis can be 
tested accurately only by matching controls for sex related 
variables. It cannot otherwise be assumed that patients and 
controls are equally exposed to HSV-2. This is. 'perhaps a 
generalisation which is more applicable to HSV-1. 
0 
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Thus although the findings in this study confirm previous C) 
findings, it cannot be concluded that previous infection by 
HSV-1 protects from subsequent HSV-2 infection. 
B. Previous HSV-1 infection protects from malignant transforma- 
tion by HSV-2. 
Of eighty-six British, Sri Lankan and Malawian patients 
with cervical anaplasia'in this study who possessed antibody 
to herpes simplex virus, four (4.6%) possessed only HSV-2 
specific antibody. The expected number was 3-7. This study 
therefore. provides no evidence to support this hypothesis. 
Preliminary data from a prospective-study conducted by Nahmias 
et al (1978) on five hundred ninety-six women with genital 
herpes said they had identified twenty-five patilents. who 
showed serological evidence of primary HSV-2 infection, i. e. 
these patients showed no evidence of previous HSV-1 infection. 
Cervical anaplasia developed in seven (28%) of the twenty-five 
patients with primary genital herpes and 14.6% in the total 
group of five hundred ninety-six patients. The authors how- 
ever admit that the serological methods used to demonstrate 
HSV-2 infection may have been imprecise and state their in- 
tention to retest sera for HSV-1 and HSV-2 specific antibody 
by ELISA. If HSV-1 antibody is detected in these sera, their 
findings will be negated. A similar result was encoiintered 
in this study. Fifty-eight sera were independently tested by 
CF and ELISA. In three of fifty-eight only HSV-2 specific 
antibody was detected by CF, but in all three HSV-1 specific 
antibody also was detected by ELISA. 
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HERPES SIMPLEX VACCINE 
Prevention of Marek's disease by vaccination with Tur- 
key herpes virus vaccine has focused attention on the possibility 
of preventing other herpes virus related diseases by vaccina- 
tion. The different types of vaccines which have been success- 
fully used in Marek's disease are a) an avirulent Turkey herpes 
virus, b) an attenuated. live Marek's disease virus, and 
c) a viral capsid vaccine (Purchase, 1976)... 
The suggestion has been made by Epstein (1976) that 
Epstein-Barr related diseases may be prevented by va'ccination, 
and by Melnick (1976) and Skinner et al (1978) that cervical 
carcinoma may be prevented by a herpes simplex vaccine. A' 
pre-requisite for such a human' vaccine would be that it should 
be free of viral nucleic acid, and therefore of potential 
oncogenes. 
Two types of herpes simplex vaccines have been prepared: 
a heat-inactivated HSV-1 and HSV-2 vaccines developed in 
Germany (Nasemann and Wassilew, 1979), and a virus particle- 
free vaccine developed in Biimingham, prepared by Nonidet 
NP-40 and formalin treatment of HSV-1 infected cell extracts 
(Skinner et al, 1978). 
Clinical trialshave been conducted with the German 
vaccine and the authors claim that the vaccine has been of 
value in the control of recurrent genital herpes. However 
the results'reported are not very convincing. Of eleven 
patients who received vaccine, there was no clinical improve- 
ment in four, one patient-had no further*recurrences, and in 
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six the periods between recurrences were longer than they were 
prior to the administration of the vaccine and the attacks 
themselves were of shorter duration than before. The period 
of follow up of these patients was inadequate since it extended 
to only six months. This vaccine carries the added disad-\-antage 
of not being free of viral nucleic acid. 
The vaccine developed by the Birmingham workers is free 
of viral DNA. ' It has not yet been used in a clinical trial. 
However, its protective effect has been established, for'when 
administered'intraperitoneally to mice which were later chal'- 
lenged by intravaginally introduced HSV-2, they were protected. 
vacc: ine d, m; r;, AecP when Ke 6 dor-a of Or" The protective ef f ect of the,,,. -. LUocs- f rom 10 P-f. u- 
to 107 p. f. u.., but the authors argue that penile lesions in 




p. f. u. 
It is hoped by workers in the field, that herpes simplex vac- 
cines would have two potential uses. Firstly, in the preven- 
tion or the modification of recurrent genital herpes and second- 
ly in the prevention of cervical carcinoma. 
It is not yet known whether cervical anaplasia is more 
likely to-result from recurrent attacks of genital herpes 
rather than a single attack. If it is shown-that recurrent 
attacks carry a higher risk of cbrvical anaplasia, and a vac- 
cine can prevent such attacks, then a vaccine would ýbe useful 
in the prevention of some cases of cervical carcinoma. 
Another unknown factor which requires study is the possi- 
bility that different s. trains of HSV-2 may be of varying onco- 
genic potential. If_such strains exist, it may be preferable 
to use them in vaccines prepared for the prevention of cervical 
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carcinoma'provided of course that they are free of viral 
nucleic acid. On the other hand, workers such as Skinner 
et Ill (1977) have suggested that previous HSV-1 infection may 
protect, implying that HSV-1 ,, accines should be used. In L 
this context, animal experiments conducted by Duff, Dollar 
and Rapp (1973) sound a note of caution. Newborn Syrian hamsters 
were immunised with HSV-1 and HSV-2 prior to challenge with 
HSV-2 transformed cells. The animals formed neutralising anti- 
bodies to-HSV but did not display any degree of transplantation 
immunity when compared with control animals injected with SV-40 
and medium 199 respectively. Also surprisingly tumor metastasds 
were significantly enhanced in HSV-1 immunised animals and sup- 
pressed in SV-40 immunised animals. 
These experiments point to the possibi 
I lity that HSV-1 may 
enhance the oncogenic effect of HSV-2. Could this be the rea- 
son why the majority of women with cervical anaplasia in the 
studies reported in this thesis as well as in other studies, 
possess HSV-1 as well as HSV-2 specific antibodies? Undoubtedly, 
many points need to be clarified before it would seem worthwhile 
or ethical to conduct vaccine trials on humans. 
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PREVIOUS INVESTIGATIONS ON ANTIBODIES TO MEMBRANE ANTIGENS OF 
HSV-2 INFECTED CELLS IN PATIENTS WITH CERVICAL ýNAPIASIA. 
Smith et al (1972b) examined the prevalence of these anti- 
bodies in thirty patients with invasive carcinoma and in thirty 
controls. They used an indirect immunofluorescent test employ- 
ing goat . anti-human globulin conjugate which was not class 
specific. The'predominant class of antibody detected in this 
assay would therefore have been IgG. Neither the prevalence 
of membrane antibodies to HSV-2 infected cells nor their titres 
distinguished patients with invasive carcinoma from controls, 
these results being similar to IgG anti-MA results presented 
in this thesis. 
Two studies showed complement, dependent cytotoxic anti- 
bodies to HSV-2 infected cells to be of good prognostic value 
in patients with cervical anaplasia. However different results 
were. obtained on assaying, these antibodies to cell lines estab- 
lished from cervical carcinoma tissue. In the study by Thiry 
. ftt 
al (1974) patients with cervical anaplasia were subdivided 
into two groups. There were eighteen patients with dysplasia, 
_ýrcinoma 
with carcinoma in situ and stage III and IV invasive cz, 
progressing lesions i and sixty patients with normal cervical- 
smears who had previously had dysplasia or been treated for 
carcinoma in situ or invasive carcinoma, i. e. they were classi- 
fied as pateints with regressing lesions. There was a higher 
prevalence (90%) of cytotoxic antibodies in patients with re- 
gresssing lesions than those with progressing lesions (56%). 
Similarly Christenson (1977) detected higher complement dependent 
cytolytic activity to HSV-2 infected cells in forty-three 
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patients who had been successfully treated for invasive car- 
cinoma than in twenty-three terminal patients. Cytolysis was 
assayed by staining cells with trypan blue. She next assayed 
the same sera against cell lines established from cervical 
carcinoma tumor tissue. In contrast .,. to results obtained 
employing HSV-2 infected cells, higher cytolytic activity to 
cervical carcinoma cell lines was detected in. sera from terminal 
cases than survivors. This finding is interesting. It is 
possible with increase of tumor burden that there is antigenic 
competition betwepn tumor specific antigen and HSV-2 antigen 
explaining the higher cytolytic activity to cervical carcinoma 
cell lines in terminal cases. During treatment by radiotherapy 
any virus or viral antigens in the cervical epithelium is 
likely to have been destroyed. After treatment there would 
be no tumor specific antigen to offer antigenic competition. 
Thus the increased cytolytic activity to HSV-2 infected cells 
observed in survivors is suggestive of reinfection of cervical 
epithelium by virus lying in neuronal ganglia. This study 
could have been better designed had these antibodies been 
assayed in serial samples of serum collected before and after 
treatment. Nevertheless they lend some support to suggestions 
put forward in this thesis to explain the persistence of IgA 
anti-MA followin'g treatment of patients with cervical carcin- 
oma (page 292). 
Christenson and Espmark (1976) studied antibody to mem- 
brane antigens of HSV-2 infected cells by mixed haemadsorbtion 
in eighty-eight patients with cervical carcinoma, eighty-five 
controls, and seventy patients with extra-genital, non-squamous 
malignancies. Seventy-one per cent of patients with cervical 
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carcinoma possessed these antibodies in contrast with 27% 
of controls and 27% of patients with extra-genital non-squamous 
malignancies. This distinction between patients with cervical 
carcinoma and the other two groups in the study is very similar 
to that obtained between similar groups employing the IgA anti- 
MA assay in the studies reported in this thesis (Fig. 6.2). 
S 
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MARKERS OF PROGNOSTTC VALUE TN CERVTCAL CARCTNOMA 
One of the aims of this study was to determine the prog- 
nostic value of monitoring HSV-2 related antibodies, serum 
immunoglobulins (IgG and IgA), and serum carcinoembryonic 
antigen (CEA) in the serial serum samples of patients with 
invasive carcinoma. The first question which arises is whether 
there is a need for such markers of prognosis. In answer to 
this question, a brief account is given below of the develop-, 
ment of-treatment regimes in cervical carcinoma including the 
presently'used criteria for daignosis of tumor recurrences I. I 
, 
Until the end of the 19th century, once cervical carcin- 
oma was diagnosed the maximum expectation*of life was usually 
not more than two years (Stallworthy and Wiernik, 1976). 
The terminal stages of pateints with this malignancy were most 
distressing to both the patient and her familyt for such com- 
plications as severe haemorrhages, and incontinence due to 
-fistulae formation were common. Intractable pain associated 
with cachexia were inevitable terminal events. Despite ad- 
vances in management, patients with re. currences still exper- 
ience a similar terminal syndrome. -Although 
the majority 
of deaths are currently seen in the developing, countries, 
there are also many women who die of the same syndrome in 
developed countries. 
The first method of treatment for carcinoma of the ceý'- 
vix, was 'surgical, and fulfilled the principal laid do'v, n by 
John Hunter in the mid 19th century that "In destroying 
locally any'specific disease which has power of its ovyn in- 
crease the'whole must be destroyed. " Wertheim in 1898 per- 
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formed the first operation which has given him a place of 
honour in surgical history. By a strange coincidence, Marie 
and Pierre Curie isolated radioactive elements from pitch- 
blende in this same year and by 1903 radium was first used 
in the treatment of cervical carcinoma. 
By 1930-1940 radiotherapeutic centres were'established 
in many countries and the majority of women in the developed 
countries were treated for cervical carcinoma by radiotherapy. 
Many authorities such as Professor Heyman in Stockholm active- 
ly opposed the surgical treatment of cervical carcinoma. Even 
so, up to 60% pf patients, died of the terminal syn- 
drome following recurrences of, their tumors. The basic ques- 
tion which then arose was whether recurrent cervical carcin- 
oma was caused by a new tumor growing in epithelium which had 
already demonstrated malignant'potential or whether it arose 
from continuing growth of the carcinoma which was originally 
not completely destroyed by radiotherapy. The'answer to-this 
question was provided by Stallworthy who commenced his studies 
in 1939 although'publication-was delayed until 1964, (Stall- 
worthy, 1964). He showed that recurrences developed from con- 
tinuing growth of the carcinoma which was not originally 
destroyed by radiotherapy. From these observations developed 
the Oxford regime of treatment, which consists of radiotherapy 
followed in three months by a Wertheim's hysterectomy, the 
aim of which is to remove residual malignant cells. However, 
this regime is not followed by all gynaecologists. Some ad- 
minister only radiotherapy, others perform only a Wertheim's 
hysterectomy. Some follow a Wertheim's hysterectomy by ir- 
radiation of the lymph nodes. All Sri Lankan patients in 
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study and the majority of British patients were treated by 
radiotherapy alone. Two British patients had Wertheim's 
hysterectomy and one had radiotherapy prior to Wertheim's 
hysterectomy. 
Following therapy, suspicion of tumor recurrence is 
atoused only on such clinical grounds as a history of blood 
stained discharge, ulceration of the cervix or the detection C-) 
of enlarged lymph nodes. Recurrences need to develop ap- 
preciably before any of these symptoms or signs appear. 
A mark of early tumor recurrence would be useful in 
patients in ptage I or II of the disease who have only been- 
treated with radiotherapy for in such patients there is a 
place for. performing rescue surgery in the event of tumor 
recurrence. Such a measure would be more sucdessful, if the 
re. currence can be detected before it is clinically apnjarent. 
-It would.; Eklso be helpful in cases v. here difficulties arise in 
distinguishing between tumor recurrences and non-malignant 
disease. 
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FJNDINGS IN THIS STUDY 
A change in level of immunoglobulins greater than or 
equal to 10% was considered to be a rise, or fall in level as 
this is the normal -inter-test variation observed in assays 
for'total immuno-c-lobulin by'single radial' immunodiffuSion 
(Hobbs, 1970). Changes in titre of IgG anti-MA, IgA anti-Mý 
and of total IgG and IgA were assessed at two stages during 
follow up. Firstly, at the end of ten weeks from the onset 
of treatment and secondly up to the end of the period of fol- 
Iow up. The usual course of radiotherapy lasts seven to eight 
weeks. Thus ten weeks was chosen as, -ta time limit when it may 
have been expected that antibody titres and immunoglobulin 
levels would be stabilised following any disturbance caused 
by radiotherapy. Changes in level of CEA were assessed only 
at the end of the follow up period. 
More patients who later developed recurrences of their 
tumor showed a rise in level of total IgG and IgG anti-MA at 
the end of ten weeks from the onset of treatment. However, 
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this difference was not as clear cut as the changes observed 
at-the end of the period of follow up. By the end of the 
period of follow up a rise in level of total IgG was ob- 
served in five of five (100%) of patients who developed 
recurrences in comparison with five of fifteen (33%) of 
patients who remained well (P <. 01). A rise in level of 
total IgA was observed in four of five (80%), patients who 
later developed recurrences in contrast with s ix of fifteen 
, 
(40%) who remained well (P >- 05) and a rise, in titre of IgG 
anti-MA was observed in four of five (80%) patients who devel- 
oped recurrences in contrast with five of fifteeTi, (33%) who 
remained well (P <-05). Changes in IgA anti-MA and CEA did 
not provide a useful distinction between the two groups of 
patients. 
Perhaps the findings in this study would have been more 
valid had the normal changes in immunoglobulin levels been 
ass ess , ed in serial s, amples from controls. The inter-test 
variation'-'could also have'been re-established. In this man- 
ner a more accurate estimate could have been -made of what 
constituted a true rise or fall in level instead of the change 
of 10% referred to above. This could be done in future studies. 
The suggestion made by Herbermann (1977) that in the 
immunediagnosis of malignancy, several tests used concurrently 
may provide more discriminatory data than a single t-est was 
extended in this'study to the detection of tumor recurrences. 
Therefore the usefulness of all possible combinations of the 
three tests which showed promise as markers of tumor recurrence 
was evaluated. All combinations gave a greater degree of dif- 
ference between the two groups of patients than any one test 
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did (Table 6.47B), but a rise in IgG anti-MA and a rise in 
total IgG provided the best distinction. Thus four of five 
(80%) patients who developed recurrences showed this com- 
bination, of changes in contrast to one of fifteen (6%) who 
remained well. 
Although the numbers of patients in this. study are rather 
too small for firm conclusions to be drawn, these-results, 
have sufficient potential value to justify a more,. detailed 
study involving larger numbers of patients and controls; 
Nevertheless, the changes observed, cannot be attributed to 
variation in treatment. Radiotherapeutic treatment-admin- 
istered to the two groups of patients at St. Thomas' Hospital 
was similar. None of the patients were given immunosuppres- 
sive drugs. It is possible that tumor recurrences make 
patients more susceptible to chronic cervical infection and 
this may account in pa'rt'for the rise in total IgG. Whatever 
the reason for this p, henomenon, if further studies confirm 
that it occurs consistently it would still serve as a useful 
marker of tumor recurrence. In this respect it was encourag- 
ing that changes in immunoglobulin and membrane antibody in 
Sri Lankan patients were similar to those observed among 
British patients. 
Since serial serum samples from patients with invasive 
carcinoma were not collected on a monthly basis, it was not 
possible to ascertain the exact timing of these changes in 
relation to the clinical detection of recurrences, i. e. it is 
not known if these changes occurred before the recurrence 
was clinically apparent. 
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This'study did not confirm the value of CEA in the 
detection of recurrent cervical carcinoma as shown by van 
Nagell et al (1978) (page 103). The reason for this may-be 
that a different anti-CEA serum was used in the CEA assay 
employed in this study. In the study by van Nagell et al, 
Roche G-23 anti-CEA serum was used which recognises an ion 
sensitive site on the CEA molecule. However, considering the 
increasing evidence which shows the prognostic value of serial 
estimations of CEA in gastric cancer (Freeman et al, 1979) 
and colorectal cancer (reviewed in Neville and Cooper, 1976) 
it would be of interest to reassess levels of CEA in these 
sera employing the exact method employed by van Nagell et al. 
As a marker of tumor recurrence, the non-specific nature 
of immunoglobulins may be advantageous. If cervical carcinoma 
is of multiple aetiology, it is likely that all agents would 
act via a final common pathway in bringing about malignant 
change. The final immune response to the tumor despite : I! ts 
aetiology might thus be expected to be the same. The same 
argument is applicable to CEA. 
HSV-2 related antibodies which have been acclaimed as 
markers of prognostic value in cervical carcinoma are anti- 
bodies to AG-4. These antibodies were detected in a high 
proportion of untreated patients, but not in patients who had 
been successfully treated. They were also detected in patients 
who developed recurrence of their tumor (Aurelian et al, 1973, 
1974b, and 1975). Although these results showed great promise, 
'these workers have up to date not published further studies 
which have attempted to monitor these antibodies in serial 
samples of serum from a single group of patients followed 
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through from the time of initial diagnosis. Thus it is not 
known how long after therapy these antibodies became unde- 
tectable nor how long prior to clinical detection of tumor 
recurrence these antibodies reappear. 
0 
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A COMPARISON OF THE COMPLEMENT FIXATION TEST (CF), ENZYME 
LINKED IMMUNOABSORBENT ASSAY (ELISA), AND MEMBRANE ANTIBODY 
13Y FLUORESCENCE, AS ASSAYS FOR ESTIMATING PREVIOUS EXPOSURE 
TO HSV-1 AND HSV-2 
Of all tests so far developed for estimating HSV-1 and 
HSV-2 specific antibodies in sera, only the CF test (Skinner 
2-t- al, 1976) and ELISA (Grauballe and Vestergaard, 1977; and 
Vestergaard et al, 1977) employ type specific antigens. The 
type specific antibody of fifty-eight sera in this study were 
estimated by both these methods. In addition these sera were 
tested for IgG and IgA antibodies to the membrane antigens of, 
HSV-2 infected cells. The sensitivity and usefulness of each 
test was evaluated by analytmýý, - the results obtained on each 
serum by all these assays. 
Both the CF test and ELISA gave more false seronegatives 
(19% and 10% respectively) than the IgG anti-MA assay (3%)- 
Thus as a method of determining previous herpes simplex in- 
fection (HSV-1 or HSV-2), the IgG anti-MA assay was the most 
sensitive. ELISA was the most sensitive in detecting HSV-1 
specific antibody. It gave a false negative rate of 3-7% in 
contrast with a false negative rate by CF of 43%. ELISA was 
al so the most sensitive assay for HSV-2 specific antibody, 
giving a false negative rate of 17% in comparison with a 
false negative rate of 34% by CF. 
When the CF test for HSV type specific antibody was 
originally published, its efficacy in demonstrating type 
specific antibody in sera of immunised rabbits and in human 
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sera was described (Skinner et al, 1976). The test was more 
sensitive in detecting type specific antibody in convalescent 
sera than in sera collected long after initial infection. 
Thus HSV-2 specific antibody was detected in all human con-). 
valescent sera from HSV-2 infected p- atients. However, concurrent 
testing by neutralisation test and CF revealed that in the sera 
of HSV-1 seropositive nuns there was a 20% false negative rate 
for HSV-1 specific antibody by CF. Thus the higher rate of 
false negatives by the CF test in comparison with ELISA, may 
be a reflection that complement fixing antibodies in herpes 
simplex infection are shorter lasting than non-complement fixing 
antibodies. A similar loss. of complement fixing-antibodies is 
seen in other viral infections such as influenza, measles and 
rubella. Following cytomegalovirus and EBV infections complement 
fixing antibodies may persist for a long duration of time and 
these may be due to the endogenous presence of virus with 
periodic recrudescence. A parallel situation may exist in her- 
pes simplex infection, with persistence of complement fixing 
antibodies only in subjects harbouring latent herpes virus and 
who exp erience recrudescences. Another contributory factor 
to the high rate. of false negatives by-CF may be the sensitivity 
of the CF test- itself. According to Voller et al (1976) ELISA 
may be of 
Ia 
sensitivity comparable with radioimmunoassay. 
From studies conducted by Skinner et al (1976) and the 
present- study, there is no doubt that antigen employed in 
the CF test is type specific. Perhaps more profitable use 
may be made of these laboriously prepared antigens by employ- 
ing them in a sensitive assay such as ELISA or radioimmunoassay 
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for non-complement fixing antibodies. 
The IgA response to HSV-1 and HSV-2 infection was found 
to be more type specific than the IgG response. This may be 
put-to clinical use in determining infecting virus type in 
the event of failure to isolate virus. It would be of in- 
terest to determine if such IgA antibodies may be detected in 
the cerebrospinal fluids of patients with herpes encephalitis. 
On examining IgA anti-MA titres of, -forty-three British 
sera which had previously been tested by ELISA, it was found 
that a titre of greater than or equal to 1: 8 for IgA anti-MA 
indicated the presence of HSV-2 specific antibody and titres 
of less than 1: 8 its absence. As a method of estimating the 
presence of HSV-2 specific antibody this dividing titre of 
1: 8 gave a false result rate of 20% among British subjects 
and 25% among Sri Lankan subjects. Among Malawian subjects 
the corresponding titre was 1: 16 with a false result rate of 0 
17% (both false positive and false negative). This false 
result rate of 17-25% compares very favourably with correspond- 
ing false result rates by CF (34%) and_ELISA (17%). Thus 
while the IgG membrane antibody assay on HSV infected cells 
provides a very sensitive method of determining type common 
herpes simplex antibody, concurrent testing of sera by the 
IgA membrane antibody assay would be of value in determing 
which type specific antibody was present. However, it does 
not differentiate between sera containing HSV-2 specific anti- 
body alone and sera which contain both HSV-1 and HSV-2 specific 
antibody. Nevertheless this is not a great disadvantage for 
only five sera among all those tested in this study had HSV-2 
specific antibody alone. 
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The higher dividing titre of 1: 16 observed among Malawian 
subjects is in keeping with the geographic variation in titre 
of IgG anti-MA and IgA anti-MA that was observed k 
in this 
study. Malawian subjects possessed higher titres than sub- 
jects from other countries. This geographic variation may 
have resulted from an inter-country variation in the back- 
ground prevalence of HSV-1 infection. It may'also be a re- 
flection of the influence of such environmental factors as 
parasitic infections which may alter the immune reactions to 
certain antigens (McFarlane, 1973)- 
The dividing titre of 1: 16 also provides an explanation 
for Ahe fact that similar proportions of Malawian patients 
and controls possessed IgA anti-MA greater, than 1: 4 (Table 6.2). 
In contrast, a significantly higher proportion (66%) of 
Malawian patients with invasive carcinoma had IgA anti-MA 






1. STUDIES RELEVANT TO SCREENING FOR CERVICAL CANCER 
It was found that the cervical screening programme 
which has been in operation for over ten years in the-U. Ký has 
made no impact on incidence rates or mortality rates from the 
tumor. Some possible contributory factors were identified 
in this-study. Firstly, although the incidence of cervical 
anaplasia in women below thirty-five years is rising, ýhe 
present screening policy- is to perform-routine cervical smears 
only on výormn above this age. This study provided evidence 
which supported recent suggestions made that this age should 
be reduced. Secondly, data obtained from this study suggested 
that the screening programme was not being sufficiently pro- 
moted among women in the lower socio-economic groups and 
among postimenopausal women. 
There is a need to screen by Papanicolaou smear, Malawian, 
Sudanese, and Sri Lankan women, as they have an early age 
specific incidence of the tumor. As cervical carcinoma was 
found to occur well within the child bearing age in these 
countries, screening could be conducted at antenatal clinics. 
PIDEMIOLOGICAL ASPECTS OF CERVICAL CARCINOM 
This study confirmed previous findings that early initia- 
tion of coitus was an epidemiological feature of patients 
with'cervical anaplasia among patients in all four countries 
. 
in this study. It is, therefore concluded that the relation- 
ship between early initiation of coitus, genital herpes and 
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cervical anaplasia requires further clarification before 
HSV-2 could be accepted as being a causal agent of cervical 
anaplasia. 
STUDIES ON ANTIBODIES TO THE MEMBRANE ANTIGENS OF HSV-2 
INFECTED CELLS 
The IgA response to the membrane antigens (MA) of HSV-2 
infected cells was found to be more type specific than the 
IgG response. This finding has potential clinical value. 
In the absence of clinical herpetic infection the hypo- 
thesis was put forward that IgA anti-MA resulted from the ex- 
pression of early viral proteins by latent HSV-2 virus which 
lay at sites outside the nervous system. A high prevalence 
of IgA anti-MA was detected in patients with cervical ana- 
plasia in titres similar to those observed in convalescent 
sera of patients with genital herpes. It was therefore sug- 
gested that a high proportion of these patients have not 
only been previously infected with HSV-2 býxt may continue to 
ha: rbour latent virus. 
The high prevalence of IgA anti-MA in patients with non- 
genital squamous carcinoma was explained by evidence-suggest- 
ive of a cross reacting antigen between HSV-2 infected cells 
and squamous carcinoma cells. Antibodies to this antigen- 
were detected by the IgA membrane fluorescence assay. They 
were in part contributory towards the high titres of IgA anti- 
MA in patients with carcinoma in situ and invasive carcinoma, 
and to the rise in titre of IgA anti-MA with increase with the 
stage of disease. It was concluded that this preliminary 
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evidence for a cross reacting antigen deserved further in- 
vestigation as antibody to it in patients with cervical car- 
cinoma could contribute towards a false result of elevated 
antibody titres to HSV antigen. 
STUDIES ON THE PREVALENCE OF HSV-2 SPECIFIC ANTIBODIES 
(ELISAY TN PATIENTS WITH CERVICAL ANAPLAS! 
HSV-2 was associated with cervical anaplasia in Britain, 
Sri Lanka and Malawi since patients with cervical anaplasia 
had a significantly higher prevalence of HSV-2 specific 
antibody when compared rith controls. However -the - prevalence 
of HSV-2 specific antibody in cohorts of British patients and 
controls suggested that the virus may have a role as a co- 
variable of the real carcinogen rather than be the causal, 
agent itself., Everr-its role as A'-co - -variab: Ie was hdt'uni- 
versal sincb-up to 48% with cervical- carcinoma! tin the Sudan 
did-not show evidence of previous-infection by HSV-2- Among 
patients withcervical anaplasia from Malawi and Britain 
this lack of HSV-2 specific antibody was more apparent in 
women who developed cervical carcinoma at an older age. 
STUDIES ON THE PREVALENCE OF HSV-2 SPECIFIC ANTIBODY (ELIS 
AND IgA ANTIBODY TO THE MEMBRANE ANTIGENS OF HSV-2 INFECTED 
CELLS IN PATIENTS WITH MALICINANCIES OTHER TUN OERVICAL 
CARCINOMA 
There was insufficient evidence to support that HSV-2 
was associated with extra-genital non-squamous malignancies 
and with other genital malignancies, but non-genital squamous 
malignancies were nearly as strongly associated with HSV-2 
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as cervical anaplasia. Antibody to a cross reacting antigen 
between HSV-2 infected cells and squamous carcinoma cells 
may have contributed to this phenomenon. Firm conclusions 
cannot be drawn until sera from a larger number of patients 
with non-genital squamous carcinomas are examined and attempts 
made to characterise this cross reacting antigen. It is 
therefore concluded that patients with extra-genital, squamous 
malignancies should form an important control group in future 
studies on the nature of the association between HSV-2 and 
cervical carcinoma. 
STUDIES ON THE PROSPECT OF PREVENTING GENITAL HERPES ANDZOR 
QERVICAL CARCINOMA BY THE USE OF HERPES SIMPLEX VACCIN S 
There was no evidence from this study to show that pre- 
vious HSV-1 infection protected from subsequent HSV-2 infection 
or from developing cervical carcinoma. 
Z. STUDIES ON MARKERS OF PROGNOSTIC VALUE IN CERVICAL CARCINOMA 
Rising levels of total IgG, total IgA and IgG anti-MA 
(HSV-2) were associated with tumor recurrences. A combination 
of a rise in total IgG and IgG anti-MA were the best markers 
of tumor recurrences. However this finding needs to be con- 
firmed in larger numbers of patients. Investigations also 
need to be carried out as to the exact timing of these changes 
in relation to occult tumor recurrences in'order to assess 
the clinical value of these serological markers. 
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q. 
-"STUDIES'. COMPARING THE SENSITIVITY OF ENZYME LTNKED TMMUNO- 
ABSORBENT ASSAY (ELISA), COMPLEMENT FIXATION--(CF) AND 
MEMBRANE FLUORESCENCE FOR DETECTING PREVIOUS INFECTION 
BY HSV-1 AND HSV-2 
The IgG membrane fluorescence assay was the most sensi- 
tive in detecting type common antibodies. The ELISA tech- 
nique-was the most sensitive in detecting HSV-1 and HSV-2 
specific antibodies. The higher false negative rate for 
type common antibody and HSV-1 and HSV-2 specific antibody 
by the CF test may be an indication that in contrast with 
non-complement dependent antibodies complement dependent 
antibodies in herpes simplex infection are time dependent. 
The IgA membrane antibody assay was useful in determin- 
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FUTURE STUDIES 
STUDIES THAT WOULD CLARIFY THE RELATIONSHIP BETWEEN EARLY 
INITIATION OF COITUS, CERVICAL ANAPLASIA. AND GENITAL HERPES 
If 
ANDTHE ROLE PLAYED BY OTHER SEXUALLY TRANSMITTED AGENTS. 
A prospective study on patients presenting at different 
ages with their first attack of genital herpes with cervical 
involvement would help to clarify this question. It would 
be necessary to conduct regular colposcopic examination of 
their cervices, - e. g. once in three to six months. Abnormal 
colposbopic f! 7ndihgb should be confirmed by Pap smears and/or 
biopsies. Such a study should aim to establish whether col- 
poscopically abnormal transformation zones develop more frequent- 
ly following genital herpes infection during adolescence, or f ol- 
lowing first pregnancy than at other times. In addition it 
could be established whether a single attack of genital herpes 
or recurrent attacks have the same or different effects on 
the cervical epithelium. The follow up period should be 
long in order to-assess whether abnormal lesions which develop 
are reversible or persistent. A group of women with abnormal 
transformation zones who do not give a previous history of 
genital herpes could form a suitable control group, and may 
be picked out at colposcopy clinics. Antibodies to*HSV-2, 
mycoplasma,. chlamydiae, gonococci, cytomegalovirus and human 
papilloma should be monitored in the sera collected at each 
visit for colposcopic'examination. Thus the role of many 
sexually transmitted'agents may be studied. - A history re- 
lating to ethnic origin, social class, and sex related variables 
would be necessary for the meaningful analysis of results. 
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STUDIES DESIGNED TO ESTABLISH THE SITE OF LATENCY OF HSV-2 
If there is latent virus in cervical epithelium it is 
likely that HSV-2 specific antibody would be found in cer- 
vical. mucus. It is usually not possible to collect cervical 
mucus from patients with cervical carcinoma. Thus cervical 
mucus and cervical epithelial tissue from women with healthy 
cervices, with a previous history of a single attack of geni- 
tal herpes, with recurrent attacks of genital herpes, with 
carcinoma in situ and with dysplasia could be used. Levels 
of total immunoglobulin and IgG and IgA antibodies to the 
membrane antigens of HSV-2 infected cells could be examined 
in cervical mucus specimens. 
Exfoliated cells I andpreferably cryostat-sections of 
biopsy materials could be examined for herpes antigens and 
herpes*DNA. Anti-HSV sera 'raised in animals, or monospecific 
sera raised in animals to HSV glycoproteins could be used in 
either a fluorescent test or a peroxidase label test in 
the study of herpes antigens. The methods of in situ hybrid- 
isation used by McDougal (page 314)'could be used to detect 
herpes DNA. Since in this study there__was evidence for a 
cross reacting antigen between HSV-2 infected cells andý 
squamous carcinoma. cells, biopsy material from squamous car- 
cinomas would form important control material in the. herpes 
antigen studies. 
If biopsy material is collected, it would be relevent to 
determine the class of antibody and the herpes specificity of 
antibodies in plasma cells in the cervical epithelium. 
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In countries where Wertheim's hysterectomy is performed 
without prior radiotherapy, such investigations could be ex- 
tended to studies on class specificity and herpes'specificityý 
of antibodies eluted from cancerous tissue. 
STUDIES ON AN ANTIGEN COMMON TO HSV-2 INFECTED CELLS AND 
SQUAMOUS CARCINOMA CELLS 
Antibodies to such an antigen appeared to be detected 
by the IgA membrane fluorescence assay used in the studies 
reported in this thesis. Thus IgG should be removed from the 
sera of patients with cervical carcinoma and non-genital 
squamous carcinoma which contained high IgA anti-MA titres. 
Such IgG free fractions could be tested by the intermediate 
gel technique of crossed immunoelectrophoresis described by, 
Vestergaard et al-(1979). against solubilised: HSV-2 infected 
cells and squamous carcinoma cells. IgG free fractions of 
the following control sera should also be used in the study: 
1. IgA-anti-MA positive sera from patients with genital herpes, 
dysplasia and from women with healthy cervices. 
2. IgA anti-MA negative sera. 
Depending on the results of the above studies-$ methods could 
be devised to characterise this cross reacting antigen further. 
STUDIES TO EXAMINE THE POSSIBILITY THAT THE AETIOLOGY OF CERVICAL 
CARCINOMA SHOWS GEOGRAPHIC VARIATION AND VARIES ACCORDING TO AGE. 
Sera from two or more contrasting epidemiological groups 
could be examined, e. g. patients with invasive carcinoma 
and controls from: 
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1 'a country where an association of the tumor with HSV-2 
has been established, 
2. a country where no such association has been established, and 
3- . an epidemiolbgical-'group which has' a low incidence of the 
tumor. 
Controls should be matched for ethnic origin, sex, age, social 
clas and sex related variables. 
In addition sera should. be collected in each country 
from patients with non-genital squamous carcinomas. 
Knowledge of the pattern of sexually transmitted dis- 
ease in the environment f rom which each sample is drawn 
would be, necessary for analysis of such data. 
It would be possible in such a study to draw conclusions 
from an inverted case control prevalence of'HSV-1 antibody 
(see page* 317)' 
IN VITRO STUDIES WHICH MAY INDICATE WHETHER HSV-2 IS CAUSALLY 
Few transformation experiments have been conducted on 
human cells (see Table 1 -5) Vesterinen et al(1975) have shown that, 
it is possible to establish cell lines from squamous epithelium 
and columnar epithelium covering the cervix. Thus attempts 
could be made to transform with HSV-2 cell lines established 
from normal squamous epithelium. If such attempts are suc- 
cessful, the antigens on these transformed cells could be com- 
pared with those on cell lines in low passage which have been 
esta blished from squamous cervical carcinoma biopsy material. 
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Control cell lines established from biopsy material from 
non-genital squamous carcinomas should also be'used. 
STUDIES WHICH MAY IDENTIFY FACTORS CONTRIBUTING TOWARDS THE 
FAILURE OF THE-PRESENT SCREENING PROGRAMME IN THE U. K. TO 
REDUCE INCIDENCE RATES AND MORTALITY RATES FROM CERVICAL 
CARCINOMA 
An assessment needs to be made of the proportion of 
those at risk who are being screened at present. Also an 
estimation according to regions of the proportion of invas- 
ive carcinomas being detected by smears and the proportion 
due to clinical symptoms, would identify areas where the 
programme is ineffective. Accurate information on the in- 
cidence of invasive-carcinoma according . to social . class 
ethnic origin and age on a regional basis would identify 
high risk groups which the screening programme has failed to 
reach'adequately. An assessment should be made of the ef- 
ficiency of the present system in ensuring re-call for fol- 
1 ow up of women who have had abnormal smears. 
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INFORMATION - PATIENTS 
A. GENERAL INFORMATION 
Name: CB No: 
Age: 
Ethnic origin: 
Busband's occupation: Social class: 
Patient's occupation: 
Age at marriage: 
Number of pregnancies: 
B. DIAGNOSIS AT TIME OF COLLECTING FIRST SPECIMEN OF SERUM 
Tick off what is applicable 
Dysplasia [---I 
CA in situ r-1 
Invasive CA f--j 
CA in situ reverted to normal after coýisation 
Dysplasia reverted to normal (1) spontaneously, ý 
r7 (2) after r-1 
Treated invasive CA no recurrence conisation 
Treated invasive CA showing recurrence 
C. CLINICAL STAGE OF NEOPLASM 





D. PAPANICOLAOU STAIN REPORT 
E. TREATMENT,. -. ýi 
Form of treatment tick off what is applicable: Radiotherapy 
Hysterectomy 
Date treatment vas instituted: 
Date treatment vas discontinued: 
Date recurrence výs' noticed: 
F SPECIMENS 















Not married a) dependent on parents 
b) self-supporting 
Divorced 0 livingwith boy-friend 
Separated 
Number of children: 
EMPLO711ENT STATUS 
*Husbaud/boy-friend/fatherlsell 
Employed job: a) manager 
b) foreman. 
c trained, self-employed 





Patient's occupation-. Social class: 
MEDICAL HISTORy 




Previous histýry'of-- a) -genital herpes 
b) non-genital herpes 




EQUIPMENT AND MATERIALS REQUIRED FOR ASSAYING ANTIBODIES TO 
MEMBRANE ANTTGENS OFýHERPES SIMPLEX INFECTED CELLS. AND VIRUS 
QAPSID ANTIGENS-OF HSV-2 INFECTED CELLS. 
1. Polystyrene bottlesý, 
',, 150 cm 2 
2. Microtitre plat es 
U-shaped 
3. Disposable pipettes,,, 
_ 0.025 ml (cat., no. 7770207o6) 
0.05-, ml. (cat., no. -ý77-021-06) 
4. -Finn Pipette 
5 P1 - 50 rl 
Costar 
Flow Laboratories 
Titertek Microtitration equip- 
ment - Flow Laboratories. 
Jencons Scientific Ltd. 
5. Disposable tipsý . _Alpha 
Laboratories. 
6&- Hand Multidiluter--"ýý"', `, 
'(cat. no. 77-100-00)" Titerek 
Flow Laboratories. 
7. Microscope slides 
C. E. Payne and Sons Ltd. 76x 25 , mm, 10 
8. Multispot MicroScope-Sllde's 
_C. 
A. ' Hendley and Company. 
g., Round Cover-Slips 
13 mm diameter No. 0 
10. RectangularýGlass cov6r'slips- 
22 x 64immFNo. '-12" 
11. Rotor Mixer 
de Luxel 
12. Shaker,, 
Chance Propper Ltd. 
Chance Propper Ltd. 





14. Fluorescent, Microscope 
with epifluorescence; condenser 
15. Ultrasonic disintegrator 
PG 100, Model, 150 W. 
16. Heat'Sealable Ampoules 
2 ml, (cat. No. 508) 
17. Rabbit Kidney Cells (RK 13) 
RK 13 cell line (Glaxo RK 13) was 
MSA Scientific Instruments 
Zeiss 
MSE Scientific Instruments 
Sterilin Ltd. 
obtained from the Medical 
Research Council,, laboratories. The cells used in this study 
were all'below., theý40th"passage. The cells were grown till the 
cell sheet was confluent"Ord day usually) and left on mainten- 
ance medium for, 2-days prior to splitting. The cells were split 
one to three using'a-;. ýtrypsin and versene solution. 
Storage of cells 
Cells from one 150'ýým 
2'ý, 'bo til e were suspended in 3 ml of minimal 
essential medium containing, 20%, Fetal Calf Serum (B20) and 10% 
Dimethylesulph"o'xide (B29)'.,. '-'_Th1s"was. aliquoted in one ml. quant- 
itiep in heat sealable ampoules (B16), frozen in a liquid nitrogen 
cylinder and stored, in a, gaspýase-nitrogen cylinder. 
Seeding of cells-', ý 
The cellsýin each, --, ampoule'. were--thawed at 37 
0 C, washed once in 
growth medium, centrifuged at 1000 xg for 10 minutes in a bench 
centrifuge, 'and resuspended in'50-ml-of-growth medium in a 
2 
-0 - 150 cm bottle. 
18. Growth Medium 
Minimal Essential Medium Eagle (Modified) 
with Earl Is: salts', ý,,, '*:,, 
with 0.85 9/1-'sodium'bicarbonate-, 
5% Fetal calf. -serum 
1% Glutamine,.,, 
1-3% of, a 4.4%, sodium. bicarbonate solution 




19. Maintenance Medium 
MEM as above 
2% Fetal Calf serum 
1% Gluta'mine 
2.4% of a 4.41o solution of sodium bicarbonate 
2% Penicillin and Streptomycin solution 
20. Fetal Calf Serum 
(Cat. No. 29-101754) Flow Laboratories 
21. Glutamine 
Sterile 200 mM L-Glutamine (Cat. No. 16-801-48) 
Flow Laboratories 
22.4.4% Sodium Bicarbonate' 
44 gms sodium bicarbonate 
100 ml, distilled water 
I ml 1% phenol red 
The bicarbonate solution was prepared using the materials 
above. Dry ice was added to saturate the solution with 
, carbonicýacidýand 25, -mlialiquots were sterilized 
by autoclave. 
23. Trypsin and versene solution 
a) 1 gm of versene (EDTA-diaminoethane tetra acetic*acid 
disodium salt)" BDH Chemicals Ltd. 
This was dissolved', in, 2-'LoffPBS (B25). The solution 
was autoclaved in aliquots of 100 ml and stored at 40C. 
b) Sterile freeze-dried 5% trypsin 
-Wellcome Laboratories 
One vial. ofi. trypsin"-was. ýreconstituted in 10 ml of versene 
solution and made up to 200 ml with more versene solution. 
'05%-versene and 0.25% trypsin. This gave a, dilution*of Oe 
This solution was'aliquoted and stored at -200C. 
24. ýenicillin and Streptomycin Solution 
Penicillin. one,,. ampoule . 
(1,., million units) 
Streptomycin 
.. 
one,,, ampoule', (1,. "million g) 
100 ml-,, sterile, distill ed-water. 
Aliquots of 12 ml were stored at -200C (penicillin 10,000 
units/ml and streptomycin 10,000 . g/ml). 
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25. Phosphate buffered saline (PBS) 
PBS, Dulbecco 'A, ' 
' was prepared 
by dissolving one tablet 
(Oxoid Ltd. ) in, 100 ml of deionized water, sterilized by 
autoclaving for 15, minutes,, at 15 lbs pressure and stored 
, at room temperature. 
26. Veronal buffer (5k) 
83 gms NaCl and 10.19 gms Na-5-5'diethyl barbiturate was 
dissolved in 1500 ml distilled water. 31-2 ml of NII HCl 
was added to this. The buffer was made up to 2000 ml, and 
stored at'4oCo 
Before use, a 5-fold dilution of. the above 5x buffer was 
prepared by adding distilled water. 
27. glycerol- 
- Analytic reagent BDH Chemicals Ltd. 
28. Acetone 
Amlytic reagent BDH Chemicals Ltd. 
29. DMSO (Dimethyl sulphoxide) 
Stored at room temperature Hopkins and Williams. 
30 . Virus 
Both strains of HSV used-were provided by Dr. G. R. B. Skinner, 
of the Department of Virology, The Medical School, Birming- 
ham, England. 
HSV-1 
Strains HF, the, HFEM deri-ýative of the Rockefeller strain 
HF (Wildy, 1955) was used. 
HSV-2 
BRY - an isolate from a 19 year old patient with recurrent 
genita]L herpes was used. 
Both viruses had been passaged several times in*tissue 
culture prior to use. They were employed as prototype 
HSV-1 and HSV-2 in the study on the differentiation of 
type I and type 2 strains of HSV by indirect immunofluorescent 
technique (Geder and Skinner, 1971)- 
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Propagation of virus 
Virus was grown in RK 13 cells which were inoculated on the 
3rd or 4th day after splitting with 5 P. f. u. per cell. Virus 
was allowed to adsorb for one hour at room temperature after 
which the virus inoculum was discarded., 50 ml of. maintenance 
medium was added'and the cells incubated at 37 0C for approxi- 
Mately 12 hours until a 75% CPE developed. The cells were 
shaken into the medium with., the., use, of sterile glass beads. 
The medium containing the.; suspensionýof infected cells was 
aliquoted into, 20 mlýallquotsinWniversals and snap-frozen 
in dry ice and methanol. ''t:, --This wasfstored at -70 
0 C. Prior to 
use, 'the cell suspensionlwas,, sonicated for 10 seconds 
(16 at 20 Kc/sec)., 
ý1_. Conjugate-Fluorescein conjugated animal antialobulin 
1. Rabbit antihuman IgG-Fluorescein isothiocyanate Batch, No. 4-572 
2. Rabbit antihuman IgA-Fluorescein, isothi, ocyanate Batch 10-173 





Eggs - Fertile eggs incubated at 100OF for 10-12 days. 
Dentist's drill Citenco Elstree 
Method 
The eggs were candled, and using a carborundum disc fixed to 
the dentist's drill a perforation was made in the shell over 
the air sac and a triangular portion of the shell removed over 
the embryo. Care was 
ýaken that this triangular portion did 
not lie over blood'vessels,, and that the drilling process did 
not penetrate deeper than the shell. A light scratch was made 
on the shell membrane. with a sterile injection needle and the 
chorioallantoic membrane (CAM) dropped by sucking with a large 
teat placed over, the,. perforation over the air sac. The eggs 
Were candled again to check that the CAM had dropped. 
V-iX: us dilutions 
10-fold dilutions of. the virus was made in sterile PBS in 
bijoux bottles in an ice bath. 
Inoculation of virus onto CAMs, 
0.1 ml of. each virus dilution was inoculated onto each CAM of 
eggs. Al., l, ml-disposable syringe with a 25 gauge injection 
needle was used. 2. CAMs. were inoculated with 0.1 ml of PBS. 
The eggs were gently rocked after inoculation to spread the 
inoculum on the CAM. * 
Incubation and the, reading of CAMs 
The performations-on the shell were sealed with cellotape, and 
the eggs incubated at 370C for 72 hours. Th6-'-CAMs were" har- 
vested, washed, and those"containing 20-50 pocks were used in 
estimating virus titre. The mean pock count on the three CAMs 
inoculated with that dilution of virus-was used. 
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APPENDIX D 
Method for production of pig liver Dowder 
Materials 
Pig's liver 




Whatman 54 filter paper W and R Balston Ltd. 
A -fresh pig liver was obtained with the portal vessels intact. 
The liver'. was washed with tap water through the venous system 
until pale. - It was next cut into pieces and washed with saline. 
The pieces were homogenised with 3 volumes of saline, and 
centrifuged at 2000 rpm for 45 minutes. 
The sediment was resuspended in saline containing 0.01% thiomersal, 
and left at 40C overnight. The suspension was centrifuged at 
2000. rpm for 30 minutes. 
The sediment was resuspended in saline with 0.01% thiomersal 
and, left overnight. The suspension was rehomogenised, and 
passed through a double layer of muslin. The filtrate was 
centrifuged at 2000 rpm for 45 minutes. 
The sediment was resuspended, in one litre of acetone and filtered 
through a funnel using Whatman 54 filter paper. The sediment 
was washed further with acetone until white. It was dried at 
37 0C in the incubator, and ground to a fine powder in a homogeniser 
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APPENDIX E 
Purification and treatment of conjugates prior to use 
Freeze-dried IgG and IgA conjugate (Appendix B31) was reconstituted 
with sterile distilled water according to the manufacturer's 
instructions. It was absorbed with pig liver powder (PLP) 
(Appendix D) to purify it of unreacted fluorescent material. 
Absorption with -pig liver powder 
100 mg of PLP per ml of reconstituted conjugate was used. The 
PLP was washed twice with distilled water and once in PBS prior 
to use. It was shaken gently with conjugate for one hour at 40C. 
The mixture was centrifuged at 3000 rpm in a bench centrifuge 
and the purified conjugate aliquoted and stored at -70 
0 C. 
Absorntion with control cells 
About 2-3 hours prior to use, a1t2 dilution of the conjugate 
was prepared in PBS and absorbed with uninfected RK 13 cells. 
The cells used. thus for absorbing may be harvested and stored 
at -70 0C over long periods of time. Approximately 8x 106 cells 
(cells from one 75 cm2 bottle) were used per 0.4 ml of 1: 2 
dilution conjugate. Absorption was carried out with gentle 
shaking at +40C for one hour. At the end of one hour, the 
mixture was centrifuged at 3000 rpm in a bench centrifuge and 
the conjugate was diluted with PBS to its use dilution. 
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APPFNT)IX F 
Trentment of sera showimp, non-specific fluorescence 
Theca cara were absorbed with control cells on the day they 
were being tested. A 1: 2 dilution of serum was prepared in 
PBS by adding 0.2 ml of PBS to 0.2 ml of serum. This was 
gently shaken with approximately 8x 106 RK 13 cells (cells 
harvested from one 75 cm2 bottle) for one hour at 370C. The 
Gorum call cuspension was centrifuged at 3000 rpm in a ben6h 
centrifuge for 5 minutes. Next the serum was absorbed with 
RK 13 Cella of the same quantity as above, for one hour at 40C. 
The Cella were removed by centrifugation and the serum assayed 
immediately as the antibody titre of serum absorbed thus at a 
1t2 dilution deteriorated on storing. 
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AM. NDTX G 
? L'r-tterlnIfL-nnd e-nuirmel3t required for serum IgG and Ig 
determinrition by sinrle radial immunodiffusion 
1) Accra assay IgG and IgA regular level single radial immuno- 
diffusion plates. 
ICG - code no. 61-303-1 
IgA - code no. 61-301-1 
stored at 40C in the inverted position 
Miles Laboratories 
2) Accra ausay reference human sera, high. mid-range, and low 
for both IgG and IgA. 
Stored at 40C. 
Micropipette 
capillary pipette delivering 10 microlitres 
Diameter measuring template 
Behringwerke AG 
X-ray viewer Wardray Products Ltd. 
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F-mlipment -ind materials required for Rubella and measles HAI tests. 
1. Microtitre plates 
V-shaped (cat. no. 76-321-05) Flow Laboratories 
2. Dilutors 
Linbro, 0.025 ml (cat. no. 76-742-00) Flow Laboratories 
3. HAI dilucnt 
To 96 mi of veronal buffer, 2 ml of a 10% solution of 
bovine plasma albumen and 1 ml each of a 10% solution of 
calcium chloride and 8% magnesium sulphate solution were 
added. The mixture was shaken and the pH adjusted to 6-7 
with sodium bicarbonate (0.044%). 
Rubellar HAI antigen 
Cat. no. 40-809-41 
Meacloo HAI antigen 
Cat. no. ORAO 09 
Flow Laboratories 
Behring Diagnostics 
Veronal buffered saline (CFT diluent) 
This wan prepared using CFT diluent tablets (Oxoid Ltd). 
Each tablet was dissolved In 100 ml deionized water. 
Formula g/litre 
Barbitono 0.575 
sodium chloride 8-500 
magnesium chloride 0.168 
calcium chloride 0.028 
barbitone soluble 0.185 
PH 7.2 (approx. ) 
Bovine plasma albumin 
A 10% solution of BPA powder (Armour Pharmaceutical Co. Ltd) 
was propared in PBS 'A' (Appendix B25). The solution was 




Levels of total IgG and IgA and titres of IgG anti-MA and 
IgA anti-MA in patients with invasive carcinoma from Britain, 
Sri Lanka and Malawi were analysed by a multi-way analysis of 
variance to take into account a combination of factors such as 
race, age and stage of disease. The computer program GLIM 
was used as-observations in the various groups were unequal. 
For the actual analysis, logariths of the measurements were 
used bLtt results shown below show 95% confidence intervals for 
the mean ratios in actual measurements. This analysis was done 
by R. W. Morris of the Department of Community Medicine at 
St. Thomas' Hospital. 
TgG anti-MA 
Race was overall 
factors (i. e. stage 
ferences in estimat 
shown below. 
If M-B = Ratio 
M-SL =, 'o 
a significant factor when adjusted for other 
of disease and age) (P4 0.01). The dif- 
ed measurements for the various races are 
of Malawians to British 
it it " Sri Lankans 
2.4756--l-M-B 9831 
Mean = 5.4466 
0.6422 4- M-SL 4- 1 . 7393 
Mean = 1.2422 
The other two factors (stage, age) were'not significant. 
2) IgA anti-MA 
No significant results were found. In a model including all 
three factors, estimated meas*urements were highest for Malawians 
and lowest for British, but the overall difference was not sig- 
nificant. ' They were lowest for patients in stages 1 and 2, and 
highest for'"those in stage 4, suggesting some trend according 
to stage of disease: however this result is not significant. 
412 
Total IgG 
In the usual model incorporating all three factors, the 
overall effect of race was found to be highly significant 
(P-4 0.01); estimated measurements for British were lower than 
the other two races. 
If SL-B = Ratio of Sri Lankans to British 
. M-B = 11 " Malawians of of 
1.412 4- SL-B -=::: 2.1606 
Mean = 1.7467 
1.27 894 M-B 4.2.1255 
Mean = 1.6487- 
Estimated measurements increased according, to stage but 
the, overall difference was not significant. 
If ST4-1 = Ratio of stage 4 patients to stage 1 patients 
1.0282i%ý,. ST4-1, <- 2.1797 
Mean = 1.497 
Total IgA 
Estimated measurements were-lower for Malawians than the 
other two races. 
Let B-M = Ratio of British to Malawians 
B-SL= is Sri Lankans 
0- 9833 zr,, B -M ýS 1.6441 0.7326 B-SL 1.1261 
and Mean = 1.2715 Mean = 0-9083 
The overall test for the effect of 'race' gave a p-value 
of less than 0.1 but greater than 0.05. 
The estimated measurements increased according to stage 
of disease, and this time the overall effect of 'stage' was 
significant (P<0.01). 
Let ST2-1 = Ratio of Stage 2 patients to Stage 1 patients 
ST3-1 = of 3 to of of of 
I 
to 
ST4-1 = it 4 is it of of of 
o. 9494, < ST2-1e,,, 1.64o3 
Mean = 1.2422 
i. ol6o, < ST3-l-< 1.8228 
Mean = 1.361 
1.49894 ST4-1, <, 3.3112 
.. Mean = 2.22? 8 
413 
The older the patient, the lower the estimated measure- 
ment. This effect has a p-value of around 0.1. 
If F= Factor by which the measurement is multiplied 
every year. 
0.9990<_ F <ý,, l . 0139 
Mean = 1.0064 
5)--IP-A anti-MA was once again analysed - using total IgA as 
another factor (covariate). So the model used to analyse 
specific IgA included age, race, stage and total IgA. 
IgA anti-DIA seemed to decrease with increasing total IgA. 
When total IgA was doubled, specific IgA was multiplied by 
a factor F. - 
0 . 3682 1ý F iL 1 . 1338 
Mean = 0.6461 
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KAWASAKI DISEASE: A WORLDWIDE SURVEY 
SIR, -Kawasaki disease, an acute febrile, mucocutancous 
condition, has become an important disease of infants and 
young children. About 12 000 cases had been registered. 
throughout Japan by 1976, and there have lately been reports 
from other countries. This disease causes great concern 
because 1-2% of those afflicted die suddenly from coronary 
thrombosis months or even years after apparently complete re- 
covery. Furthermore, more than 60% of survivors examined by 
angiocardiography have been found to have some abnormali- 
ties, including aneurysm in the coronary arteries. The ninth 
revision of the W. H. O. International Classification of Diseases, 
which came into effect on Jan. 1,1979, adopts Kawasaki dis- 
, case under the. separate rubric (446-1) of "mucocutaneous 
lymphnode syndrome (MCLS)". 
A current nationwide survey being done by the M. C. LS. 
Research Committee in Japan indicates that the number of the 
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Kawasaki disease registered in jaýan. 
additional' cases were reported throughout Japan dunng 
1977-78, resulting in a total of 18 182 cases (10 884 males and 
7298 females). Of these cases, 184 were fatal (1-0%). However, 
the death-rate has lately declined; it was 1.2-2-6% before- 
1973,1.0% in 1974,0.7% in 1975-76, and 0.5% in 1977-78. 
This decrease may be partly due toý changes in therapy such as 
the use of aspirin, rather than steroids, and coronaryýartery 
surgery. 
The male: fcmale ratio is 1-5: 1; -the disease peaks around 1 
year of age; the incidence is higher in April to September and 
in December to January; no distinct geographical pattern in 
incidence has emerged. 
. The Japan M. C. 1-S. Research Committee is undertaking a 
worldwide postal survey to clarify the atiological features of 
the disease- would appreciate it if Lancet readers would kindly 
provide us with information on their experience of the disease 
outside Japan. We can provide diagnostic guidelines. with col- 
our illustrations if asked. 
1. SHIGEMATSU 
H. TAmASHIRO 
Japan M. CLS. Research Cornmiueeý 
r/o Depamment of Epiderniology, 
S. SHIBATA 
institute of Public Health, T. KAWASAKI 
Tokyo 108, Japan S. KuSAKAWA 
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SCREENING FOR CERVICAL CANCER - 
SlRj--Although the dcath-rate from cervical cancer of 
women below the age of 35 is rising in the UK, the total 
number of deaths is small. ' The recommendation by the Bri- 
tish Society of Cytologists, that screening below. the age of 30 
years2 be selective 3eemj to have been determined by the cost 
and effort of screening millions of women when set against the 
benefit of saving- this small proportion of lives. We feel- that 
age-specific incidence rather than age-specific mortality is the 
better criterion of assessing the problem of cervical carcinoma 
in younger women. As part of a survey into the association 
between cervical carcinoma and the herpes type 2 virus in pa- 
tients attending St Thomas' Hospital, we found the incidence 
of premalignant and malignant cervical lesions in this age- 
group to be high. 39 of 166 (23%) patients with dysplasia, car- 
cinoma-in-situ,. and invasive carcinoma were aged 30 years or 
younger. Of thew, 23 had dysplasia, 11 had carcinoma-in-situ, 
and 5 had iavasive carcinoma-mi. e., 16 (14%) of a total of 114 
patients requiring immediate treatment (patients with carcino- 
ma-in-situ and invasive carcinoma) were 30 years or younger. 
8 of 39 (21%) patients below the age of 30 years were West In- 
than in origin. Approximately 80% of both West Indian and 
Caucasian patients in this age-group were in social classes I-11L 
36 of 70 patients who presented with clinical invasive car- 
cinoma were. aged 50-70. Since the time for a tumout to 
evolve from a premalignant to a malignant stage has not been 
established, ind may well be dependent on many unknown fac- 
tors, we disagree with Melcher and Tnehan' that screening is 
no longer necessary in symptom-free postmenopausal Women 
who have previously had a negative smear.. 
Although a cervical screening programme has been carried 
-out 
izi the UK for over 10 years, the incidence and mortality 
from cervical cancer in the UK has not decreased appreciably, 
and it would be of interest to know what proportion of the 
population at risk are in fact being screened. In British Colum- 
bia4 where all sexually active women above the age of 20 were 
screened, a 33% reduction in incidence rate was achieved in 17 
years, In Toledo, USA' where, over a period of 19 years, the 
proportion being screened was stepped up gradually from 
approximately 15% to 90% of those at risk, a 66% reduction. 
in the incidence rate was achieved. Similarly, in Louiscville, 
Kentucky, 6 where screening began in 195 6,94% of the popul*- 
tion at risk were being screened by 1967. A 57% decrease in 
incidence rate and a 51% decrease in mortality was observed 
from 1955 to 1973. In contrast, in Auckland, where only some 
20% of the women at risk were being screened, - the incidence 
and mortality rates which were already falling before the cam- 
paign, did not show an accelerated reSponSe. 7 
There are basically two criteria by which the cost benefit of 
widespread cervical screening and thereby the detection of 
early cervical lesions may be assessed-the benefit to the pa- 
tient and the benefit to the health services. Ile treatment of 
early invasive carcinoma involves extensive surgery or radio. 
therapy which is often debilitating and which always castrates. 
Thus, though the cure-rates in early cervical carcinoma are 
good, the price is high. Compared with this, the benefit to theý 
patient of a simple curative procedure applied to preinvasive 
lesions which involves the removal of selected areas of abnor- 
1. Anonymous. Screening for cervical cancer in young women. Lances 1978; ii:. 
1029-30. 
2. Spriggs Al, Husain OAN. Screening for cervical cancer in young women. -,, Lancet 1979; H: 1202. 
3. Melcher DH. I Inchan J. Screening cervical cancer. Lancet 1979; L 40-41. 
4. Worth A. Screening programme. BrMedy 1973; iii: 36. S. Kim K. Rigal D, Patrick JR, Walters JX, Bennett A, Warren N, Claybrook 
JR, Parekh RR. The changing trends of uterine cancer and cytolow. a 
study of morbidity and mortality trends over a 20-year period. canew 1978; 42t2439-49. 
6. Christopherson WM. Man population screening for cervix cancer- Tanwri 1976; 62t297-301. 






mal cervical epithelium, are only too obvious. In terms of the 
expenses incurred by the health services in treating the more 
advanced lesions, it was estimated in the U. S. A. that for every dollar spent, 9 were Saved. $ 
LALITHA N. MENDIS 
Departrncntýs orVirology and Gynzcology, 
JENNIFERM. BEST 
St'rhornee Hoiphal and AWical School, 
R. W. TAYLOR 
London SE I 7EH J. E. BANATVALA 
RISK OF MYOCARDIAL INFARCTION IN 
ORAL-CONTRACEPTIVE USERS 
SIR*--Dr Jick (June 2, p. 1187), commenting on our study' 
of oral c, ontraceptives (OCs) and myocardial infarction, argues 
that our study was seriously biased, but we find his reasons un- 
persuasive. 
Avoidance of OCs by women with predisposing 
ýOndidons 
such as angina or diabetes-together with the raýrjty of these 
conditions-does mean that our study "cannot provide infor- 
matiorx on the hazards of OC use in such women. " We agree, 
aýd so stated. By the same token, Jick's speculation about the 
possibility that OC use might depend on the severity of a 
predisposing condition such as hypertension seems amt. ý We are not. familiar with any study, or theory, connecting 
the "coronary-prone, personality type to "the decision to con- 
tinue or discontinue OCs in the face of repeated warnings. " 
For this reason, personality type, as well as many other fami- 
liar risk indicators of myocardial infarction, were not discussed 
as potentially confounding variables. 
Jick draws attention to our figure of 539 controls without 
predisposing conditions-This was, a transcribing error which 
we regret. In fact; there wire 539 controls with, and 1203 
without, predisposing conditions. Thus the proportion of con- 
trols without predisposing conditions Was 69%, a figure that 
accords well with those in other studies. 
Jick gives no'reason-and we cannot think of any-why, 
among women not using OCs, those protected from pregnancy 
by, stcrilisation should have been excluded (while users of 
intrauterine devices, diaphragms, and so on, were acceptable). 
Ile even suggests that women whose husbands had had vasec- 
tomies should have, been excluded, as if a husband's contra- 
ccptive practice could be a risk factor for myocardial infarction 
in the wife: We saw no reason to make allowance for vasectomy 
and hence we , 
did not record data On it. However, we did 
record da-a on tubal ligation. Exclusion- of women who bad 
tubal ligations did not materially change any of the estimates 
of OC clfect upon myocardial iafarction risk. Nor did the 
further exclusion of predisposed women, together with women 
over 45 years of age, appreciably diminish the discordance 
between our results and those of Jick et al.: 2.1 from the data 
in the accompanying table the rate ratio among women below 
the age of 45 was 6.4, whereas in Jick's study the correspond- 
ing estimate among women below the age of 46 was 15. .` 
, In attempting to explain the 
discordant results between'our 
study and his, Jick concentrates on what- he sees as possible 
biases in our study"but does not respond to our reservations 
about possible selection bias in his own investigation. When we 
sought permission , 
to interview patients we frequently found 
the physician and patient eager to collaborate if OCs were in 
use at the time of the infarction; conversely, we were often told 
that it was unnecessaky to proceed with the interview if OCs 
were not in use. Such a tendency is- conducive to an upward 
bias in the exposure-rate among the enrolled cases and, there- 
by, in the magnitude of the observed association. For this rea- 
8. Programme analysis. Disease control programs.: cancer. Washington, D. C_ 
US Department offlealth, Education andWclfam 1966: 14-19. 
1. Shapiro S, Slone D, Rosenberg 1, Kaufman DW, Stolley PD, Micttinen OS. 
Oral-contraceptive (Lw in relation to myocardial infarcuon. Lancer 1979; 
i: 743-47. 
2. jick H, Dinan B, Rothman KI. Oral contraceptives and nonfatal myocardial 
infarction. jAWA 1978; 239: 1403--06.1 
1 3. Jick H, Dinan B, Herman R, Rothman Kj. Myocardial Infarction and other 
vascul. ir diseases in young womenjAMA 1979; 24012549-52. 
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RELATION OF MYOCARDIAL INFARCTION TO RECENT* OC USE, 
PREDISPOSING CONDITIONSt AND TUBAL LIGATIONS EXCLUDED 
Age (yr) Category No. of women No. of users - 
25-29 MI 4 -3 (7j%) ,,, - Control 203 
-54(27%,, 
),,, -, 
30-34 Ml 7 5(71%) 
Control 257 26(10%) 
35-39 MI it 3(2711q) 
Control 1% 23(12%) 
40-44 hil 23 4(17%) 
Control 171 6 (49c) 
45-49 Ml 33 . 3 (99. ( 
Control 172 4(37c) 
*Last use within the mouth before admission. 
tDefined as: ponderal index (weight Dbyheiglit [in12) >0.04 (I ra-454 
g; I in=2.54 cm); treat6d diabetes; history of lipid abnormality; 
treated hypertension; treated angina pectoris, history of pre-eclamptic 
toxxmia. 
son we aimed at a 100% participation-rate within a pr"cined 
sampling frame. We achieved a rate of 94%, while -Jick was 
able to interview only 15% of the potential cases considqed 
eligible for study. We continue to be concerned that the par- 
ticipation of such a small subgroup might have been enhanced 
by knowledge, on the part of the consenting persons, of OC. 
use. 
SAMUEL SHAPIRO 
Drug Epidemiol4My Unit. 
Boston University Medical Center, DENNISSLONE 
Cambridge, Massachusetts 02139, U. S. A. OLLI S. MIETTINEN 
KEPATOCELLULAR CARCINOAU IN A PATIENT ON 
ORAL CONTRACEPTION WHO ILAD BEEN 
EXPOSEDTOHEPATMS B VIRUS 
Sllt, m-Hepatic tumours in patients on oral or'systemic . con- 
. 
traceptives have been reported. ' Usually they are benign aden- 
omas ' 
2.3, and primary hepatocellular carcinoma (PHCQ is 
rarer. However, in endemic regions (especially in Mrica and 
Asia) where hepatitis B virus (HBV) is prevalent, the incidence 
of PHCC is also high, 4 and -over the put decade oral contra- 
ception has been introduced into many developing countries. 
We report here the earlier than usual development of PHCC. 
in a patient who hid evidence of previous asymptornatic HBv, 
exposure and who was on the pill at the same time- -I 
The patient, a female Chinese, age 29, presented in Jan- 
uary, 1979, with- a 2-month history of pruritus, epigastric dis- 
comfort, and weight loss. There was no hizz, ory of hepatitis or 
liver disease. In 1972 she started tiking 'Anovular, (norcthis- 
terone acetate 4 mg, ethinylcestradiol 50 jig) and she had been 
on 'Ovral' (levonogesterol 0.5 mg and cthinylccstradiol 50 pg) 
since 1974. She was emaciated. There were no signs OfCbroniC 
liver disease. The right and left lobes of the liver were enlarged 
to 16 cm and 15 cm, respectively. Spleen was 3 cm enlarged. 
A bruit over the right lobe was present. The pesults of investi. 
gations were: bilirubin 1.2 mg/dl, alkaline phosphatase 184 
units (normal <100), SGOT 135 IU/1 (normal. <40), SGFT 
>200 IVA; at, 7antitrypsin 538 mg/dl (130-320), ct, -acid-glyco- 
protein 180 mg/dl (45-110); hepatoma liver antigen positive; s 
ct-fetoprotein 1100 ng/ml, HBA, negative counte-unmunoelec. 
1. Christopherson WM, Mays ET, Burravis G. Hepatoccilular carcinoma in 
young women onoral contracerAives. Lexca 1978; i: 3L 
2. Baum JK, Holtz F, Bookincin jj, Klein EW. Possible association betwom 
benign hepatomas and oral contraceptiveLLancer 1973; iL926-929. 
3. Anon. Liver turtiours and the pill. BritMedl 1977; 1ý0. 
4. Szmuness W. Hepatocellular carcinonia and the hepatitis B virtue evkk= 
for a causal essociation. ProgrMed Virot 1973; 24: 40-69. -1 . -- 
. 
S. Outs Cj, Yo SL Presence of a bepatoms4ivw antigen in the sere of patients 
with primary hepatoccHular carcinoma. Siagapm Afed 1 1979; ý 
201 
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